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Recently, the redox cofactor NAD+ has been implicated as a potentially key biomolecule in the quest 
for healthy ageing, with its function as a rate-limiting cofactor for the deacetylase SIRT1 widely 
believed to be key.  
Consequently, there is a heightened interest in better understanding the regulation of the 
NAD+/SIRT1 axis and identifying mechanisms that increase NAD+ levels. Within this work, the 
circadian regulation of NAD+ in human PBMCs (peripheral blood monocytes) in vivo and NHDFs 
(normal human dermal fibroblasts) in vitro is characterised, with NAD+ levels found to be temporally 
regulated by an endogenous mechanism dependent on the ‘master circadian regulator’ BMAL1 
(brain and muscle ARNT-like 1). Importantly, this introduces the prospect of co-ordinating NAD+ 
targeting interventions with the diurnal oscillations of NAD+ - whereby timepoints associated with a 
daily nadir are preferentially targeted for NAD+ enhancement. 
The demonstrated efficacy of a ‘multi-targeted’ approach at enhancing NAD+ titres was another 
important feature of this work, with the use of multiple dietary compounds targeting various steps 
in NAD+ synthesis and degradation pathways shown to be effective at increasing NAD+ both in vitro 
and within a small human cohort (n=2). At present supplementation with the NAD+ precursor NR 
(nicotinamide riboside) is the most widely used intervention for the purpose of enhancing NAD+, 
however the results presented here suggest a multi-targeted approach merits further investigation 
and may eventually offer a superior alternative to NR. 
Although widely regarded as beneficial for physiological health, there are scenarios whereby 
increased NAD+ may be undesirable, for example pathologies fuelled by upregulated energy 
metabolism pathways. It is shown herein that TGF-β (transforming growth factor beta) induced 
fibrotic signalling in vitro is accompanied by increased glycolysis, which is indispensable for the 
enhanced expression of the pro-fibrotic marker collagen I. Furthermore, inhibition of NAD+ synthesis 
by blocking NAMPT activity via FK866 attenuated TGF-β mediated collagen I upregulation, 
highlighting that reducing NAD+ levels can prevent fibrotic events in vitro. 
Thus, this work contributes to the biogerontology field by identifying mechanisms and interventions 
that modulate NAD+ levels, potentially providing the basis for new strategies with the purpose of 
enhancing human healthspan. Such strategies should be used with caution in diseases associated 
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Chapter 1. Introduction 
1.1 The Role of NAD+ and NAD+ Dependent Enzymes in Ageing 
1.1.1 Ageing 
Physiological ageing is an inevitable process that, for those who live long enough, will eventually 
cause mortality. The inescapable reality of ageing has fascinated humans for thousands of years and 
until relatively recently the underlying biological mechanisms have been a source of great mystery. 
As the mystique unravels, a key point of contention is whether ageing is an intentional genetically 
programmed process or an unintentional consequence of gradual damage accumulation.  
From an evolutionary perspective, ageing as a genetically defined mechanism to induce mortality 
makes sense - it protects against over-population and depletion of resources, whilst it also promotes 
evolution of the species by ensuring a stagnant genome isn’t contributing to the gene pool over 
multiple generations. If true, this would suggest inactivation of the pro-ageing genes or re-activation 
of anti-ageing genes that had been switched on or off would prevent the ageing process. The inability 
however to detect any such genes in model organisms however has shifted the general consensus 
towards a model whereby ageing is caused by ‘wear and tear’, i.e. gradual physical deterioration 
accompanied by the inability to fully repair it.  
Despite this, genes that modulate lifespan and the rate of ageing have been identified in lower 
organisms [1-5], however their homologues in murine models generally lack this capacity. One such 
example is the age-1 gene in C. elegans, in which mutations have been reported to increase lifespan 
from 1.7-fold [6, 7] to as high as almost 10-fold [8]. The age-1 gene codes for the class‐I 
phosphatidylinositol 3‐kinase (PI3K) catalytic subunit, a key downstream target in Insulin/IGF-1 
signalling (IIS) which regulates multiple cellular process such as proliferation and metabolism. The 
central role played by the IIS pathway in C. elegans longevity was re-enforced by further studies 
which found that mutations to the daf-2 (homologue of the mammalian insulin like growth factor 
receptor 1) gene caused a 2.3-fold increase in lifespan, via a mechanism dependent on daf-16 
(homologue of the mammalian forkhead box FoxO transcription factor) activity [9]. Although not as 
emphatic, significant life extension by inhibition of multiple mediators within the IIS pathway was 
also observed within Drosophila [10-12], suggesting acceleration of the ageing process via IIS may 
be a conserved mechanism. 
Typically, when applied to mouse models however, the effects of IIS inhibition on lifespan have been 
much more modest [13, 14], perhaps owing to the increased complexity of the IIS pathway within 
mammals. Notably however, overexpression of KLOTHO (an inhibitor of IIS signalling in mice) 
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significantly enhanced lifespan in transgenic mice, with the enhancement in average lifespan varying 
from 19 – 30% depending on sex and the particular transgenic allele expressed [15]. 
Hence, it appears that certain pathways such IIS signalling play a key role in promoting/combating 
ageing and their manipulation may decelerate the process – by slowing the rate at which pro-ageing 
molecular changes occur and/or facilitating their repair. 
1.1.2 Calorie Restriction  
To date, the intervention with the most repeated success at extending lifespan and delaying age-
related diseases is calorie restriction (CR) – defined as a diet without malnourishment which consists 
of up to 60% less calories than what would be considered ad libitum feeding, with the extent of the 
calorie deficit depending on the organism. It should be noted that the terms ‘calorie restriction’ and 
‘dietary restriction’ are often used interchangeably when referring to a low-calorie diet. The CR 
mediated enhancement of lifespan appears to be conserved across numerous eukaryotes including: 
yeast [16, 17], flies [18, 19], worms [20-22], rodents [23-25] and most recently rhesus macaque [26-
28], although conflicting findings [29] and results interpretation [30] have been reported for the 
latter. The conservation across higher and lower Eukarya suggests that rather than bodyweight or 
percentage body fat, intracellular changes are key to the lifespan-extending CR phenotype. 
Importantly, both early (from birth or infant years) and late (adulthood) onset CR have extended 
lifespan and slowed age-related physiological decline [31-34], which is significant given the 
impracticality of early onset CR in humans which are required to be well fed to ensure proper 
development during infancy and adolescence. 
Naturally, slowing the rate of energy metabolism – an obvious consequence of CR – has long been 
suspected as an essential component of the CR phenotype. By reducing energy precursors and 
therefore energy metabolism, this places less strain on mitochondria thus extending their ‘shelf-life’ 
and delaying the pro-ageing effects associated with dysfunctional mitochondria [35-37]. Aside from 
lowering basal levels of energy metabolism [38], other protective pathways are known to be 
upregulated by CR [39-42]. The development of this protective response to CR can be explained in 
evolutionary terms as an adaptation to times of low food availability, resulting in upregulation of 
stress response pathways to ensure survival during such times of hardship. This fits well with the 
‘disposable soma theory of ageing’ [43] which posits that the energy costs of reproduction versus 
body maintenance/repair are in competition for the body’s finite energy reserve. In times of plentiful 
food and hence energy the body focuses on fuelling reproduction, however in times of food shortage 




A suspected key target of CR is mTORC1 (mechanistic target of rapamycin complex 1) [41, 44, 45], a 
protein complex which dictates the cellular response to multiple stimuli including nutrient 
availability and growth factor signalling. Indeed, gene editing approaches to inhibit mTOR signalling 
extended lifespan in C. elegans and Drosophila, however were unable to further extend lifespan 
under conditions of CR [46, 47]. Furthermore, the prototypical small molecule inhibitor of mTOR, 
rapamycin, has been shown to extend the lifespan of mice [48, 49], although a similar relationship 
between CR and mTOR signalling has yet to be verified in murine models.  
It’s important to acknowledge that adherence to a CR diet is impractical for many given the likely 
decline in physical strength and risks associated with low bodyweight, hence interventions which 
resemble CR at the signalling level, aka CR mimetics, are of massive interest. Although rapamycin 
falls into this category, it was originally developed as an immunosuppressant and thus carries 
potentially dangerous side effects rendering it unsuitable as an anti-ageing therapeutic. Promisingly, 
a number of rapalogues (compounds designed to mimic rapamycin) have been developed as anti-
cancer agents ([50, 51] to combat certain cancers which depend on MTORC1 to upregulate 
biosynthetic pathways and promote proliferation. The efficacy of other rapalogues at replicating the 
lifespan extending effects of rapamycin has yet to be demonstrated, however this remains an 
emerging avenue of ageing research [52]. 
In addition to MTORC1, there is growing evidence that the benefits of CR are mediated through NAD+ 
and SIRT1. Moroz et al. showed that the activity of the NAD+ salvage pathway was essential for CR 
mediated lifespan extension in C. elegans, whereby although the benefit of CR was reduced in both 
sir-2.1 (C. elegans homologue of SIRT1) and pnc-1 (NAD+ salvage pathway enzyme) overexpressing 
mutants [53], it was attenuated more so in the pnc-1 overexpressors - suggesting that CR benefits 
mediated through NAD+ may have mechanisms supplementary to SIRT1 activation. Furthermore, a 
mouse strain overexpressing the NADH dehydrogenases NQO1 and CYB5R3 (which yield NAD+ as a 
catalytic byproduct) was reported to resemble the CR phenotype [54]. 
The link between SIR2/SIRT1 and CR has been extensively investigated, with a particularly notable 
study by Rogina et al. demonstrating that CR was unable to further extend lifespan in the long living 
Sir2 overexpressing flies, whilst also being unable to induce any enhancement of longevity in 
mutants with low Sir2 activity [55]. In rodents, the developmental impairment that occurs in Sirt1 
heterozygous knockout mice makes the dependency of CR on SIRT1 harder to assess, however for 
those that survive development, no benefit in response to CR for the Sirt1-/- mutants has been 
reported [56]. Furthermore, mice genetically engineered to constitutively overexpress Sirt1 
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metabolically resemble WT mice fed a CR diet, whilst also exhibiting the same enhanced glucose 
tolerance and reduced insulin level which is characteristic of a CR regimens [57]. 
1.1.3 SIRT1  
The sirtuin (silent mating type information regulation 2 homolog) family of enzymes (Table 1.1.3.1) 
are the mammalian homologues of yeast Sir2, with its orthologue SIRT1 in particular attracting 
significant attention for its purported role as a potential regulator of the ageing process.  This 
attention began when it was discovered that the SIR2 gene extended lifespan in yeast [58] and was 
essential for the lifespan enhancing effects of CR [16]. The excitement surrounding SIRT1 was further 
amplified when overexpression of SIR2 orthologs in Drosophila [55, 59], C. elegans [2] and mouse 
neurons [60] resulted in significant lifespan extension. Furthermore, the discovery of small molecule 
SIRT1/Sir2 activators which also mediated lifespan extension in the same model organisms [61-64] 
gave hope that SIRT1 could be pharmacologically targeted with similar effects in humans. 
Alternatively, a number of studies refuted the central importance of SIRT1/Sir2 as regulators of 
longevity, whereby upregulation of their expression failed to enhance lifespan [65-67]. Hence, just 
how important SIRT1 is in human ageing remains a point of contention in the biogerontology field.  
SIRT1, similar to the majority of the sirtuins, functions as a deacetylase which targets acetylated 
residues on histones and other protein substrates, allowing it to modulate a wide array of cellular 
processes. The deacetylation is a hydrolytic reaction requiring NAD+, with O-acetyl-ADP-ribose and 
nicotinamide yielded as by-products. In vitro, nicotinamide functions as a non-competitive inhibitor 
of SIRT1 [68] and thus prevents overactivation of SIRT1 via a negative feedback loop - potentially a 
mechanism to prevent rapid depletion of NAD+ reserves via excessive SIRT1 activity. It should be 
noted however that the inhibitory effects of nicotinamide on SIRT1 activity have yet to be 
demonstrated in vivo. 
 Importantly, NAD+ is the rate-limiting cofactor for SIRT1 activity, with the age-dependent decrease 
in NAD+ believed to drive the impaired SIRT1 activity that also occurs with increasing age [69, 70]. 
Given SIRT1 exerts regulatory control of glycolysis [71, 72] and OXPHOS (oxidative phosphorylation) 
[56, 73] (the two metabolic processes which are key determinants of the redox status of the cellular 
NAD+ pool), it appears plausible that NAD+ levels represent the fulcrum point in a bidirectional 
relationship between SIRT1 activity and energy metabolism.   
As mentioned already a key substrate of SIRT1 are acetylated histone residues, with H4 lysine 16 
(H4K16), H3 lysine 9 (H3K9), H3 lysine 14 (H3K14) and H1 lysine 26 (H1K26) particularly prominent 
targets [74-76]. By inducing histone deacetylation this allows tighter packing of DNA, thus impairing 
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the accessibility of promoter regions to transcription factors. Consequently, SIRT1 generally 
functions as a transcriptional repressor.  
The cellular acetylation profile or ‘acetylome’ is another example of the bidirectional relationship 
between SIRT1 activity and energy metabolism, not just via NAD+-fuelled deacetylation but also in 
this instance the availability of acetyl CoA which is the acetyl group donor for most acetyltransferases 
and thus SIRT1 antagonists [77]. During what would be considered a well-fed physiological state (no 
calorie deficit), acetyl CoA accumulates via glycolysis and is subsequently utilised for lipid synthesis 
in the cytoplasm or histone acetylation in the nucleus. Such conditions are also associated with lower 
NAD+ and therefore lower SIRT1 activity, further promoting higher levels of acetylation. Conversely, 
the activation of starvation mode via calorie restriction forces energy metabolism to attain optimal 
efficiency [78] – hence higher levels of OXPHOS at the expense of glycolysis. This increases the 
shuttling of acetyl CoA into the TCA (tricarboxylic acid) cycle within the mitochondria, in turn yielding 
more intermediates that can be used for respiration. As a consequence, cytoplasmic and nuclear 
acetyl CoA levels are significantly reduced thus impairing histone acetylation, an effect exacerbated 
by increased NAD+ from elevated OXPHOS, which consequently enhances SIRT1 activity and thus 
further histone deacetylation. 
In addition to histones, a number of transcription factors are important targets of SIRT1 which 
underpins its ability modulate such a large range of pathways [79-81]. One substrate of particular 
interest is the critical tumour suppressor protein P53 (tumour protein P53), often referred to as ‘the 
guardian of the genome’. This is a reference to its prominent role in co-ordinating the response to 
DNA damaging stimuli, during which it initiates cell cycle arrest and activation of the DDR (DNA 
damage response) pathway [82]. Furthermore, P53 represents a vital obstacle to tumour 
development: not only does it stall the cell cycle to facilitate DNA repair, but it also activates 
apoptosis when the DNA damage is too severe, thus preventing the proliferation of potentially pro-
tumourigenic cells. Indeed, its importance as a tumour suppressor is highlighted by the presence of 
P53 mutations in over 50% of cancers [83].  
Under normal circumstances, the expression of P53 is kept at very low levels to ensure its activation 
of cell cycle arrest and apoptotic pathways only occurs when absolutely necessary, with this control 
largely exerted by MDM2 (murine double minute 2) which binds P53 and signals for its degradation 
via ubiquitination [84, 85]. However, in response to DNA damaging stimuli the MDM2 mediated 
inhibition is relieved and P53 levels rapidly accumulate in the nucleus, with other post-translational 
modifications taking the place of MDM2 in eliciting tight control of P53 activity. Multiple lysine 
residues on P53 can become acetylated in response to stressors, resulting in increased stability by 
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preventing the addition of degradation signalling ubiquitin chains whilst also causing a 
conformational change which enhances its DNA binding affinity – hence acetylation strongly 
promotes P53 activation [86, 87].  
CBP/P300 [88], TIP60 [87] and hMOF [89] are well established acetyltransferases that target P53, 
whereas SIRT1 [90, 91] and the PID/HDAC complex [92] are the known deacetylases. Thus, at face 
value it would seem likely that SIRT1 represses P53 induced apoptosis, and whilst largely true, this 
isn’t always the case. Under conditions of increased intracellular ROS (reactive oxygen species), 
SIRT1 deacetylation of P53 prevents P53 localisation to the nucleus [93] and hence prevents 
transcriptional upregulation of pro-apoptotic factors. On the other hand, SIRT1 activity in the 
presence of persistently high intracellular ROS leads to an accumulation of cytoplasmic P53 which 
can eventually result in P53 translocation into the mitochondria, inducing apoptosis via 
mitochondrial membrane depolarisation [93].  
The inhibitory effects of SIRT1 on P53 are somewhat of a double-edged sword however, with 
increased SIRT1 expression or dependency on SIRT1 activity identified in a number of cancers [94-
99] – possibly due to its antagonism of P53 activity. The potential pro-tumourigenic effects of SIRT1 
are further emphasised by the efficacy of the specific SIRT1 inhibitor Sirtinol at inducing growth 
arrest in both breast and lung cancer cells in vitro [100]. It is important to acknowledge that SIRT1 
has also been widely implicated as being anti-tumourigenic [101-104], highlighting the extremely 
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Table 1.1.3.1 The mammalian sirtuin family. 
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1.1.4 PARP1   
Like SIRT1, PARP1 (poly-ADP ribose polymerase 1) requires NAD+ for its enzymatic activity, however 
it utilises NAD+ to synthesis ADP ribose subunits which it adds to protein substrates as a multi-subunit 
poly-(ADP ribose) (PAR) chain [129]. Its primary function is the recruitment of DNA repair enzymes 
to sites of single strand DNA breaks, facilitating both BER (base excision repair) and NER (nucleotide 
excision repair) [130]. Indeed, the central role for PARP1 in the repair of single strand breaks has 
been exploited to treat BRCA1 and BRCA2 deficient breast cancer tumours which have impaired 
repair of double strand breaks via homologous recombination (HR). By inhibiting PARP1, single 
strand breaks become double strand breaks which cannot be repaired properly within the tumour 
tissue due to the impaired BRCA1/BRCA2 function, thus killing the cancer cells, whereas healthy cells 
are protected due to their possession of a functional BRCA dependent HR pathway [131]. 
Given that every day a typical mammalian cell experiences thousands of DNA lesions, PARP1 plays 
an integral role in supporting the maintenance of genomic stability. Upon detection of a single strand 
break via its zinc finger, PARP1 undergoes auto ADP-ribosylation which recruits repair enzymes such 
as the scaffold protein XRCC1 and ligase III to the site of the damage and thus initiates the repair 
process [132]. The DNA damage checkpoint protein ATM is also recruited by the presence of PAR 
chains, thus inducing cell cycle arrest and initiating the DDR pathway. To prevent unnecessary cell 
cycle arrest/DDR activation PAR subunits are rapidly degraded by PARG (Poly ADP-ribose 
glycohydrolase) [133], thus returning PARP1 to its regular conformation such that it can carry on 
surveying the genome for other DNA lesions. 
As an NAD+ dependent enzyme however, it has been theorised that PARP1 and other NAD+ 
consumers such as SIRT1 are competing with each other for a limited supply of NAD+, hence an 
increase in the activity of PARP1 could reduce the activity of SIRT1, or at least its potential to function 
at maximum capacity. Similarly, the opposite would hold true – excessive SIRT1 activity would limit 
the NAD+ availability for PARP1 activity.  This hypothetical competition between PARP1 and SIRT1 
would become further intensified with increasing age given the age-related decline in NAD+ and 
increase in DNA damage [134-136].  
If PARP1 and SIRT1 do indeed exist in an NAD+-dependent equilibrium, then this suggests another 
mechanism by which age related accumulation of DNA damage could contribute to ageing: 
overactivation of PARP1 which hinders the activity of SIRT1. Given both enzymes perform essential 
functions (Figure 1.1.4.1), from a healthspan-promoting perspective it would be hard to justify 
inhibition of PARP1 for the purpose of enhancing SIRT1 activity or vice versa. This therefore suggests 
the optimal approach would be to ensure maintenance of high cellular NAD+ levels, such that 
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upregulated PARP1 and SIRT1 activity can both be supported without compromising the capacity of 
the other.  
1.1.5 CD38 
CD38 (Cluster of differentiation 38) is a cell surface molecule which although ubiquitous [137], is 
particularly highly expressed in immune cells where it functions as a cyclic ADP ribose hydrolase. The 
major reaction catalysed by CD38 is the hydrolysis of NAD+ to yield ADPR and nicotinamide, although 
it also converts a small amount of ADPR to cyclic-ADPR via a cyclase reaction [138]. Additionally, 
CD38 can also catalyse the production of NAADP from NADP and nicotinic acid (NA), which like 
cADPR and ADPR plays an important role as a second messenger in calcium signalling.  
CD38 catalysis is renowned for being highly inefficient, requiring approximately 100 molecules of 
NAD+  per molecule of ADPR generated [139], hence it has been widely posited that inhibition of 
CD38 could be an attractive intervention to enhance NAD+ levels. Its ability to activate calcium 
signalling is known, however although thought to be related to immune regulation, the exact 
physiological role CD38 fulfils is poorly understood.  The idea that its function may be dispensable is 
largely borne out of the observed improvement in the mitochondrial function of CD38-/- mice 
without any reported adverse effects [140]. Moreover, Camacho-Pereira et al. also show that CD38 
expression drastically increases in multiple mouse tissues with age, which combined with their 
observation that CD38-/- mice are protected from age-related NAD+ decline [140] frames CD38 as a 
potentially key driver of decreasing NAD+ levels. Additionally, these findings are corroborated by a 
study whereby mice were treated with the specific CD38 inhibitor 78c [141] which enhanced NAD+ 
in multiple tissues. 
 It’s worth noting that the CD38 homologue CD157 is also likely to contribute to NAD+ degradation, 
however whilst it exhibits NAD+ hydrolysis it has a much higher affinity for NR (nicotinamide riboside) 
as a substrate which it converts to nicotinic acid riboside (NAR) [142]. Hence, it may be that high 
levels of CD157 lower NAD+ levels by depriving NR from entering the salvage pathway rather than 
hydrolysing NAD+. An inhibitor of CD157 has been characterised [143], however to date there has 
been no investigation into the efficacy of inhibiting CD157 in vivo as an intervention to increase NAD+ 





NAD+ is best known for its role as an essential intermediate in energy metabolism where it functions 
as a substrate for glycolysis and the TCA cycle, undergoing reduction to NADH such that it can then 
transport electrons to complex I in the electron transport chain (ETC) and become oxidised back to 
NAD+ (Figure 1.1.6.1). Consequently, the ratio of NAD+/NADH generally reflects the balance between 
the two main energy producing pathways glycolysis and OXPHOS, with comparatively higher levels 
of OXPHOS generating more NAD+, whereas a shift towards glycolysis and away from OXPHOS driven 
energy production increases the conversion of NAD+ to NADH. With regards to their efficiency at 
producing ATP, OXPHOS is far more optimal – generating 30-36 ATP molecules per cycle, compared 
to glycolysis’ net gain of 2 molecules per cycle. This enhanced efficiency means under typical 
conditions approximately 95% of cellular energy is yielded by OXPHOS. However, this places a 
 
Figure 1.1.4.1 Cellular NAD+ metabolism.  
NAD+ homeostasis is controlled by multiple intracellular processes. The intermembrane proteins CD157 and 
CD38 utilise NAD+ for ADPR synthesis in the cytoplasm, whilst it is regenerated by complex I during 
mitochondrial respiration (purple compartment). In the nucleus (green compartment) NAD+ is an essential 
cofactor for SIRT1, a deacetylase responsible for regulation of P53 stability and transcription via the acetylation 
status of histones H3 and H4. Additionally, nuclear NAD+ facilitates PARP1 auto-poly(ADPR)-ribosylation, a key 
step in activating repair of DNA damage in response to lesions induced by ROS.  
 
Abbreviations: I, II, III, IV and V – complexes I, II, III, IV and V, ADPR – adenosine phosphate ribose, H3/4 – 





significant burden on the enzymes which facilitate OXPHOS as part of the ETC, found embedded 
within the inner mitochondrial membrane. It has been well established that analogous to a car 
engine, with increasing age damage accumulation causes a reduction in the power output of 
mitochondria and thus their ability to generate ATP in an efficient manner is weakened. This is 
reflected by decreased NAD+ and increased NADH levels, with reduced OXPHOS driving the 
equilibrium back towards glycolysis [144], thus increasing the dependency on an inferior ATP 
producing pathway which manifests as an age-related decline in ATP.  
It seems probable that in addition to functional impairments in elderly mitochondria, other age-
related processes also contribute to NAD+ depletion, thus exacerbating the problem of reduced 
mitochondrial function by depriving it of its key energy precursor. This therefore has become a 
central area of focus within biogerontology – how can the age-related decline in mitochondrial 
function be protected against or even reversed? Whilst enhanced NAD+ levels would seem a 
beneficial approach, this only addresses one aspect of the problem, akin to providing an improved 
fuel source to an engine that is still old and rusty. Indeed, this reflects the sobering reality of the 
quest for genuine anti-ageing interventions, which will need to target multiple cellular pathways in 
order to be truly effective. 
As already discussed, in addition to its role as an essential energy intermediate, NAD+ is also a 
cofactor for a number of enzymes: namely PARP1-2, the sirtuins and CD38. Similar to OXPHOS, in 
the context of ageing their collective relationship with NAD+ is bidirectional in the sense that reduced 
NAD+ impairs the activity of SIRT1, thus impairing antioxidant defence systems and creating an 
environment more susceptible to DNA damage, resulting in PARP1 activation and further NAD+ 
depletion. 
As a consequence of this dual role as both an energy intermediate and an enzyme cofactor it links 
the two together: activity of the NAD+ dependent enzymes is affected by energy metabolism via its 
regulation of the NAD+/NADH balance, whilst NAD+ dependent enzymes also influence energy 








 Figure 1.1.6.1 Glycolysis, OXPHOS and the TCA cycle. 
The 3 main ATP producing pathways within eukaryotes are depicted. Every molecule of glucose that undergoes 
glycolysis yields 2 molecules of pyruvate. During aerobic respiration, i.e. when pyruvate is converted to acetyl CoA as 
opposed to lactate, the successive breakdown of glucose by glycolysis and then 2 molecules of pyruvate via the TCA 
cycle produces a net gain of 9 NADH and 2 FADH2 per glucose. These can then donate electrons to the electron 
transport chain (ETC) which induce transient conformational changes as they pass through the complexes, creating 
an electrochemical gradient. The electrochemical gradient drives the catalytic activity of complex V (C V) which then 
produces ATP. Via this mechanism, each NADH and FADH2 yield 2.5 and 1.5 molecules of ATP respectively, resulting 
in an approximate net gain of 28 ATP per glucose molecule metabolised by glycolysis and the TCA cycle. 
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1.2 NAD+ As an Anti-Ageing Therapeutic 
1.2.1 Interventions to Increase NAD+ 
Given the inability of NAD+ to cross the plasma membrane due to its bulky size, efforts to increase 
cellular NAD+ in human studies have focused on the use of precursors. It should be noted, that whilst 
it is generally accepted that circulating NAD+ is unable to enter cells, there may be some tissue 
dependent exceptions – e.g. the finding that NAD+ was able to cross the blood brain barrier and 
enter neurons via a mechanism dependent on the transmembrane protein connexin-43 [145].  
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are the precursors that have 
been most widely investigated for their ability to enhance NAD+, with both currently marketed as 
commercially available ‘anti-ageing’ treatments. Intensified by the apparent commercial value of 
effective NAD+ enhancers, which precursor represents the superior option is a hot topic of debate.  
Ratajczak et al. found that NMN was unable to enhance NAD+ levels in mice lacking the Nrk1 gene 
which converts NR to NMN [146], suggesting that NMN must first be converted to NR extracellularly 
prior to entering cells. This was further supported in the same study by in vitro radiolabelling 
experiments which found that treating HepG2 cells with labelled NMN caused a sudden spike in 
extracellular NR containing the label, suggesting that an extracellular protein must be converting 
NMN to NR before uptake. The authors implicate CD73, an enzyme previously shown to hydrolyse 
NMN to NR and adenosine. Recently this was countered however by Grozio et al. who discovered an 
NMN transporter in mouse cells and tissue named Slc12a8 [147]. Although a human homologue 
exists its expression hasn’t been characterised for different human tissues, hence it may be that 
NMN is directly taken up by some cell types whereas others first require its conversion to NR.  
Outside the focus on NR/NMN, the alternative NAD+ precursors nicotinic acid (NA) and nicotinamide 
(NAM) have both also shown an excellent ability to enhance NAD+ in human studies [148-151], 
however as a side effect the former causes severe flushing hence is only recommended in the 
treatment of pellagra (a disorder caused by vitamin B3 deficiency) and dyslipidemia. Indeed, 8 weeks 
taking 100mg of daily NA supplementation accounts for the largest published increase in human 
NAD+ within a healthy multiple person cohort, reported at 575% of the baseline value [148]. 
Interestingly, this study also found that NAD+ levels gradually increased over the 8-week treatment 
period, which is surprising given the expectation that the NAD+ synthesis and recycling pathways 
would become less efficient by way of de-sensitisation to the increasing precursor availability. It’s 
worth noting only 2 participants were used however and a later study found that the same daily 
dosage of NA only mildly enhanced NAD+ [149], an effect limited to participants who began the study 
with low NAD+ levels. The latter study only measured NAD+ before and after a 14-week period, hence 
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it is possible that the less emphatic results were due to de-sensitisation to the NA over this much 
longer treatment period. 
The largest human increase in NAD+ reported for NR is approximately 217% [152], significantly less 
than that for NA, although the caveats concerning this study have been discussed. On the other 
hand, no data on the efficacy of NMN at enhancing NAD+ in humans has been reported, however it 
has been shown to be effective at raising NAD+ in mice, with increases as high as 3-fold reported in 
mouse aorta [153]. Recently, the novel precursor dihydronicotinamide riboside (NRH) was tested for 
its ability to enhance NAD+, producing remarkable results in mice. 48 hours after an intraperitoneal 
injection of NRH dissolved in PBS, NAD+ levels rose 2.4 fold in blood, 2.2-fold in the brain and 5.4 fold 
in liver tissue [154]. By comparison, injections of NR and NMN only increased liver NAD+ 1.3 and 1.5-
fold respectively in the same study [154]. 
Another novel compound recently emerging as a potential NAD+ enhancer is the hypolipidemic 
treatment acipimox, which is a derivative of NA that lacks the flushing as a side effect. Although the 
authors made no mention of its effect on NAD+ levels in vivo, acipimox was shown to increase ATP 
content, ETC protein levels and the expression of a number of genes downstream of NAD+ 
metabolism in muscle tissues from type 2A diabetes patients receiving the treatment [155]. 
Additionally, they also showed that acipimox enhanced NAD+ levels in cultured C2C12 myoblasts. 
These promising results provided the stimulus for an ongoing clinical trial investigating the efficacy 
of acipimox at improving muscle symptoms in a subset of mitochondrial disease patients (AIMM - 
Acipimox in Mitochondrial Myopathy Study).   
Being such a prominent and inefficient NAD+ consumer, it is surprising that inhibition of CD38 as a 
strategy to increase NAD+ has received relatively modest attention compared to precursor 
supplementation. Notable findings thus far include the ability of the CD38 inhibitor apigenin to 
approximately double NAD+ in liver tissue from mice fed a high fat diet [156]. Additionally, as already 
discussed, 78c is a pharmacological CD38 inhibitor which has been shown to significantly enhance 
NAD+ in mouse liver, skeletal muscle and spleen tissue [141]. Hence, an intervention combining both 
CD38 inhibition and precursor supplementation would appear to represent a promising multi-
targeting strategy to increase NAD+ enhancements. 
Indeed, one problem with an approach taken to increase NAD+ that solely focuses on precursors is 
that it neglects the underlying mechanisms which have caused NAD+ depletion. Consequently, 
therapeutics that target CD38 driven depletion, aberrant energy metabolism and dysregulation of 
the NAD+ synthesis/recycling pathways should theoretically represent a superior alternative as they 
tackle the root causes of decreased NAD+, rather than looking for a quick fix. If it is the altered levels 
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of specific proteins that is driving decreased NAD+ it is likely these will also limit the efficacy of 
precursor supplementation, perhaps explaining why the likes of NR and NMN have failed to induce 
the kind of increases that would restore the NAD+ levels of a 60 year-old to say that of a 20 year-old. 
As a result, the utility of a multi-targeted approach is becomingly increasingly appreciated and may 
pave the way for interventions with an enhanced ability to restore cellular NAD+ to optimal levels. 
1.2.2 Benefits of Enhanced NAD+ in Disease Models  
Given the widespread focus of NAD+ enhancement is to promote healthy ageing, combating age-
related diseases also pertains to this objective. To this end, NAD+ targeted interventions have been 
implemented in a wide range of age-related disease models. In particular, the increasing incidence 
of Alzheimer’s disease (AD) in western societies has placed a strong emphasis on investigating the 
disease-modifying properties of NAD+ enhancement in AD and other models characterised by 
progressive cognitive decline [157-162]. 
One mutant which demonstrates the possible benefit of enhanced NAD+ in the context of 
neurological disease is the remarkable spontaneous Wlds mouse mutant, which due to a tandem 
DNA triplication overexpresses a chimeric protein containing the first 70 amino acids of the 
ubiquitination protein UBE4B linked to the full NMNAT1 protein [163, 164]. Transection of neurons 
derived from Wlds mice in vitro exhibit a large delay to the development of axonopathy compared 
to wild-type mouse neurons, with a mutation introduced into the NMNAT1 portion of the WLDs 
chimeric protein ablating the delayed axonopathy. Furthermore, NA, NAM and NR have all been 
shown to delay axonopathy induced in vitro, although the former two required the concomitant 
overexpression of NAD+ salvage pathway genes [165].  
NAD+ precursor supplementation has also been shown to improve neurological function in a number 
of AD models, with oral and nanoparticle-mediated delivery of NAM able to profoundly reverse 
cognitive and histopathological markers of AD [166-168]. In transgenic mice overexpressing amyloid 
precursor protein (APP), supplementation with NMN attenuated changes to the levels of 
mitochondrial fusion/fission proteins, reduced APP levels and improved mitochondrial function in 
brain tissue homogenates [169]. In the same model, a different study found NMN potently reduced 
hippocampal and cortical amyloid beta levels, prevented the appearance of diffuse plaques and 
improved the performance of the transgenic mice at memory tests [162]. NR supplementation had 
a similar outcome in the Tg2576 mice AD model, with 3 months consumption found to reduce 
amyloid beta fibrils, improve synaptic plasticity and promote mitochondrial gene expression [170]. 
Hence, evidence is accumulating that NAD+ precursors can prevent the defining features of AD 
pathology in rodent models. 
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Aside from AD mice, the benefits of increased NAD+ for mitochondrial function is further highlighted 
by the ability of NMN to enhance lifespan by 90% in a mouse mitochondrial disease model of Leigh 
Syndrome [171], although it’s important to note that NAD+ levels were only enhanced in cardiac and 
skeletal muscle and not brain tissue. Additionally, the murine Sco2KOKI mitochondrial disease model 
showed improvements in motor performance, ETC gene expression and skeletal muscle NAD+ levels 
in response to supplementation with NR, whilst PARP1 inhibition also improved motor performance 
and mitochondrial function in skeletal muscle [172]. Deletor mice resemble adult‐onset 
mitochondrial myopathy (MM) and thus exhibit progressive muscle dysfunction, which occurs due 
to the accumulation of mtDNA (mitochondrial DNA) deletions resulting from a mutation present in 
the mitochondrial replicative helicase Twinkle. These mice were also shown to benefit from NR 
treatment as a result of rejuvenated mitochondrial function [173], whereby the accumulation of 
mtDNA deletions and morphologically abnormal mitochondria was inhibited. On the back of these 
promising results the same group conducted a recently completed clinical trial using NAM in MM 
patients [151], with another trial once again using NAM in an MM cohort currently ongoing 
(NCT04538521). 
NR has also displayed an impressive ability to preserve hepatic function in mice with diet induced 
liver fibrosis [174, 175]. Particularly noteworthy was the discovery that in mice fed ethanol daily, NR 
was able to attenuate multiple markers of liver damage, increase liver NAD+ levels by over 300% and 
restore both mtDNA and SIRT1 levels to those in the non-ethanol treated littermates [176]. NR also 
exerted a similarly protective effect against age related liver pathology in elderly mice, significantly 
reducing levels of the liver damage marker AST (aspartate transaminase) whilst also dramatically 
improving steatosis scores [177]. Thus, from the findings in various animal models it appears the 
protection against age-related pathologies via enhanced NAD+ extends to multiple different tissues. 
1.2.3 NAD+ Interventions as an Anti-Ageing Approach in Model Organisms 
In a number of organisms there is mounting evidence that both manipulating enzymes involved in 
NAD+ metabolism and precursor supplementation can extend lifespan and healthspan. Although 
Drosophila lack a homologue of NAMPT, D-NAAM (Drosophila nicotinamidase) is an enzyme which 
converts NAM to NA, a critical step in Drosophila NAD+ synthesis. In addition to increasing the 
NAD+/NADH ratio, overexpression of D-NAAM also increased lifespan by 30% [178]. This increase 
was absent in Sir2 mutants, hence implying increased Sir2 activity via enhanced NAD+ is fuelling the 
long-lived phenotype.  
Further evidence for SIRT1/Sir2 mediated lifespan extension via increased NAD+ is provided by C. 
elegans fed with NR and NAM or treated with pharmacological PARP inhibitors. Both interventions 
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enhanced NAD+ levels and longevity in C. elegans, however the lifespan extension was once again 
absent in sir-2.1 mutants [179]. 
In contrast, there is no evidence for significant lifespan extension in healthy mammalian organisms 
chronically supplemented with NAD+ precursors, which has been sparsely investigated aside from 
one study noting a 5% lifespan increase in mice consuming NR [180]. However, this study also found 
6 weeks of NR treatment improved physical endurance, mitochondrial function and replenished 
muscle stem cell levels in elderly mice – highlighting a positive effect of NR supplementation on 
healthspan, if not longevity. 1 week of ingesting NMN was also shown to have a similar effect in aged 
mice by reducing muscle atrophy, upregulating mitochondrial biogenesis and stimulating OXPHOS 
[181]. 
Furthermore, a longer term 12-month NMN supplementation regime in mice beginning at 5 months 
resulted in a remarkable attenuation of all age-related physiological changes measured, including: 
energy metabolism, serum lipid profile, weight gain, insulin sensitivity, mineral bone density and 
skeletal muscle mitochondrial respiration [182].  
NMN was also found to induce remarkable improvements to the exercise capacity of elderly mice, 
with two months of NMN supplementation restoring the capillary density of 20-month old mice to 
that of 6-month old mice, whilst also resulting in a 56-80% increase in the distance covered by the 
elderly mice on a treadmill when running to exhaustion [183]. Moreover, these benefits of NMN 
supplementation were absent in Sirt-/- mice, suggesting NMN is mediating these effects through 
increased SIRT1 activity. The recent literature therefore implies that NMN can improve the muscular 
and vascular capacity of elderly mice by restoring mitochondrial function – indicative of enhanced 
healthspan. 
Accelerated ageing models resembling the human diseases ataxia telangiectasia (AT) and Werner 
syndrome (WS) provide a useful tool for testing the efficacy of potential anti-ageing interventions. 
Both AT and WS are genetic disorders resulting from mutations to key DNA repair genes [184, 185], 
thus resulting in a faster rate of DNA damage accumulation which translates to an accelerated ageing 
phenotype. NR and NMN were both able to restore lifespan in C. elegans AT and WS models to wild-
type levels [186, 187], with 14 days of NR treatment also able to dramatically improve lifespan in an 
AT mouse model [187]. Lymphoma is over-represented in AT patients [188], thus it would be useful 
to determine how NAD+ mediated lifespan increase in AT mice influences lymphoma incidence.  
Aside from precursor supplementation, pharmacologically targeting CD38 activity has also proven 
successful at attenuating various ageing biomarkers in elderly mice using the specific 
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thiazoloquin(az)olin(on)e CD38 inhibitor 78c. As well as increasing NAD+ in multiple tissues, 78c 
improved glucose tolerance, lowered insulin and improved various exercise parameters. In skeletal 
muscle from the aged mice the authors found that 78c reduced DNA damage, dampened the 
expression of various genes associated with fibrosis and inflammation and increased lysine 
acetylation, a marker of SIRT1 activity [141]. The efficacy of 78c is a particularly useful development 
given the other known CD38 inhibitors apigenin and quercetin are undermined by low bioavailability.  
1.2.4 A darkside to NAD+? 
Whilst the efforts to identify NAD+ enhancing strategies intensifies, it’s important to consider the 
potential drawbacks of increased NAD+ under certain circumstances: highlighted by the elevated 
NAD+ levels found in various cancer cells due to increased expression of the rate-limiting NAD+ 
salvage pathway enzyme NAMPT [189, 190]. 
 Regarding NAD+ synthesis/recycling pathways, NAMPT in particular has garnered attention for its 
pro-tumourigenic function, with its expression shown to negatively correlate with survival in 
multiple different cancers [189, 191, 192]. Moreover, targeting NAMPT with the small molecule 
inhibitor FK866 has shown potent anti-cancer effects in both in vitro and in vivo models [193-196], 
prompting its use in phase I and II clinical trials [197, 198] albeit without a favourable outcome 
despite being well-tolerated. One mechanism by which NAMPT inhibition was shown to specifically 
kill breast cancer cells lines was the stabilisation of the SIRT1 target p73, due to an increase in its 
acetylation [199]. It has also been suggested that impairment of antioxidant defence systems due to 
depleted NAD+ may make cancer cells highly susceptible to the abundance of ROS they produce 
[200], outlining another reason cancer cells require an adequate supply of NAD+. 
On the other hand, some studies implicate an anti-tumorigenic role for increased NAD+, for example 
the finding that increased SIRT1 activity suppressed tumour formation in a mouse model of colon 
cancer via downregulated β-catenin signalling [104]. Additionally, mitochondria specific increases in 
NAD+ impaired the clonogenicity and thus the tumour forming potential of glioblastoma tumour-
initiating cells, which the authors speculated may be due to increased SIRT3 activity [201]. 
NAMPT has also been framed as a driver of cellular senescence, with oncogene induced senescence 
in IMR90 cells shown to coincide with increased NAMPT expression and NAD+ levels [202]. NAMPT 
inhibition using FK866 or shRNA knockdown suppressed development of the SASP (senescence 
associated secretory phenotype) in this model, with the downstream upregulation of OXPHOS and 
glycolysis shown to be key to NAMPT’s pro-senescent effects. NAMPT can also be found 
extracellularly where it’s suspected to primarily function as a cytokine, often referred to as visfatin 
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or eNAMPT (extracellular NAMPT). Villalobos et al. showed that the presence of elevated eNAMPT 
in culture media potently induces senescence in human umbilical vein endothelial cells (HUVEC) in a 
dose-dependent manner [203]. Interestingly, they found FK866 attenuated these effects whereas 
NMN (the product of NAMPT activity) also promoted senescence. This implies eNAMPT must either 
become intracellular to elicit pro-senescent effects or perhaps does so via the extracellular 
conversion of NAM to NMN. 
The notion that NAMPT is pro-senescent is controversial however, with other studies presenting 
contrasting findings. For example, FK866 was shown to induce senescence in young mesenchymal 
stem cells (MSCs) [204, 205], whilst overexpression of NAMPT using a lentiviral vector protected 
MSCs derived from old mice against senescence [204]. FK866 was also shown to induce senescence 
in human vascular smooth muscle cells (SMCs) [206], with induced overexpression of NAMPT once 
again found to suppress replicative senescence. Consequently, the jury is still out on the role of 
NAMPT and NAD+ levels in the development of senescence which is likely to be nuanced and tissue 
dependent. It should be noted that all the studies referenced have only investigated the role of 
NAMPT in senescence using in vitro models, hence results from in vivo studies are needed to better 
characterise the involvement of NAMPT and NAD+ in senescent pathways. 
Although enhanced NAD+ would generally be considered beneficial for physical performance via 
improved mitochondrial function, one study found that NR supplementation decreased exercise 
performance in rats [207]. Furthermore, the NR treated rats had higher levels of the oxidative stress 
marker F2-isoprostane, combined with lowered levels of a number of antioxidant enzymes [208]. The 
authors attributed these adverse effects of NR to their use of young healthy rats, suggesting that 
supplementation with NAD+ precursors should be reserved for the elderly. Contrastingly, Canto et 
al. found that consumption of NR resulted in a small but non-significant increase in VO2max (maximal 
oxygen uptake during exercise) of young mice [89]. They did find however that NR significantly 
improved the VO2max in mice fed a high fat diet, therefore re-iterating that the beneficial effects of 
enhanced NAD+ may be limited to ageing/disease conditions. 
1.3 Circadian Rhythms 
1.3.1 Circadian Regulation of Biological Processes 
In order to utilise physiological resources more efficiently, mammals have developed a regulatory 
system whereby certain pathways follow a 24-hour pattern of varying levels of activity. The classical 
example is circulating levels of the sleep promoting hormone melatonin, which for someone with a 
typical sleep wake cycle is present at very low levels around the usual waking hours, before gradually 
increasing in the late afternoon and reaching a peak around bed-time [209]. Thus, circadian control 
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means the sleep promoting effects of melatonin are only experienced around the time sleep is 
required, whereas they’re absent when the body needs to be awake and alert. Furthermore, 
melatonin can regulate multiple cellular pathways throughout the body by binding to melatonin 
receptors, thus allowing physiological processes like blood pressure, thermoregulation and 
metabolism to be co-ordinated to the light-dark cycle and by extension our daily routine. 
This rhythmicity of melatonin release and indeed other hormones which follow a 24-hour pattern is 
controlled by the suprachiasmatic nucleus (SCN), a tiny structure within the hypothalamus which 
receives direct input from optic nerves. This input of photosensory information allows entrainment 
of the SCN such that it uses the 24-hour light dark cycle as a compass for the 24-hour period. This 
also allows it to be ‘re-calibrated’, for example if moving to a different timezone. In addition to 
melatonin, there is evidence that the SCN regulates the daily fluctuations of other hormones such 
as leptin, ghrelin, cortisol, growth hormone and insulin [210]. The circulating levels of these 
hormones can then themselves regulate processes within peripheral cells, therefore acting as an 
intermediary by which circadian control is transmitted from the SCN to other tissues. 
In addition to input from the SCN, it appears most cells have an endogenous regulatory clock which 
is synchronised by signalling from the SCN – in a similar way to how the SCN is calibrated by the 
external light-dark cycle. At the molecular level, the clock in both SCN cells and those in the periphery 
is regulated by a core group of enzymes: BMAL1, CLOCK, PER1, PER2, CRY1, CRY2, REV-ERBα and 
REV-ERBβ [211-214]. These comprise a feedback loop in which BMAL1 and CLOCK form a 
transcriptionally active dimer which can promote transcription of genes with an E-box containing 
promoter [215]. Amongst the genes whose expression is upregulated are PER1/2 and CRY1/2 which 
function as transcriptional repressors of BMAL1 and CLOCK [216], thus completing a negative 
feedback loop which underpins the rhythmicity of all genes under circadian control. 
1.3.2 Circadian Rhythms and Ageing 
It’s well established that circadian rhythms change with age, which explains the shift in sleep 
patterns of the elderly who tend to sleep and wake at earlier times [217, 218]. Additionally, the 
oscillations of core body temperature [219, 220], time of optimal cognitive performance [221-223] 
and circulating cortisol [224, 225] have also been shown to change with age, emphasising the 
widespread effects of altering the circadian cycle. In mice ablation of the Bmal1 gene [226] or 
mutations in Clock [227] and Per2 [228] were capable of promoting a pro-ageing phenotype, whilst 
in humans irregular sleeping patterns caused by shift work have been associated with an increased 
risk for age-related illnesses such as cancer [229-231] and cardiovascular disease [232].  
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At the molecular level, a number of genes implicated within the ageing process are known to be 
under circadian control, including SIRT1, PARP1 and NAMPT [233]. The circadian regulation of 
NAMPT has been shown in mouse liver tissue to result in a daily oscillation of intracellular NAD+ 
[234], hence SIRT1 and PARP1 activity would be expected to mirror this oscillation under conditions 
of rate-limiting NAD+. Consequently, the ability of cells to initiate an anti-inflammatory, antioxidant 
or DNA damage response via SIRT1 or PARP1 may be affected by the time of day, especially in the 
elderly.  
As well as being under circadian control, SIRT1 itself has been implicated as a key regulator of the 
circadian clock through its ability to promote BMAL1 activity via deacetylation which prevents the 
binding repressors like PER2 and CRY1/2 [234]. Ramsey et al. also showed that the BMAL1:CLOCK 
dimer upregulated NAMPT expression in mouse liver samples and MEFs [234], thus identifying a 
positive feedback loop whereby BMAL:CLOCK enhance NAD+ through NAMPT which increases SIRT1 
activity, subsequently increasing BMAL1:CLOCK promoter binding and completing the loop (Figure 
1.3.1).  
This provides a molecular basis for a putative mechanism by which declining NAD+ levels could 
modify circadian rhythms with age. Of course, if BMAL1 and NAD+ comprise a feedback loop then 
the reverse may also be true if BMAL1 expression decreases with age, as has been suggested by the 
finding that white blood cell BMAL1 mRNA levels decreased with age in healthy females [235]. At 
the endocrine level the ability of the pineal gland to synthesise and secrete melatonin may be 
impaired with age [236], thus representing another physiological change which could drive age 
associated alterations to circadian rhythms. Given melatonin has been shown to modulate SIRT1 
activity [237, 238], the ability of the SCN to regulate peripheral circadian clocks via melatonin may 
very well be dependent on SIRT1. Hence, NAD+ and SIRT1 appear to be key players in circadian 








1.4.1 Epigenetic Regulation by MicroRNAs 
In addition to DNA and histone modifications, microRNAs (miRNAs) represent another omnipresent 
epigenetic mechanism that regulates gene expression (Figure 1.4.1). miRNAs are very short 
oligonucleotides (20-25 nucleotides in length) which bind to the 3’ UTR of mRNAs (also the 5’UTR in 
rare instances), creating an RNA duplex that gets degraded by the endonuclease activity of the 
RISC:Dicer complex [239]. The genes for miRNAs are usually located in introns and are transcribed 
to yield a pri-miRNA molecule which undergoes further processing to form the 70-nucleotide pre-
miRNA duplex, before being exported to the cytoplasm. Once in the cytoplasm the pre-miRNA 
undergoes unwinding and cleavage mediated by Dicer to create the 20-25 nucleotide mature miRNA, 
after which it associates with the RISC complex. The miRNA can subsequently bind target mRNAs 
 
Figure: 1.3.1 Circadian regulation of SIRT1 and NAD+. 
The SCN can regulate circadian rhythms in peripheral cells by controlling the secretion of hormones such as 
melatonin from the pineal gland. At the intracellular level, the CLOCK:BMAL1 heterodimer can bind the E-box 
region in the NAMPT promoter which upregulates its expression. NAMPT can then increase NAD+ synthesis 
which in turn promotes SIRT1 activity. SIRT1 mediated deacetylation of BMAL1 subsequently creates a 
positive feedback loop by preventing the binding of the BMAL1 repressors CRY1/2 to the BMAL1:CLOCK 
heterodimer. SIRT1 further promotes BMAL1:CLOCK activity by deacetylating PER2, another repressor of the 
BMAL1:CLOCK. SIRT1 mediated deacetylation of PER2 promotes its degradation by the proteasome, thus 
preventing it from interacting with BMAL1:CLOCK. A negative feedback arm exists in the system however due 
to the ability BMAL1:CLOCK to bind the PER1/2 and CRY1/2 promoters and increase their expression. 
Consequently, these positive and negative feedback arms create the temporal oscillations in BMAL1 activity 
which constitute circadian rhythmicity at the molecular level. 
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At present approximately 2578 different mature miRNAs have been identified 
(http://www.mirbase.org/), emphasising the extensive regulation of gene expression commanded 
by the miRNA pool. Regarding their contribution to disease there has been a particular focus on their 
role in cancer, with cancer promoting miRNAs aptly labelled ‘oncomiRs’. Of the oncomiRs identified 
to date, miR-155 is one of the most prominent, found to be upregulated in multiple different tumour 
types [240-243]. Its tumour promoting activity is thought to be multifaceted, with upregulation of 
glycolysis via hexokinase II, inhibition of apoptotic gene expression and activation of the β-
catenin/Wnt pathway all pro-tumourigenic mechanisms attributed to miR-155 [243]. Additionally, 
its status as a pro-inflammatory mediator has been augmented by its elevation in inflammatory 
disorders such as Crohn’s disease [244] and rheumatoid arthritis [245], whilst it’s also been shown 
 
Figure 1.4.1 miRNA mediated gene repression.  
Following transcription pri-miRNA is cleaved into pre-miRNA before being exported to the cytoplasm where 
it interacts with Dicer and undergoes further cleavage during which the stem-loop is removed. The RISC 
complex is then formed, with the guide strand which is complementary to the target mRNA bound by 
Argonaute. This allows degradation of the passenger strand by the RISC complex, whilst the guide strand 
remains intact. The guide strand can then bind its target mRNAs, culminating in the destruction of both 




to be critical for the disease pathogenesis in mouse models of multiple sclerosis [246, 247]. Relating 
to circadian rhythms, Curtis et al.  demonstrated in mice that Bmal1 transcripts contain two binding 
sites to which mir-155 binds in response to a pro-inflammatory stimulus [248] and thus exerts 
regulation over circadian rhythm. The effects of miRNAs are known to be cell dependent therefore 
it isn’t known how ubiquitous this mechanism throughout different tissues is and indeed even 
whether it is also conserved in humans. 
1.5 Fibrosis 
1.5.1 Fibrosis as an Age-Related Disease 
Fibrosis is the process which causes the formation of scar tissue, often as a result of physical trauma 
or a prolonged inflammatory response. Many organs can be affected by fibrosis, ultimately resulting 
in tissue dysfunction. The ‘scar’ is a result of the excessive differentiation of fibroblasts into 
myofibroblasts and their abundant secretion of collagen and other extracellular matrix ECM proteins 
in response to a pro-fibrotic stimulus such as TGF-β or various other cytokines.  Where fibrosis is 
modest, the scar tissue will often be replaced with new healthy tissue, however as we get older the 
body’s ability to replace the scar tissue is impaired – likely due to depletion of the stem cell reserve 
[249], the growing presence of senescent cells [250] and persistent low-level inflammation [251].  
The accumulation of fibrotic lesions and the body’s dwindling ability to repair them with age is a 
particular concern with regards to cardiac tissue, with heart failure a leading cause of hospitalisation 
for those over the age of 65 [252-254]. Idiopathic pulmonary fibrosis (IPF) is another prominent 
cause of disability for elderly populations, with age a significant risk factor [255, 256]. Additionally, 
renal fibrosis and liver fibrosis are also over-represented in those over the age of 50 [257, 258] – 
highlighting that an increased risk for fibrosis in multiple organs is an important and often 
overlooked aspect of the ageing phenotype.  
Consequently, preventing the development of fibrosis or mediating its repair is a key goal in the 
quest for healthy ageing. Although there are differences to the fibroblasts resident in different 
tissues, the mechanism by which they instigate fibrosis is largely the same: an inflammatory 
response provoking excessive ECM secretion. Hence a better understanding of fibrosis in an organ 
such as skin could also translate to an improved understanding of fibrosis in other tissues. 
1.5.2 Systemic Sclerosis 
A condition characterised by skin fibrosis, and thus a useful model for understanding the molecular 
mechanisms which drive fibrosis is systemic sclerosis (SSc). SSc is an idiopathic autoimmune disease 
in which fibrosis first appears in the skin, before progressing to internal organs in approximately half 
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of the patients. Internal organ involvement is what differentiates the two subsets of SSc: limited SSC 
(lSSc) is localised to the skin, whereas the much more aggressive diffuse SSc (dSSc) begins with a 
more severe skin fibrosis followed by pulmonary, renal and cardiac involvement which eventually 
causes mortality. The aetiology is unknown, however the pro-fibrotic cytokine TGF-β is strongly 
implicated as playing a key role [259, 260]. Additionally, epigenetic mechanisms including histone 
acetylation are becoming increasingly suspected as important features of SSc pathogenesis, as has 
been reviewed previously [261]. Thus, if histone acetylation is a central modulator of fibrotic 
pathways this suggests a possible role for the histone deacetylase SIRT1. 
1.5.3 TGF-β 
TGF-β is a potent inducer of the fibroblast to myofibroblast transition and subsequent upregulation 
of pro-fibrotic genes, hence its use as the quintessential in vitro inducer of fibrosis. Although usually 
regarded as a pro-fibrotic and pro-inflammatory cytokine, TGF-β embodies the term pleiotropic – 
able to both promote and inhibit processes like inflammation and proliferation depending on the 
extracellular environment and the cell type it binds to.  
In the context of fibroblasts, TGF-β stimulates proliferation, fibroblast to myofibroblast 
differentiation, ECM synthesis and impaired secretion of matrix proteases – combining to create the 
perfect storm for the development of fibrosis. Under healthy conditions these effects constitute the 
wound healing response which is an essential mechanism for tissue repair following damage, 
however persistent TGF-β signalling will begin to have a counter-productive outcome. In many ways, 
this resembles the chronic inflammatory response underlying diseases such as osteoarthritis, 
multiple sclerosis, and rheumatoid arthritis, whereby a protective mechanism becomes damaging if 
overactivated. 
The TGF-β family contains three distinct isoforms which exist as homodimers – TGF-β1, TGF-β2 and 
TGF-β3. Being cytokines they function extracellularly, binding to the TGFβR1 (TGF-β1 receptor 1) 
which then recruits and phosphorylates TGFβR2 (TGF-β1 receptor 2), initiating a signalling cascade. 
TGF-β signalling is generally categorised as either SMAD-dependent or SMAD-independent [262, 
263], reflecting the prominent role SMAD proteins play in transducing TGF-β driven effects. Of 
particular importance are SMAD2 and SMAD3 which are phosphorylated by TGFβR1, resulting in the 
formation of a complex containing SMAD2, SMAD3 and SMAD4 which translocates to the nucleus 
and transcriptionally upregulates profibrotic genes, whilst also indirectly downregulating antifibrotic 
targets [264]. The master control TGF-β has over fibrotic pathways is facilitated by the wide range 
of genes targeted by the SMAD complex including ECM proteins, profibrotic miRNAs, tissue inhibitor 
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of matrix metalloproteinases (TIMPs) and inhibitors of antifibrotic miRNA transcription [261, 265, 
266]. 
1.6 Metabolism and Disease 
Terms such as ‘metabolic re-modelling’ and ‘metabolic re-programming’ have become something of 
a recent trend owing to the increasing acceptance that metabolic changes are pivotal in a number 
of non-metabolic diseases (by classical definition) [267-270]. Indeed, the existence of a wide range 
of illnesses resulting from impairment of various metabolic pathways (termed metabolic disorders) 
highlights the importance of maintaining the correct function of these pathways. Included in these 
metabolic disorders are a number of conditions caused by mutations in TCA cycle genes which are 
characterised by symptoms including neurodegeneration and developmental delay [271-273], whilst 
a wide range of mitochondrial disorders occur due to mutations in both mtDNA and nDNA 
mitochondrial genes [274]. 
1.6.1 The Warburg Effect 
The most notorious and indeed original example of metabolic re-programming is cancer and the 
‘Warburg effect’ [275]. The Warburg effect is the seemingly counter-intuitive upregulation of 
glycolysis in cancer cells even in the presence of adequate oxygen for OXPHOS, thus is also more 
informatively termed ‘aerobic glycolysis’. Given glycolysis is a far less efficient pathway for ATP 
production compared to OXPHOS – producing approximately 2 ATP per round in contrast to OXPHOS’ 
30-36 ATP – the massively enhanced levels in cancer cells of the former seems odd, especially given 
their high demand for ATP due to rapid growth. The prevailing theory explaining this is that it’s the 
biosynthetic intermediates that are produced as byproducts in the glycolytic chain that are 
important, providing the building blocks for the abundant macromolecule synthesis that supports 
tumourigenicity. It is also a common misconception that the Warburg effect involves glycolysis being 
enhanced at the expense of OXPHOS: this isn’t necessarily the case. Many cancer cells also have high 
levels of OXPHOS to support their high ATP demand [276], augmenting the idea that the importance 
of glycolysis in cancer is the generation of biosynthetic intermediates rather than ATP production. 
Rather than viewing glycolysis and OXPHOS as two alternative pathways for ATP synthesis between 
which an equilibrium exists, it is important to remember that they’re intrinsically linked via the TCA 
cycle.  
1.6.2 Glutaminolysis and mTOR 
Aside from glycolysis and OXPHOS, another key metabolic pathway implicated in multiple diseases 
is glutaminolysis: a 2-step process whereby glutamine is converted to α-ketoglutarate via glutamate. 
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α-Ketoglutarate is an essential metabolite under growth conditions, functioning as a key precursor 
for amino acid synthesis and lipid metabolism, whilst also supporting energy production by feeding 
into step four of the TCA cycle. Additionally, the transamination of glutamine to glutamate which 
constitutes the initial step in glutaminolysis provides nitrogen required for amino acid synthesis, with 
glutamate itself also able to be funnelled as a substrate into amino acid synthesis pathways.  
Given it performs a very similar role in facilitating rapid growth, it is perhaps unsurprising that like 
glycolysis, glutaminolysis is also regarded as a critical component of cancer development [277]. 
Similarly, a spike in glutamine metabolism occurs during T cell activation suggesting it may also be 
important in autoimmunity [278, 279].  
One anabolic mechanism thought to be promoted by glutaminolysis but not glycolysis is activation 
of the mTORC1 complex [280]. mTORC1 is a multi-subunit complex which contains mTOR as its key 
catalytic subunit: a serine/threonine kinase regarded as the ‘master regulator’ of intracellular 
anabolic pathways [281]. The relationship between glutaminolysis and mTOR is bidirectional with α-
ketoglutarate activating mTOR via prolyl hydroxylases, whilst the subsequent mTOR mediated 
enhancement of nutrient uptake facilitates glutaminolysis through increased glutamine availability. 
mTOR is also known to enhance glycolysis via HIF-1α [282] and thus this represents yet another 
pathway through which α-ketoglutarate promotes growth. 
Importantly, as mentioned previously mTOR activity can be attenuated by the immunosuppressant 
rapamycin. Indeed, the use of rapamycin has proven to be effective at blocking disease pathogenesis 
in a number of tumour containing mice [283-285] and pro-fibrotic rodent models [286-289].  
1.6.3 Mitochondrial Dysfunction: Cause or Consequence of Ageing? 
Mitochondria are a focal point of many theories regarding the molecular basis for ageing, hence it 
stands to reason that mitochondrial driven metabolism may also be key. The first mitochondrial 
ageing theory to gain widespread support was the ‘mitochondrial free radical theory of aging’ 
(MFRTA) which posits that mtROS (mitochondrial ROS), which are unavoidable byproducts of the 
ETC, cause the intracellular damage underpinning physiological decline [290]. Complexes I and III in 
the ETC produce the superoxide anion which via fenton chemistry is eventually converted to the 
hydroxyl radical, a highly reactive ROS that oxidises proteins, lipids and DNA. The MFRTA proposes 
that mitochondrial function declines with age due to the accumulation of mutations within the 
mitochondrial genome, resulting in less efficient electron transfer and more mtROS production. This 
forms a vicious cycle whereby mtROS induce mtDNA damage, which in turn induces higher mtROS 
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production and more mtDNA damage, augmented by the cell’s impaired antioxidant capacity due to 
mtROS damage to proteins and nuclear DNA. 
Since then however, mitochondrial theories of ageing have undergone various refinements and 
doubts have been raised about the contribution of mtROS to ageing: upregulation of mitochondrial 
antioxidants failed to increase lifespan in mice [291], whilst reduced levels of the mitochondrial 
antioxidant SOD2 in heterozygous Sod2+/- mice increased oxidative stress yet failed to reduce 
lifespan [292]. Most recently, the role of mitochondria in ageing has focused on its relationship with 
inflammation and senescence, with mitochondrial dysfunction found to be essential for the 
development of the SASP [35, 293]. The mechanisms proposed differ however, with activation of the 
SASP via a persistent DDR induced by mtROS oxidation of nuclear DNA one model [35, 294].  
Alternatively, it has also been shown that mitochondrial induced senescence is dependent on a 
lowered NAD+/NADH, which drives senescence via P53 stabilisation downstream of AMPK activation 
[293]. 
There is also evidence which suggests dysfunctional mitochondria trigger the SASP by activating the 
cGAS-STING pathway, a mediator of innate immunity. cGAS is a sensor for cytoplasmic double 
stranded DNA (dsDNA), thought to have primarily evolved to detect infiltrating viruses, which upon 
sensing dsDNA activates the transcriptional activator STING which in turn increases transcription of 
a number pro-inflammatory genes [295]. Damaged mitochondria release mtDNA fragments which 
can increase inflammation via NLRP3 inflammasome activation [296] and also bind to cGAS [297], 
thus stimulating an immune response. Whilst cytoplasmic mtDNA binding constitutes a neat 
mechanism of cGAS activation downstream of mitochondrial dysfunction, Vizioli et al. found that it 
was actually nDNA fragments resulting from aberrant mitochondria to nucleus retrograde signalling 
that caused cGAS-STING induced senescence [298]. It therefore appears likely that mitochondria are 









1.7 Aims and Objectives 
The important role of NAD+ and SIRT1 in healthy ageing is becoming increasingly accepted, however 
the influence of factors such as circadian rhythms, NAD+ precursor supplementation and the activity 
other NAD+ consuming enzymes on NAD+ homeostasis and SIRT1 activity requires further 
investigation. By better understanding these interactions, this will provide valuable information on 
how to optimise NAD+ focused strategies for the purpose of enhancing SIRT1 activity therapeutically 
– with the ultimate goal of extending human healthspan.  
Specific questions to address: 
1. Can PARP1 inhibition enhance SIRT1 activity via increased availability of NAD+? 
2. Do NAD+ levels follow a circadian rhythm in dermal fibroblasts and how does this impact 
SIRT1 activity? 
3. Can naturally occurring compounds targeting enzymes involved in NAD+ metabolism 
enhance NAD+ levels and protect cells against oxidative stress in vitro? 
4. What is the efficacy of these compounds at enhancing human PBMC NAD+ levels if 
implemented as a dietary supplement in vivo? 













Chapter 2. Materials and Methods 
2.1 Ethics 
Full ethical approval was obtained from the Northumbria University ethics committee for all work 
reported within this thesis (internal submission references 743 and 9040). 
2.2 Reagents 
All reagents and plasticware (Greiner) used were purchased from Sigma-Aldrich unless otherwise 
stated. 
2.3 Cell Culture 
2.3.1 Cell Culture Conditions 
Unless otherwise stated, cells were grown in high glucose Dulbecco's Modified Eagle's Medium 
(DMEM) (Gibco cat no. 21969035, Thermo Fisher Scientific, Paisley, Scotland, UK) supplemented 
with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 2mM L-glutamine (all Gibco, 
Thermo Fisher Scientific, Paisley, Scotland, UK) and kept in an incubator (Heracell VIOS 160i, Thermo) 
at a temperature of 37°C and with an atmosphere of 5% CO2.  
For adherent cells, culturing was performed by detaching the cells using a 0.05% w/v Trypsin 0.02% 
v/v EDTA solution (Gibco, Thermo Fisher Scientific, Paisley, UK), before collecting a cell pellet by 
centrifugation and then adding the re-suspended cells to the new flask(s). For suspension cells, these 
were passaged by adding the suspension to new flasks containing media using the appropriate 
dilution factor. 
When passaging or harvesting cells for downstream experimental analysis (where cytotoxicity 
wouldn’t be expected), viability was assessed by mixing 10-20ul of cell suspension with an equal 
volume of 0.4% trypan blue solution (Gibco, Thermo Fisher Scientific, Paisley, UK). Cells were then 
added to a haemocytometer (Hawksley, Lancing, Sussex, UK) and visualised using a bright-field 
microscope at 10x magnification to determine the presence of cell death in the form of cells stained 
blue.  
2.3.2 NHDFs 
Primary derived NHDFs (normal human dermal fibroblasts) (n=3) were received as gifts from Dr 
Nicola Fullard (Durham University, UK), Dr Julie Worrell (Newcastle University, UK) and Dr Richard 
Stratton (UCL, UK). NHDFs were routinely passaged every 5-7 days (typically a 1:3 split) and used at 
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passage number <25. NHDFs were typically seeded down at a density of 2,000 cells/well for 96-well 
plates, 8,000 cells/well for 24-well plates and 60,000 cells/well for 6-well plates during experiments. 
2.3.3 SSc Patient Dermal Fibroblasts  
Dermal fibroblasts derived from skin lesions of SSc patients (n=4) and dermal fibroblasts from 
age/gender matched controls (n=3) were obtained as a gift from Dr Richard Stratton (UCL, UK). These 
were grown and passaged/seeded down for experiments following the same conditions as NHDFs 
and were used at passage number 4–9. 
2.3.4 miR-155KO and Wild-Type Primary Derived Mouse Dermal and Lung Fibroblasts 
Skin and lung tissue explants from miR-155-/-  C57BL/6 and wild-type C57BL/6 mouse littermates (n=5 
for each genotype) were received as a gift from Dr Mariola Kurowska-Stolarska (Glasgow University, 
UK). On arrival the explants were minced up using a sterile scalpel and embedded onto the surface 
of a 6-well plate which had been scratched several times with the scalpel. The plates were then 
incubated under standard culturing conditions and the media were replaced every 2 - 3 days. Once 
the fibroblasts had extensively migrated from the tissue as determined by visualising under a bright-
field microscope, the remaining pieces of tissue were discarded and the fibroblasts cultured into a 
T25 flask. The cells were then used for experiments after reaching passage 5 with the same seeding 
densities as used for NHDFs. An n=4 for each genotype is used for experiments involving these 
fibroblasts due to failure of the fibroblasts to migrate from the skin explant for 1 miR-155KO and 1 
WT explant. 
2.3.5 Bmal1KO and Wild-Type Primary Derived Lung Fibroblasts 
Mouse lung fibroblasts (MLFs) derived from Bmal1-/- and wild-type C57BL/6 mice littermates (n=2) 
were provided as a gift from Dr Steven O’Reilly (Durham University, UK). These were grown under 
standard conditions and used for experiments between passage numbers 16 and 25, with the same 
seeding densities as NHDFs. 
2.3.6 Jurkat Cell Line  
These cells were grown in suspension in Roswell Park Memorial Institute (RPMI) 1640 Medium (cat 
no. 21875034, Thermo Fisher Scientific, Paisley, UK) supplemented with 10% foetal bovine serum 
(FBS), 1% penicillin/streptomycin, and 2mM L-glutamine (all Gibco, Thermo Fisher Scientific, Paisley, 
UK) and kept at a temperature of 37°C in an atmosphere of 5% CO2. Cells were split at a confluency 
of 2-3 million cells/ml whereby they were seeded down and used for experiments at a density of 




All cells were cryopreserved after reaching 70-80% confluency. Following trypsinisation for adherent 
cells, the pellets were re-suspended in the appropriate culture media at a concentration of 
approximately 1 million cells/ml and chilled on ice. DMSO (cat no. D2650, Sigma-Aldrich, Gillingham, 
UK) was then slowly added dropwise onto the cells to a final concentration of 10% v/v, before the 
cells were added to cryovials and placed in a pre-cooled (4°C) Mr Frosty (Nalgene) container at -80°C 
overnight. The next day the cryovials were transferred to a -150°C freezer for long term storage. 
2.3.10 Induction of Fibrosis Using TGF-β 
The standard method used to induce fibrosis in vitro is treating cells with TGF-β. Due to the potential 
presence of TGF-β in FBS, NHDFs were serum starved (media lacking FBS) overnight prior to the 
addition of 10ng/ml TGF-β (stored as a 10ug/ml stock in filter sterilised dH2O). Before adding the 
TGF-β, the culture media were replaced with fresh media containing reduced FBS (0.1%). Afterwards, 
no further media changes were made for the duration of the experiment. Although low serum may 
be an unnatural environment for cells, this was found to yield the most reproducible results and 
didn’t induce any cytotoxic effects as determined by staining cells with trypan blue, whereby the 
presence of cells stained blue by the trypan blue dye would indicate a porous plasma membrane and 
thus cell death.  
2.3.11 Cell Transfection  
Gene knockdown studies were performed by transfecting cells with siRNA or miRNA mimic 
oligonucleotides using a ‘forward transfection’ protocol. Cells were seeded down in a 24-well plate 
at 30-40% confluency and left to adhere overnight. The next day HiPerFect transfection reagent 
(Qiagen, Manchester, UK) ((no of wells + 1) x 0.8ul) and the siRNA/miRNA mimic (4x final 
concentration) were added to FBS and antibiotic free DMEM ((no of wells + 1) x 15ul), before being 
left for 15 minutes at RT (room temperature) to allow transfection complex formation. During this 
time, the media in the 24-well plate were removed and replaced with 45ul of culture media 
containing no antibiotic. 15ul of the transfection reagent/oligonucleotide mix was then added 
dropwise into each well and the media replaced 8 hours later with regular antibiotic-containing 
culture media. The efficacy of the BMAL1 siRNA (human), Bmal1 siRNA (mouse) and miR-155 mimic 
at knocking down their targets was confirmed by western blotting and qPCR for a range of 
concentrations (typically 25nM, 50nM, 75nM, 100nM and 125nM) after 48 and 72 hours, which 




Table 2.3.11.1 Oligonucleotides used for gene silencing studies. 
Oligonucleotide Manufacturer Working Concentration  
BMAL1 siRNA (Human)  Qiagen (cat no. SI00023016) 100nM 
Bmal1 siRNA (Mouse) Invitrogen  (cat no. 
4390771) 
75nM 
Silencer™ Negative Control 
No. 1 siRNA  
Sigma (cat no. SIC OO1) (100nM human, 75nM mouse) 
miR-155 mimic (Mouse) Qiagen (cat no. 219600) 50nM 
miRIDIAN miRNA Negative 
Control #1 
Dharmacon (cat no. HMC0002)  50nM 
 
2.3.12 Compounds Added to Cells In Vitro 
All compounds (Table 2.3.10.1) used in the cell culture work presented within this thesis were 
dissolved in either DMSO (Sigma-Aldrich, Gillingham, UK), sterile filtered molecular grade ethanol 
(Fisher) or sterile filtered dH2O. Optimal doses for viability assays were determined by titrating over 
a range of doses, with the appropriate dose range determined from the literature.   
Table 2.3.12.1 Compounds used for in vitro work 
Compound  Supplier (cat no.) Solvent Working 
concentration 
2-deoxyglucose (2-DG) Sigma-Aldrich (D3179) dH2O 10 - 50mM 
3PO Selleck Chemicals (SML1343-5MG) DMSO 8uM 
α-lipoic acid (ALA) Nuchido Ltd. DMSO 20 - 100uM 
Antimycin A Sigma-Aldrich (A8674-25MG) DMSO 0.5uM 
Apigenin  Selleck Chemicals (S2262) DMSO 10 - 100uM 
Compound 968 (G968) Sigma-Aldrich (352010) DMSO 10uM 
Dexamethasone Sigma-Aldrich (D4902) DMSO 100nM 
EGCG Nuchido Ltd. DMSO 4uM 
EX527 Selleck Chemicals (S1541) DMSO 40uM 
FCCP Sigma-Aldrich (C2920-10MG) ethanol 1uM 
FK866 Selleck Chemicals (S2799) DMSO 2 - 200nM 
Glucose Sigma-Aldrich (G7021) dH2O 10mM 
Nicotinamide (NAM) Sigma-Aldrich (N0636) dH2O 100uM - 1mM 
Oligomycin Sigma-Aldrich (O4876) DMSO 1uM 
Quercetin Selleck Chemicals (S2391) DMSO 18 - 89uM 
Rapamycin  Selleck Chemicals (S1039) DMSO 500nM 
Resazurin Santa Cruz Biotechnology (sc-206037) 1x PBS 0.02% w/v 
Resveratrol (RSV) Selleck Chemicals (S3168) DMSO 60uM, 100uM 
Rotenone Sigma-Aldrich (R8875-1G) DMSO 0.5uM 
Rucaparib Selleck Chemicals (S4948) DMSO 1-10uM 
Rutin Nuchido Ltd. DMSO 4 - 74uM 
Sodium Pyruvate Sigma-Aldrich (P5280) dH2O 1mM 
(tert-butyl 
hydroperoxide) tbh7ox 
Sigma-Aldrich (458139) - 20 – 140uM 
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2.4 Blood Sampling 
2.4.1 Participant Recruitment 
For the experiments investigating human in vivo NAD+ levels in response to NR and the NCD cocktails, 
participants were recruited by word of mouth before they were screened for their eligibility to take 
part. The exclusion criteria for participation was: 
• Regular consumption of supplements containing niacin (vitamin B3), niacinamide nicotinamide 
riboside or nicotinamide mononucleotide 
• Food allergies or sensitivities  
• Currently taking blood pressure medication 
• Currently taking blood thinning medication (e.g. aspirin, warfarin, heparin) 
• History or current diagnosis of drug/alcohol abuse   
• History of kidney or liver disease, or other severe diseases of the gastrointestinal tract (e.g. iron 
accumulation, iron utilization disorders, hypercalcaemia, hypercalcaemia), that are likely to 
interfere with metabolism/absorption/secretion of the product under investigation 
• History of neurological or psychiatric illness (excluding depressive illness and anxiety) 
• Blood disorders (e.g. anaemia, haemophilia, thrombocytosis) 
• Heart disorder, or vascular illness 
• Chronic gastrointestinal problems (e.g. Inflammatory Bowel Disease, Irritable Bowel Syndrome, 
celiac disease) 
• Any known active infections 
• Diagnosed with or may be at risk of having syphilis, hepatitis, the Human T - lymphotropic virus, 
the Human Immunodeficiency Virus or any other infectious blood-borne disease (due to the 
health risk this poses to the phlebotomist) 
• Health condition that would prevent fulfilment of the study requirements  
• Currently participating in or in the past 3 weeks participated in other clinical or nutrition 
intervention studies 
2.4.2 Blood Collection 
All blood samples for the NR study were obtained by venepuncture from the basilic, cephalic or 
median cubital vein. 8ml of blood was drawn into a vacutainer (sodium heparin, BD), inverted 2-3 
times and then immediately placed on ice. For the NCD cocktail studies the baseline and full 
treatment day blood samples were taken every 2 hours over a 12-hour period (8am – 8pm) by 




2.4.3 PBMC Isolation 
PBMCs (peripheral blood mononuclear cells) were isolated from whole blood immediately following 
collection of the sample, with the blood and the subsequently isolated PBMCs kept on ice 
throughout the entire process, unless being centrifuged at 3ᵒC. 15ml of lymphoprep (Stemcell 
technologies, Cambridge, UK) was added to a 50ml falcon tube and 8ml of blood gently mixed with 
16ml of sterile 1x PBS 2% FBS solution was then carefully layered on top of the lymphoprep, ensuring 
minimal mixing between the lymphoprep and the diluted blood interface. When the blood obtained 
was less than 8ml, the process was the same but with the volume of 1x PBS 2% FBS solution added 
equal to twice the volume of blood. 
The lymphoprep/blood containing tube was then centrifuged at 1000xg, 12 minutes, 3°C, with the 
deceleration set to 0. The PBMCs were then visible as a cloudy layer between the plasma and 
lymphoprep fractions, allowing them to be extracted by pipetting into a 15ml tube containing 12ml 
of ice-cold 1x PBS 2% FBS. Plasma was also removed and immediately stored in cryovials at -80°C. 
The PBMC suspension was then centrifuged at 500xg, 8 minutes, 3°C, with the deceleration returned 
to the maximum. The subsequent pellet was re-suspended in 400ul 100% FBS and mixed before the 
addition of an equal volume of 80% FBS 20% DMSO, with the PBMCs then added to a cryovial and 
placed in a Mr Frosty in the -80°C overnight. The next day the cells were transferred to the -150°C. 
2.5 NAD+ Measurements 
NAD+ measurements were performed following an optimised protocol using a commercially 
available kit (NAD/NADH Glo, Promega, Southampton, UK). For in vivo measurements, 1 human 
sample from each study visit was assayed as technical duplicates. For in vitro measurements, 3 
culture plate technical replicates for each condition were assayed in duplicate. The experiment was 
repeated and the average of the experimental means was used to give the data presented herein. 
2.5.1 NAD+ Measurements in PBMC, Blood and Plasma Samples 
For in vivo measurements, PBMCs were thawed on ice and then added to 20ml ice cold 1x PBS before 
being centrifuged at 600xg, 8 minutes, 3°C. The pellet was then resuspended in 200ul of 1x PBS, 
before 10ul of this suspension was then added to 90ul 1x PBS, giving a final concentration of 200,000-
400,000 cells/ml. In a white, flat-bottomed 96-well plate 20ul of each biological sample was then 
added to a well containing 20ul of 0.2M NaOH 1% Dodecyltrimethylammonium bromide before 20ul 
of 0.4M HCl was added. The plate was sealed with parafilm and then incubated at 60°C for 15 
minutes, before being allowed to cool for 10 minutes at RT after which 20ul of 0.5M Trizma was 
added to each well. 40ul of each well was then added to the adjacent well leaving a total volume of 
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40ul in all wells, to which 40ul of freshly prepared ‘glo reagent’ (made up using reagents provided 
with the kit) was added. The plate was kept in the dark at room temperature for 30-45 minutes 
before luminescence was read using a luminometer (Spark 10M, Tecan, Mannedorf, Switzerland) 
with an integration time of 1 second per well. An NAD+ standard curve containing concentrations 
from 5nM – 400nM made by diluting lyophilised NAD+ in 1x PBS was also added to the plate alongside 
the samples, allowing the concentration of NAD+ for each sample to be calculated. Subsequently, a 
BCA (bicinchoninic assay) assay was performed so that NAD+ could be normalised to protein 
concentration. 
To prepare samples for protein quantification, 10x RIPA (radio-immunoprecipitation) buffer (100 
mM Tris-Cl pH 8.0, 1% sodium deoxycholate, 1% SDS, 10% Triton X-100, 1.4M NaCl) was then added 
to the remaining cell suspensions which were vigorously vortexed and then left on ice to lyse for 30 
minutes. The supernatant was then collected and the pellet discarded after centrifuging at 12,000xg, 
12 minutes, 3ᵒC. After diluting the supernatant 3-fold in 1x PBS, a micro-BCA assay (micro-BCA assay 
kit, Thermo Fisher Scientific, Paisley, UK) was performed at 37ᵒC for 2-6 hours and the absorbance 
at 562nm read using a plate reader (FLUOstar Omega, BMG Labtech, Aylesbury, England). The ng 
NAD+/ml for each sample was then divided by the ug/ml total protein such that the NAD+ levels were 
subsequently expressed as ng NAD+/ug protein. 
2.5.2 NAD+ Measurements in Primary Derived Cells and Cell Lines 
For the in vitro NAD+ measurements, adherent cells were washed 3 times in the well-plate using ice 
cold 1x PBS before being scraped off in 1x PBS, collected in an Eppendorf tube and then immediately 
frozen at -80ᵒC. For the Jurkat cell line, the cells were collected by centrifugation at 300xg for 5 
minutes, re-suspended in 1x PBS and once again pelleted by centrifugation. The cells were then re-
suspended in 200ul of 1x PBS and frozen at -80ᵒC. On the day of the assay, cells were thawed on ice 
and the protocol conducted as for the in vivo measurements. For NHDFs cells were diluted in 100ul 
1x PBS to a final concentration of 50,000-100,000 cells/ml whereas they were diluted to 200,000-
400,000 for the Jurkats. 
2.6 Energy Metabolism Assays 
2.6.1 OXPHOS – Mitochondrial Stress Assay 
Parameters of OXPHOS were assessed using the ‘Seahorse XF cell mito stress test’ programme on 
the Seahorse XFp Analyser (Agilent, Stockport, UK), whereby OXPHOS activity is measured by the 
change in O2 concentration (pmol O2/min) within the cell media. Cells were seeded down in a 6-well 
or 24-well plate and the experimental conditions set up accordingly. 24 hours before the assay, cells 
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in the 6-well or 24-well plate were trypsinised and seeded down in a seahorse miniplate at a 
concentration of 2000-3000 cells/well before being centrifuged at 600xg for 2 minutes to promote 
adherence. The remaining cells were re-plated onto a 6-well/24-well plate. Experimental conditions 
in the seahorse miniplate were set up to replicate those of the 6-well and 24-well plates, whilst the 
seahorse cartridge was hydrated in XF calibrant (Agilent, Stockport, UK) overnight. On the day of the 
assay, the cells in the miniplate were washed twice with seahorse XF base media (Agilent, Stockport, 
UK) and incubated at 37°C, no CO2 in seahorse base media supplemented with 10mM D-glucose, 
2mM L-glutamine and 1mM sodium pyruvate.  
10x stocks of 10uM oligomycin, 10uM FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone) 
and 5uM rotenone/antimycin A were freshly prepared in the seahorse base media and then loaded 
into the seahorse cartridge such that oligomycin would first be added to the wells, followed by FCCP 
and finally rotenone/antimycin A. The assay was then run under the machine programme ‘mito 
stress test’. The cells in the 6-well/24-well plate with identical experimental conditions in parallel 
were then lysed in 1x RIPA buffer in preparation to be used for western blotting. 
After completion of the mitochondrial stress test, the cells in the seahorse miniplate were washed 
twice in ice cold 1x PBS and then lysed in 1x RIPA buffer for 30 minutes, before the supernatant was 
collected and the pellet discarded. The supernatant was then diluted 6-fold in 1x PBS, allowing a 
micro BCA assay to then be performed to determine the protein content within each sample. Once 
the protein content was calculated, the OCR (oxygen consumption rate) values generated by the 
mitochondrial stress test were divided by the total protein such that the results were expressed as 
OCR/ug protein.  
‘Basal respiration’ was then calculated by subtracting the OCR/ug protein after oligomycin treatment 
from the OCR/ug protein after the addition of rotenone/antimycin A. The difference in OCR/ug 
following the FCCP treatment and antimycin A/rotenone treatments constituted ‘maximal 
respiration’, whilst ‘respiratory reserve’ was the difference in the basal and post FCCP addition 
OCR/ug. Finally, ATP production was determined by calculating the difference between the basal 
and post oligomycin OCR/ug protein. 
2.6.2 Glycolysis - Glycolysis Stress Assay 
Parameters of glycolysis were measured using the ‘Seahorse XF glycolysis stress test’ protocol on the 
Seahorse XFp Analyser. Experiments were set up in a seahorse miniplate using the same protocol as 
the OXPHOS assays, however the media used was seahorse base media supplemented with only 
2mM L-glutamine. 10x stocks of 100mM D-glucose, 10uM oligomycin and 500mM 2-DG (2-
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deoxyglucose) were freshly prepared in seahorse media and added to the sensor cartridge such that 
during the assay D-glucose would be added first to the wells, followed by oligomycin and then 2-DG. 
The XFp analyser then measured the basal ECAR (extracellular acidification rate – mpH/min) and the 
ECAR following the addition of the compounds mentioned for each well in the miniplate.  
As for the OXPHOS assays, protein content was calculated for each miniplate well by performing a 
micro BCA assay, allowing glycolytic parameters to be expressed as ECAR/ug protein. Levels of ‘basal 
glycolysis’ were calculated by subtracting the ECAR following 2-DG treatment from the ECAR after 
glucose addition. ‘Glycolytic capacity’ was the difference in the ECAR/ug protein` following 2-DG and 
oligomycin addition, whilst ‘glycolytic reserve’ was the difference in the ECAR/ug protein between 
the glucose and oligomycin treatments. 
2.7 Western Blotting 
2.7.1 Protein Extraction 
Well plates containing cells were transferred to ice and the cells were washed twice in ice cold 1x 
PBS before 1x RIPA buffer (10 mM Tris-Cl pH 8.0, 0.1% sodium deoxycholate, 0.1% SDS, 1% Triton X-
100, 140mM NaCl) was added to each well (24 well plate – 40ul, 12 well plate – 60ul, 6-well plate – 
100ul). The cells were then scraped from the plate and collected in 500ul Eppendorf tubes before 
being kept on ice for 30 minutes to promote cell lysis. The lysates were then centrifuged at 12,000xg, 
12 minutes, 3ᵒC and the supernatant was added to a fresh tube whilst the pellet of debris was 
discarded. A 10ul sample of the supernatant was used to perform a BCA assay (Pierce BCA assay kit, 
Thermo Fisher Scientific, Paisley, UK) to determine protein concentration, which was read at an 
absorbance of 562nm using a plate reader (FLUOstar Omega, BMG Labtech, Aylesbury, UK). The 
amount of each sample required to load 20ug protein was then calculated and 6x laemmli buffer 
(375 mM tris-HCl pH 6.8, 6% SDS, 4.8% glycerol, 9% 2-mercaptoethanol, 0.03% bromophenol blue) 
added to a final concentration of 1x, before samples were then stored at -20°C for <6 months prior 
to western blotting. 
2.7.2 SDS-PAGE 
On the day of running the SDS-PAGE gel, the lysates in laemmli were thawed on ice before being 
boiled at 90°C for 5 minutes using a heating block. For 10 and 15-well assays, samples were run on 
a 10% acrylamide gel with a 6% acrylamide stacking gel at a constant voltage of 100V in 1x running 
buffer (25Mm Tris, 192mM glycine, 0.1% SDS) until the dye front reached the bottom of the gel. For 
16-24 well assays, samples were run on precast 26-well gels (cat no. 5671085, Bio-Rad, Watford, UK) 
at a constant voltage of 185V, once again until the dye front reached the bottom of the gel. 
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2.7.3 Western Blot Transfer 
After completion of the SDS-PAGE, the gel was rinsed in dH2O and the protein was then transferred 
to a nitrocellulose membrane (0.45um cat no. 1620115, Bio-Rad, Watford, UK) in 1x transfer buffer 
(25mM Tris, 192mM glycine, 20% MeOH) at a constant voltage of 30V for 19 hours at 4°C. For regular 
size gels, a Mini Trans Blot-Cell (cat no. 1703935, Bio-Rad, Watford, UK) was used, whereas the Trans-
Blot Cell (cat no. 1703939, Bio-Rad, Watford, UK) was used for 26-well gels. 
2.7.4 Immunoblotting 
The blot was then rinsed in dH2O and left to air dry for 45-60 minutes before loading and transfer 
quality was inspected by incubating the blot in ponceau red solution (0.1% Ponceau S, 0.5% acetic 
acid) on a rocker for 5-10 minutes and then washing off background staining by rinsing 2-3 times in 
dH2O. Images of the ponceau staining were then taken using a printer scanner after wrapping the 
blot in clingfilm. The blot was then repeatedly washed in 1x TBST (50mM Tris, 125mM NaCl, 0.1% 
tween 20) until no ponceau stain was visible. Next, the blot was blocked in 5% milk (skimmed milk 
powder, Tesco) diluted in 1x TBST for 1 hour at RT, before being incubated in the primary antibody 
on a roller at 4°C, overnight. All primary antibodies were diluted in 5% milk and used at the 
concentrations specified in Table 2.7.4.1.  
After staining in the primary antibody, blots were washed on a rocker for 5 minutes 3 times in 1x 
TBST and then incubated in the appropriate secondary antibody, diluted in 5% milk (see table 1 for 
concentrations) for 1-2 hours on a roller at RT. Blots were then once again washed for 5 minutes, 3 
times in 1x TBST before being imaged using either ECL Western Blotting Detection Reagent (cat no. 
10754557, GE Healthcare, Chalfont St Giles, UK) or Pierce Super Signal West Dura (cat no. 34075, 



















Acetylated H3 (Ac-H3) Sigma (06-942) 1.3000 (human), 
1.5000 (mouse) 







1.1000 anti-rabbit HRP 
α-tubulin  Abcam (ab4074) 1.5000 (human, 
mouse) 
1.2000 anti-rabbit HRP 
α-SMA Abcam (ab5694) 1.3000 (human, 
mouse) 
1.2000 anti-rabbit HRP 
β-catenin Santa Cruz (H-102) 1.2000 (human, 
mouse) 
1.2000 anti-rabbit HRP 
BMAL1 Abcam (ab93806) 1.3000 (human) 1.3000 anti-rabbit HRP 
BMAL1 Gift from Imperial 
College London 
1.2000 (mouse) 1.2000 anti-mouse HRP 
Collagen I Abcam (ab138492) 1.2000 (human, 
mouse) 
1.2000 anti-rabbit HRP 
Glutaminase C/KGA Proteintech (12855-1-
AP) 
 
1.1000 (human) 1.2000 anti-rabbit HRP 
Hexokinase II Abcam (ab104836) 1.1000 (human) 1.2000 anti-mouse HRP 
Histone H3 Abcam (ab1791) 1.6000 (human, 
mouse) 






1.2000 anti-rabbit HRP 
NRF2 Abcam (ab137550) 1.500 (human) 1.1000 anti-rabbit HRP 
PARP1  Bio-Rad (VMA00016) 1.2000 (human, 
mouse) 
1.2000 anti-mouse HRP 
PAR Trevigen (4336-BPC-
100) 
1.2000 (human) 1.2000 anti-rabbit HRP 
PGC-1α Calbiochem (AB3242) 1.1000 (human) 1.2000 anti-rabbit HRP 
P53 Cell Signalling 
Technology (1C12) 
1.500 (mouse) 1.2000 anti-mouse HRP 
P53 Proteintech (10442-1-
AP) 
1.1000 (human) 1.1000 anti-rabbit HRP 
SIRT1 Abcam (ab32441) 1.2000 (human, 
mouse) 
1.2000 anti-rabbit HRP 
SIRT3 Santa-Cruz (F-10) 1.500 (human) 
1.400 (mouse) 





2.7.5 Re-Probing Blots  
Blots were stripped for re-probing where necessary by two methods. When preparing to probe using 
a primary of different species to the one used previously, the HRP (horseradish peroxidase) bound 
to the previous antibody was inactivated by incubating overnight in 10% NaN3, 1x TBS solution 
before being washed 6 times for 5 minutes in 1x TBST and then blocked in 5% milk, 1x TBST. 
Alternatively, the blot was incubated in ‘harsh stripping buffer’ (62.5mM Tris-HCl pH 6.8, 2% w/v 
SDS, 0.8% 2-mercaptothanol) at 60ᵒC for 40 minutes with gentle shaking of the blot container every 
5 minutes. The blot was then left under running tap water for 5 minutes before being washed 6 
times for 5 minutes in 1x TBST to remove all traces of 2-mercaptoethanol and SDS, thus allowing the 
blocking step to begin in preparation for the next primary antibody to be used. 
2.7.6 Densitometry Analysis  
Where a fully quantitative analysis of western blots was required, densitometry was performed on 
the specific bands of interest. The protein ladder was used as a reference to determine the bands of 
interest on blots where non-specific bands were present. Images saved as TIF files were then opened 
using ImageJ software (downloaded from imagej.nih.gov/ij/). The images were converted to 
greyscale and a rectangular box drawn such that it covered the first sample lane on the blot. A 
duplicate of this box was then copied onto all the other lanes on the blot, with each separate box 
numerically labelled. Using the ‘straight line’ tool, a line was drawn above the background signal for 
the peak corresponding to the band of interest within each lane when opening the ‘plot lanes’ 
profile. The ‘wand’ tool was then selected and used to click on these peaks within the plot lanes 
window. After selecting ‘label peaks’, a value for the relative density of all peaks is provided, whereby 
the density of each peak is expressed as a % of the density of all peaks combined. 
2.8 qPCR  
2.8.1 RNA Isolation 
Prior to and during the RNA extraction procedure pipettes, bench top, fumehood and gloves were 
cleaned using RNaseZap (Invitrogen, Thermo Fisher Scientific, Paisley, UK). All gene expression 
assays were performed on cells grown in 6-well plates so that a sufficient yield of RNA could be 
obtained. The cells were washed in ice cold 1x PBS before 1ml of TRIzol (Invitrogen, Thermo Fisher 
Scientific, Paisley, UK) was added to each well and the cells scraped from the surface of the plate. 
The cell suspension in TRIzol was then frozen at -80ᵒC before further processing. Upon thawing, 
200ul of chloroform (molecular grade, MP Biomedicals, Fisher Scientific, Loughborough, UK) was 
added and after 3 minutes the tubes were centrifuged for 15 minutes, at 12000xg, 4ᵒC. The clear 
upper phase in the tube was then carefully removed into a new low-binding Eppendorf tube and 
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incubated for 10 minutes after 500ul of isopropanol (molecular grade, Fisher Scientific, 
Loughborough, UK) was added. After another 15-minute, 12000xg, 4ᵒC spin the resulting pellet was 
re-suspended in 1ml 75% ethanol (molecular grade, Fisher Scientific, Loughborough, UK), briefly 
vortexed and centrifuged for 5 minutes at 7,500xg, 4ᵒC. The supernatant was then removed and the 
RNA pellet allowed to air dry in a pre-sterilised biosafety cabinet under laminar flow, before another 
re-suspension in 1ml 75% ethanol and spin for 5 minutes at 7,500xg, 4ᵒC. After air-drying the pellet 
was re-suspended in 40ul of nuclease free H2O (IDT, Leuven, Belgium) and placed on ice.  
For downstream miRNA analysis DNA was removed by mixing 1ul of extracted RNA with 1ul 10x 
DNase reaction buffer, 1ul DNase I (both cat no. 18068015, Thermo Fisher Scientific, Paisley, UK) and 
7ul nuclease free H2O. The tubes were then incubated for 15 minutes at RT and then 5ul 25mM EDTA 
was added to the tube which was incubated at 65ᵒC for 10 minutes to deactivate the DNase.  
2.8.2 RNA Yield Quantification 
The concentration and purity of RNA samples was assessed by measuring the absorbance at 
wavelengths of 230nm, 260nm and 280nm on a NanoDrop spectrophotometer (ND-1000, 
NanoDrop). First, a 1ul aliquot of the RNA sample was diluted by adding to 9ul of nuclease free H2O 
and vortexed. 1ul of this dilution was added to the nanodrop and the A260/A230 and A260/A280 
ratios were calculated. Only samples with a A260/A230 >1.85 and A260/A280 >2 were subsequently 
used for cDNA synthesis. The A260 value was multiplied by 40 to determine the concentration of 
RNA in ug/ml. 
2.8.3 cDNA Synthesis From mRNA 
The Maxima First Strand cDNA Synthesis Kit (cat no. K1671, Thermo Fisher Scientific, Paisley, UK) 
was used to convert RNA to cDNA, with 200 – 600ng of RNA typically used as a template for the 
reaction. The template RNA, 10x dsDNase buffer and nuclease-free H2O were added to a low binding 
Eppendorf tube, centrifuged at 200xg, 30 seconds and incubated at 37ᵒC for 3 minutes. The 5x 
reaction mix, RT enzyme mix and nuclease-free water were then added and the tubes incubated in 
a thermocycler with a 10 min 25ᵒC first step, followed by 15min at 50ᵒC and finally 5 min at 85ᵒC. 
The cDNA product was then immediately used for qPCR with the remaining cDNA stored at -80ᵒC. 
2.8.4 cDNA Synthesis From miRNA   
cDNA synthesis for miRNA expression assays were performed using the TaqMan™ MicroRNA Reverse 
Transcription Kit (cat no. 4366596, Thermo Fisher Scientific, Paisley, UK). Prior to reverse 
transcription, RNA samples were diluted into the 200ng/ml – 2ug/ml range using nuclease free H2O. 
5ul RNA was then mixed with the RT reaction mix and the reverse transcription performed in a 
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thermocycler under the following conditions: 30 minutes at 16ᵒC, 30 minutes at 42ᵒC and finally 5 
minutes at 85ᵒC. The resulting cDNA was then diluted 10-fold in nuclease free H2O and used 
immediately for qPCR, with left over sample stored at -80ᵒC. 
2.8.5 qPCR for Gene Expression Analysis 
Primers for mRNA targets were re-constituted in 0.1x TE buffer at 20x working concentration and 
kept at -80ᵒC, before use at a final concentration indicated in Table 2.6.5.1. In a semi-skirted PCR 
plate (cat no. HSL9645, Bio-Rad, Watford, UK) the primer pairs were added along with mastermix 
(PrecisionPLUS qPCR mastermix with SYBR, Primerdesign, Camberley, UK), nuclease-free H2O and 
cDNA (20-80ng). All samples used were biological triplicates and run as technical duplicates. The 
plate was sealed with an optical adhesive seal (cat no. 4360954, Thermo Fisher Scientific, Paisley, 
UK) and briefly centrifuged at 100xg to collect the mix at the bottom of the wells. Using a Bio-Rad 
CFX96 thermocycler, qPCR was then performed under the following conditions: 2 minutes at 95ᵒC 
1x cycle, then 10 seconds 95ᵒC and 60 seconds 60ᵒC for 40x cycles, with fluorescence detection using 
the FAM channel.  
2.8.6 qPCR for miRNA Expression Analysis 
The miR-155 or miR-191 (housekeeping miRNA gene) primers (Table 2.6.5.1) were added to wells of 
an optical PCR plate (cat no. 4346907, Thermo Fisher Scientific, Paisley, UK), before mastermix 
(TaqMan™ Fast Advanced Master Mix with ROX, Thermo Fisher Scientific, Paisley, UK), nuclease free 
H2O and cDNA (diluted 20-fold) were also added. All samples used were biological triplicates and run 
as technical duplicates. The plate was sealed with an optical adhesive (Thermo Fisher Scientific, 
Paisley, UK) and briefly centrifuged to collect the mix at the bottom of the wells. The qPCR was then 
performed on a qPCR thermocycler (StepOne Plus, Applied Biosystems, Carlsbad, USA) under the 
following conditions: 2 minutes at 50ᵒC for 1x cycle, 20 seconds at 95ᵒC 1x cycle, then 3 seconds at 
95ᵒC and 30 seconds at 60ᵒC for 40x cycles, with fluorescence measured through the ROX channel. 
Prior to analysis of the data the threshold value of the amplification plot was adjusted to 0.2 and the 
Cq values of the no template control wells checked for non-specific amplification. 
2.8.7 Analysis of qPCR Data 
qPCR data for mRNA and miRNA levels was analysed by the ‘2–∆∆Ct method’ [299]. After calculating 





Table 2.8.1 Primers used for qPCR. 




GGAAAAATAGGCCGAATGAT GAGCCTGGCCTGATAGTAG 250nM 
18S rRNA 
(human) 
AGGAATTGACGGAAGGGGACCAC GTGCAGCCCCGGACATCTAAGG 200nM 
ARNTL1 
(mouse) 
GCCTACTATCAGGCCAGGCTCA AGCCATTGCTGCCTCATCATTAC 400nM 
18S rRNA 
(mouse) 
GTCCTGGGTTCTGCATGATG CATTAAGGGCGTGGCGCGG 250nM 
miR-155 
(mouse) 
Unknown (ID 002571, Thermo) - 500nM 
MiR-191 
(mouse) 
Unknown (ID 002576, Thermo) - 500nM 
 
2.9 Cell Viability/Proliferation Assays 
2.9.1 Alamar Blue Cell Viability Assay  
Cell viability was quantified by the alamar blue assay, which involves incubating cells in a solution 
containing 0.02% resazurin (Santa Cruz Biotechnology). Resazurin is a non-toxic, cell permeable dye 
which can be irreversibly reduced to the highly fluorescent resorufin in the presence of the reducing 
agents NADH and NADPH. Consequently, the accumulation of resorufin and the fluorescence it emits 
corresponds to the presence of NADH and NADPH, which themselves correlate with metabolically 
active cells and hence provide a readout of viability. It should be noted that resorufin induced 
fluorescence doesn’t allow quantification of total NADH and NADPH per se, but rather reflects their 
rate of turnover – as occurs during metabolism. 
All alamar blue assays were set up in 96-well plates under normal culture conditions. 4 hours prior 
to the measurement of fluorescence, 90% of the wells’ media volume was discarded and then 
replaced with fresh media, which was repeated once more. 10% of the wells’ volume was then 
discarded and replaced with 0.2% resazurin solution, thus giving a final concentration of 0.02% 
resazurin. The 0.2% resazurin was made fresh on the day of the assay by diluting a 2% resazurin 1x 
PBS stock 10-fold in culture media. The plate was then returned to the incubator for approximately 
4 hours after which the fluorescence was then read on a plate reader (Spark 10M, Tecan, Mannedorf, 
Switzerland) at an excitation wavelength of 560nm and emission wavelength of 590nm. After 
subtracting the blank average (wells with just media and no cells) fluorescence from all wells on the 
plate, the fluorescence for each well was expressed as a percentage of the untreated control (each 
column on the well plate has its own individual untreated control), which was taken as a readout for 
viability.    
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All viability analysis involved the use of technical triplicates, with the mean % viability of the 
untreated control calculated by averaging the means of two separate biological experiments. 
Because of the day to day variability that can occur when using tbh7ox, the replicate biological 
experiments using tbh7ox were performed simultaneously, using different flasks of NHDFs for each 
experiment (different by <5 passages) and different diluted stocks of tbh7ox. 
2.9.2 XTT Cell Proliferation Assay  
The XTT (2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide) assay 
operates on the same principle as alamar blue, functioning as a readout of metabolically active cells. 
Similar to resazurin, XTT is reduced by reductants such as NADH and NADPH, however this occurs at 
the plasma membrane given XTT isn’t cell permeable. To overcome this, PMS (phenazine 
methosulfate) or menadione is used as an electron-carrier intermediate within XTT assays to transfer 
electrons from NADH or NADPH to XTT, resulting in the conversion of XTT to the orange-coloured 
dye formazan.  In the context of cell proliferation, changes in absorbance due to formazan build up 
correspond to the extent of cell proliferation, given more proliferation results in more metabolically 
active cells and hence more XTT reduction. Hence XTT and alamar blue assays can be used for both 
cytotoxicity and proliferation analysis. 
The XTT assay was found to be more sensitive and consistent than the alamar blue assay, however 
the cost of this assay was far more expensive than using alamar blue. Therefore, as a compromise 
alamar blue was used exclusively for the cytotoxicity assays which constituted a much greater 
volume of work, whereas XTT was used for cell proliferation analysis. 
To perform the assay, XTT (Sigma-Aldrich, Gillingham, UK) was diluted in DMEM (no phenol red, 
Gibco, Thermo Fisher Scientific, Paisley, UK) to a final concentration of 1mg/ml, whilst a 950ng/ml 
PMS (Sigma-Aldrich, Gillingham, UK) 1x PBS solution was also added to the same tube at a final 
concentration of 9.5ng/ml, constituting a 5x XTT working reagent. This working reagent was stored 
as single use aliquots at -20ᵒC and thawed at 56ᵒC on the day of the assay.   
4 hours prior to the assay, cells were split and seeded down in a 96-well plate at a density of 4,000 
cells/well, before being centrifuged at 300xg for 30 seconds to promote adherence. 6 hours later, in 
the well-plate 90% of the wells’ media volume was discarded and then replaced with fresh media, 
with this step repeated once more. 20% of the well volume was then discarded and replaced with 
the XTT working reagent, after which the plates were returned to the incubator.  
After 24, 48 or 72 hours the absorbance was read on a plate reader ((FLUOstar Omega, BMG Labtech, 
Aylesbury, UK) at wavelengths of 450nm and 690nm. The absorbance at 690nm was subtracted from 
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the 450nm absorbance for each well, and the blank (media with no cells) average (n=3) was then 
subtracted from all wells on the plate. By comparing the absorbances measured at different 
timepoints, the relative change in absorbance between the same timepoints indicates relative cell 
proliferation, which distinguishes this assay from regular viability analysis where only one 
measurement is made.  
2.9.3 CC50 Calculations 
CC50 (50% cytotoxic concentration) calculations for the cell viability analysis of NHDFs treated with 
tbh7ox and/or other compounds was performed using nonlinear regression within the GraphPad 
Prism software (GraphPad Software, San Diego, USA). The treatment compound concentrations 
were log transformed and a best curve was generated by the software using the equation: Y=Bottom 
+ (Top - Bottom)/(1 + (IC50/X)^HillSlope). The curve fitting was performed using least squares 
regression without any weighting. Asymptotic confidence intervals for the CC50 values were 
calculated using the Prism software at a confidence level of 95%. 
2.10 Lactate Assay 
Measurement of lactate released into the culture media of TGF-β treated and untreated NHDFs was 
performed using a commercial L-lactate assay kit (cat no. 8308, Sciencecell, Carlsbad, USA). NHDFs 
were first seeded in a 24-well plate at a density of 8,000 cells/well and the following day were treated 
with or without 10ng/ml TGF-β as detailed in section 2.3.10, using DMEM without phenol red (Gibco, 
Thermo Fisher Scientific, Paisley, UK). 24, 48, 72 and 96-hours following addition of the TGF-β the 
supernatants in each well (approximately 500ul) were collected and stored at -20ᵒC until the day of 
the assay.  
On the day of the assay, 50ul of each sample (in triplicate) was added to 200ul of the kit assay buffer 
in a 96-well plate. Additionally, the L-lactate standard provided with the kit was diluted in assay 
buffer at concentrations ranging from 0.0625 – 2mM, with 50ul of each standard added to 200ul 
assay buffer (in duplicate) in the 96-well plate along with two blanks (blank 1 - 250ul assay buffer, 
blank 2 – 50ul no phenol red DMEM and 200ul assay buffer). 2ul of the kit enzyme mix and 50ul of 
substrate mix was then added to each well and the absorbance at 490nm measured 20 minutes later 
using a plate reader ((FLUOstar Omega, BMG Labtech, Aylesbury, UK). 
The absorbance value of blank 1 was then subtracted from all standards on the assay plate and the 
absorbance of blank 2 subtracted from the NHDF supernatants on the plate. Using the equation 
produced by the standard curve the lactate concentration in the supernatants from the TGF-β 
treated/untreated NHDFs was then calculated.  
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2.11 Statistical Analysis 
All data presented within this thesis is shown as the mean +/- SD (standard deviation). In vitro 
experiments involving NHDFs were performed using either 2 or 3 biological replicates and typically 
repeated once or twice (as stated in figure legends). In vitro experiments using the miR-155KO and 
matched WT derived cells were performed using 3 or 4 biological replicates and were repeated once 
or twice (as stated in figure legends). 4 SSc dermal fibroblasts and 2 or 3 matched control dermal 
fibroblasts were used for in vitro experiments reported in Chapter 6, with these experiments 
repeated once or twice (as indicated in the figure legend). The mean and SD reported for all in vitro 
work is calculated from the means of the separate biological experiments (n=2 or n=3), thus the SD 
is the variability between the separate experiments. 
 For the in vivo work in Chapter 5, one biological sample was collected for each participant study 
day. Unless otherwise stated, for the treatment days error bars represent the error of two technical 
replicates, whereas the baseline is the mean and error are calculated from 2 or 3 biological 
replicates, as indicated in the text. 
Student’s independent t-tests were used to test for significance when analysing two datasets. In all 
instances where used, t-tests were two-tailed. For comparison of 3 or more datasets 1-way ANOVA 
was used, typically followed by a Dunnett’s post hoc test where significance between the control 
group versus all other groups was tested. In some instances where indicated, a Bonferroni post hoc 
test was performed to compare the means of all experimental groups. In Chapter 5, comparisons 
were made between datasets of different size, hence repeated measures ANOVA was used to 
account for this variability. 
For timecourse experiments multiple comparisons 2-way ANOVA was performed to test for 
significance between the experimental groups, timepoints and to identify any interaction between 
the experimental conditions and time. The 2-way ANOVA was also usually followed by a Dunnett’s 
post hoc test to compare experimental conditions against the control group.  
CC50 (50% cytotoxic concentration) calculations were also performed for viability experiments 
involving treatment with tbh7ox or inhibitors as described in section 2.9.3. 
All statistical tests were carried out using the software GraphPad Prism v5 (GraphPad Software, San 





Chapter 3. Interventions to Enhance NAD+ In Vitro 
3.1 Introduction 
Although renowned for almost a century for its role as an essential cofactor in cellular redox 
reactions, more recently NAD+ has gained increasing attention for its participation in other reactions 
– particularly those implicated in cellular ageing. SIRT1 and PARP1 are enzymes that require NAD+ 
for deacetylation and ADP-ribosylation of their substrates respectively, with both these activities 
thought to combat processes which promote ageing.  
SIRT1 is known to upregulate antioxidant defence systems [300-302], stimulate mitochondrial 
biogenesis [303-305] and dampen inflammation [306-308], whilst PARP1 detects and activates the 
repair of single strand DNA breaks [309]. Thus, under conditions of reduced NAD+ as would be 
expected to occur during ageing [70], it’s possible that the capacity of these enzymes would be 
impaired. Additionally, the accumulation of oxidative damage with age increases PARP1 activity, 
hence in the presence of lowered NAD+ this may come at the expense of SIRT1 activity thus 
exacerbating the decline in cellular function and perpetuating the ageing process. To further 
investigate this the contribution of PARP1 activity towards NAD+ depletion in NHDFs was probed, 
both under basal conditions and also during induced oxidative stress. 
Due to the heightened interest around NAD+’s function as a potentially key biomolecule in ageing, 
there is an intense search to identify compounds which can enhance NAD+ levels. At present, 
supplementation with NAD+ precursors have proven effective at achieving this goal [152, 310, 311], 
however in the context of age-related NAD+ decline precursor accessibility isn’t a driving force behind 
NAD+ depletion, hence additionally targeting the pathways facilitating the decline would seem the 
optimal approach. A number of naturally occurring polyphenols (e.g. resveratrol, apigenin) are 
known to target various enzymes involved in NAD+ metabolism and pathways affected by ageing, 
therefore represent leading candidates as potential NAD+ enhancers. This chapter will explore the 
capacity of these compounds to enhance NAD+ levels and improve resistance to oxidative stress – 
both individually and as a combination.  
3.2 Aims 
This chapter sets out to assess the ability of compounds targeting important pathways in NAD+ 
metabolism to modify NAD+ levels in vitro and whether a multi-compound approach is optimal for 
the purpose of maximum NAD+ enhancement. Additionally, identifying whether oxidative stress 
depletes NAD+ and if PARP1 can be manipulated to enhance NAD+ under such conditions is also 




The combination of multiple NAD+ targeting compounds will result in a superior enhancement of 
NAD+ compared to the single compound approach. It is expected NAD+ levels will be downregulated 
under conditions of oxidative stress, an outcome attenuated in the presence of pharmacological 

































3.4 The NAD+ precursor NAM Enhances NHDF NAD+ Levels 
First it was sought to determine the efficacy of nicotinamide (NAM) at modulating NAD+ levels in 
NHDFs. Over a 36-hour timecourse using varying doses of NAM (Figure 3.4.1), the maximal 
enhancement of NAD+ levels (measured using an NAD+ cycling assay) achieved was a 294% increase 
after 12 hours with 100uM NAM, which failed to achieve statistical significance via 1-way ANOVA 
due to the high standard deviation (SD) between replicates (SD – 248%). It should be noted that 
outlier testing using the ROUT (robust regression and outlier removal) method [312] did identify the 
100uM dose at 12 hours as the sole outlier in the data set, however the NAD+ increase recorded for 
the two individual experiments performed was 470% and 118%, suggesting that despite the high 
error across the two experiments these conditions do still promote a substantial increase in NAD+.  
 
On average, the different doses of NAM increased NAD+ by 33% after 4 hours, by 82% after 8 hours, 
109% after 12 hours and 29% after 48 hours. Additionally, after 24 hours, on average the different 
NAM doses reduced NAD+ levels by 36%. 2-way ANOVA found that the NAD+ levels in response to 
NAM are both highly time and concentration dependent (p<0.001 for both), emphasising the likely 
 
Figure 3.4.1 NHDF NAD+ levels in response to NAM treatment. 
NHDFs were treated with 0, 100, 200, 400, 600 or 100uM NAM for 4, 8, 12, 24 or 36 hours (n=3 technical 
replicates for all conditions). NAD+ levels were measured by an NAD+ cycling assay and normalised to total 
protein measured via a BCA assay. NAD+ levels are expressed as the % of the untreated control for each 
timepoint. 1-way ANOVA was performed for each timepoint and a Dunnett’s post hoc test was used to test 
for significance against the untreated control for each timepoint control. Error bars represent +/- SD. Data 
shown is the average for 2 separate biological experiments (n=2). 
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need to optimise dose and concentration when taking a precursor approach to increasing NAD+ 
titres.  
 
3.5 NHDF NAD+ Levels in Response to Dietary Compounds 
Resveratrol (RSV) is a polyphenol which previously attracted attention in the ageing field due to a 
number of studies highlighting its ability to attenuate age-related markers [63, 164, 313, 314], with 
activation of SIRT1 believed to be the dominant mechanism. How it activates SIRT1 remains 
controversial, with some suggestions it occurs via increased NAD+ [315], whilst other studies endorse 
increased SIRT1 transcription [316] or direct protein binding [317] as the mechanisms responsible. 
Apigenin is another polyphenol which has demonstrated a capacity to enhance NAD+ [156] courtesy 
of its ability to inhibit CD38: a highly inefficient consumer of NAD+ whose activity is upregulated with 
age [318].  
 
To determine whether they were capable of increasing NAD+ in NHDFs, RSV was added to NHDFs at 
doses of 60uM and 100uM and apigenin at doses of 10uM, 20uM and 50uM for 12, 24 and 48 hours 
(Figure 3.5.1). These doses were determined to constitute the appropriate range given previous 
experiments performed using RSV and apigenin within the former research group of Prof Dianne 
Ford and the other studies which have used these compounds in vitro [319-323]. It should be noted 
however that these doses are higher than what could ever be achieved in vivo, which is a limitation 
of this work. 
 
RSV was unable to induce any significant enhancement in NAD+, with a 34% decrease (p<0.05) at 
100uM after 24 hours the only notable difference. 50uM apigenin was able to significantly enhance 
NAD+ after 12 hours (56% increase, p<0.05), with non-significant increases of 23% after 24 hours and 
20% after 48 hours also recorded for this dose. 
 
Two other dietary compounds which previous studies have shown to be key regulators of metabolic 
and NAD+ related pathways are alpha lipoic acid (ALA) [324, 325] and quercetin [156, 326]. ALA 
primarily functions as an antioxidant which can also promote mitochondrial biogenesis and OXPHOS 
[327], hence would be expected to modulate NAD+ via the latter. There is also evidence that 
quercetin may increase mitochondrial function via the upstream activation of AMPK [328], which 
combined with its previously demonstrated ability to inhibit the NADases CD38 [156] and CD73 [329] 




It was therefore surprising to find that 100uM ALA significantly decreased NAD+ after 4 hours (58% 
decrease, p<0.001), 8 hours (25% decrease, p<0.05) and 16 hours (23% decrease, p<0.01), before 
rising just above basal levels after 24 hours (16% increase, non-significant) (Figure 3.5.2 A). 
Interestingly, for the first 3 timepoints NAD+ levels also appear to somewhat decrease in a dose 
dependent manner. Contrastingly, quercetin was able to significantly enhance NHDF NAD+ levels 
(Figure 3.5.2 B), however this was limited to doses of 27uM (27% increase, p<0.01) and 89uM (23% 
increase, p<0.05) after 8 hours of treatment.  Consequently, quercetin mediated upregulation of 
NHDF NAD+ levels is short-lived, showing similarity to apigenin which is especially noteworthy given 











































Figure 3.5.1 NHDF NAD+ levels in response to RSV and apigenin treatment. 
(A) NHDFs were treated with 60uM RSV, 100uM RSV or 0.1% DMSO for 12, 24 and 48 hours (n=3 technical 
replicates for all conditions). (B) NHDFs were treated with 10uM, 20uM or 50uM apigenin or 0.05% DMSO for 
12, 24 and 48 hours. NAD+ levels were measured by a cycling assay and normalised to protein via a BCA assay. 
NAD+ levels are expressed as the % NAD+ of the DMSO treated control for each timepoint. 1-way ANOVA was 
performed for each timepoint and a Dunnett’s post hoc test was used to test for significance against the DMSO 















3.6 The Multi-Targeted Intervention NTC Increases NAD+ in NHDFs but not Jurkat Cells 
Next, a combination of dietary compounds including those tested thus far was used to explore 
whether a multi-targeted supplement approach could offer superior enhancement of NAD+ levels in 
vitro, as hypothesised. The combination (Table 3.6.1) used was based on a formulation developed 
by an industry collaborator Nuchido Ltd. and is credited to them, hence is termed NTC (Nuchido 
Time+ Cocktail). The ultimate goal was to test the cocktail in human participants, however as a proof 
of concept it was deemed of use to also assess its efficacy in vitro. The Jurkat T lymphocyte cell line 
was used due to these being a type of PBMC (peripheral blood monocyte) which were the blood cells 
 
 
Figure 3.5.2 NHDF NAD+ levels in response to ALA and quercetin treatment. 
(A) NHDFs were treated with the ALA (A) and quercetin (B) doses indicated along with 0.1% DMSO (only for 
quercetin) for 4, 8, 16 and 24 hours (n=3 technical replicates for all conditions). NAD+ levels were measured 
by a cycling assay and normalised to protein via a BCA assay, shown here as % NAD+ of the 0.1% 
DMSO/untreated control for each timepoint. 1-way ANOVA was performed for each timepoint and a 
Dunnett’s post hoc test was used to test for significance against the untreated/DMSO control. Error bars 




planned to be used for the in vivo testing. Additionally, NHDFs were also used so that the efficacy of 
the cocktail could be compared to the results previously obtained for the compounds tested 
individually.  
Compared to NHDFs treated with 0.23% DMSO (the same DMSO concentration as NTC) for each 
timepoint, the NTC treatment increased NAD+ levels in the NHDFs by 53% (unpaired student’s t-test, 
p=0.016) after 12 hours and 51% (unpaired student’s t-test, p=0.023) after 24 hours, with a 3% 
decrease at the 48-hour timepoint (Figure 3.6.1 A). Hence, NTC was effective at increasing NAD+ for 
24 hours before losing its potency by 48 hours.  
 














In contrast, for the Jurkats no statistically significant increases in NAD+ tested for by 1-way ANOVA 
were recorded during the same time interval when comparing NTC and 0.23% DMSO treated cells 
(Figure 3.6.1 B). Additionally, Jurkats were also treated with 100uM NAM + 0.23% DMSO to compare 
the NTC combination against a solitary precursor, which also failed to induce any significant NAD+ 
enhancement compared to the DMSO treated controls. There was however a 73% increase in NAD+ 
for the NTC treated cells after 12 hours, whereas the NAD+ in the NAM treated Jurkats only increased 
by 25%.  
Compound  Concentration  Target 
Alpha-lipoic Acid (ALA) 100Um NQO1 
Apigenin 50Um NQO1, CD38 
Ascorbic Acid 100uM - 
Epigallocatechin Gallate (EGCG) 2uM NNMT 
Quercetin  18uM CD73, CD38, NAMPT 
Resveratrol (RSV) 20uM NRK1/2, NMNAT1 
Rutin 4uM NAMPT 
Abbreviations: NQO1 - NAD(P)H dehydrogenase (quinone) 1, NNMT - nicotinamide N-methyltransferase, 
NAMPT - nicotinamide phosphoribosyl transferase, NRK1/2 – nicotinamide riboside kinase 1/2, NMNAT - 
nicotinamide mononucleotide adenylyl transferase. 
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The favourable effects of the cocktail being limited to the NHDFs was surprising given their lower 
basal metabolic rate and anticipated lower expression of CD38 being a non-immune cell type, one 
of the key targets of the cocktail. This does however highlight that a multi-supplement approach will 



























Figure 3.6.1 NTC treated NHDF and Jurkat NAD+ levels.  
(A) NHDFs were treated for 12, 24 and 48 hours with NTC or 0.23% DMSO. (B) Jurkat cells were treated for 12, 
24 and 48 hours with NTC, 0.23% DMSO or 0.23% DMSO and 100uM NAM (n=3 technical replicates for all 
conditions). NAD+ levels were measured via a cycling assay before being normalised to protein concentration 
quantified by a BCA assay. Data is shown as % NAD+ of the DMSO treated control for each timepoint, error bars 
represent +/- SD. Statistical significance was tested for by an unpaired Student’s t-test for panel A and by 1-way 
ANOVA followed by a Dunnett’s post hoc test for all conditions at each timepoint for panel B. *p<0.05. Data 
shown is the average for 2 separate biological experiments (n=2). 
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3.7 NAD+ Levels are PARP1 Dependent Under Conditions of Oxidative Stress 
To test the hypothesis that PARP1 activity is a key determinant of cellular NAD+ levels, NHDFs were 
treated with the specific PARP1 inhibitor rucaparib (AG014699) [330] for 12, 24 and 48 hours (Figure 
3.7.2 A). The largest increases were recorded for 1uM and 5uM rucaparib doses after 12 hours, 
resulting in NAD+ increases of 32% and 20% respectively compared to the DMSO treated control, 
without achieving statistical significance. 
Although DNA damage is perpetual and thus PARP1 is constitutively active, its activity is easier to 
assess under conditions of induced DNA damage. The oxidising agent tbh7ox (tert-butyl 
hydroperoxide) can be used for this purpose by promoting extensive oxidative damage to DNA [331, 
332], resembling the type of damage which accumulates during ageing but on a drastically amplified 
scale. The easiest way to assess PARP1 activity is by measuring levels of poly(ADP-ribosyl) (PAR) 
which is the moiety PARP1 adds to its substrates in the form of a multi-branched polymer. By 
measuring protein PARylation via western blotting, a 30-minute incubation in the presence of 40uM 
tbh7ox is shown to increase PAR levels which is attenuated in NHDFs pre-treated for 24 hours with 
varying concentrations of rucaparib (Figure 3.7.1 A). 
The 10uM rucaparib dose was most effective at reducing PAR levels and thus PARP1 activity, 
however although statistically insignificant there was small decrease in NHDF viability (5%) for the 
10uM rucaparib treatment after 48 hours (Figure 3.7.1 B), hence it was decided 5uM rucaparib was 
the optimal concentration to use for further PARP1 inhibition experiments. 
To determine whether PARP1 inhibition could alter NAD+ levels under conditions of oxidative stress, 
NHDFs were treated with a low dose (40uM) or high dose (100uM) of tbh7ox following a 24-hour 
incubation with 5uM rucaparib or 0.1% DMSO. The cells were then harvested at various timepoints 
following the tbh7ox insult and NAD+ levels subsequently measured, before being expressed as a % 
of the non-tbh7ox treated control at each timepoint (Figure 3.7.2 B and C). Interestingly, as 
determined by 2-way ANOVA rucaparib was able to significantly increase NAD+ following the low 
dose of tbh7ox (p<0.05), with this effect greatest after 24 hours where the NAD+ levels were 90% 
higher in the rucaparib treated NHDFs (p<0.05). 
Contrastingly, the NAD+ levels were reduced in response to rucaparib following treatment with 
100uM tbh7ox, with significant differences recorded for 60-minute and 120-minute tbh7ox 
incubations (both p<0.01) as measured by 2-way ANOVA. This was likely due to the visibly increased 
presence of dead floating cells that occurred within the rucaparib treated NHDFs due to their 
inability to repair extensive oxidative DNA lesions under conditions of PARP1 inhibition. Hence, it 
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appears that lower levels of oxidative stress induce NAD+ depletion via increased PARP1 activity, 
however under conditions of high oxidative stress PARP1 inhibition fails to reverse this decrease due 
to the cytotoxic effect of combining PARP1 inhibition and severe oxidative damage: thus depleting 









Figure 3.7.1 Rucaparib inhibits tbh7ox induced PARylation.  
(A) NHDFs were treated for 24 hours with the concentrations of rucaparib indicated, after which 40uM 
tbh7ox was added for 30 minutes. The NHDFs were collected and the extent of PARylation was probed by 
western blotting using an anti-PAR antibody and H3 as a loading control. The image shown is 
representative of 3 separate biological experiments. (B) Densitometry analysis was performed for the blots 
(n=3) using ImageJ software, with PAR staining density for all conditions treated with tbh7ox expressed as 
a % of the PAR staining density for NHDFs treated without tbh7ox or rucaparib. Error bars represent +/- 
SD. (C) The viability of NHDFs in response to various concentrations of rucaparib for 12, 24 and 48 hours 
was assessed using an alamar blue assay (n=3 technical replicates for each concentration). Data is shown 
as % viability of the DMSO treated control, error bars represent +/- SD. The data in panel B is the average 








Figure 3.7.2 Tbh7ox regulation of NHDF NAD+ under conditions of PARP1 inhibition. 
(A) NHDFs were treated with 1uM or 5uM rucaparib or 0.1% DMSO and harvested after 12, 24 and 48-hour 
incubations so that NAD+ could be measured by an NAD+ cycling assay (n=3 technical replicates for all 
conditions). Protein levels were then quantified by a BCA assay and the NAD+ levels were expressed as % ng 
NAD+/ug protein of the DMSO treated control for each timepoint. NHDFs were also pre-treated with 5uM 
rucaparib or 0.1% DMSO for 24 hours, after which (B) 100uM of tbh7ox was added to the media and cells 
were harvested 10, 30, 60 and 120 minutes later, or (C) 40uM was added and cells harvested 10 minutes, 
30 minutes, 60 minutes and 24 hours later (n=3 technical replicates for all conditions). NAD+ levels were 
measured and expressed as done for panel A. Data is presented as % ng NAD+/ug protein of the DMSO 
treated control, error bars represent +/-SD. Significance was tested for by 1-way ANOVA for panel A and by 
2-way ANOVA with a Dunnett’s post hoc test for panels B and C. *p<0.05, **p<0.01. The results shown are 
the average of 2 separate biological experiments (n=2). 
60 
 
3.8 Quercetin and ALA Induce Antioxidant Effects in NHDFs 
The compounds previously tested for their ability to increase NAD+ levels were also tested for their 
capacity to protect against oxidative stress induced by tbh7ox. NAM, ALA, apigenin, RSV and 
quercetin have all previously been shown to elicit antioxidant effects in vitro [333-337] and in vivo 
[338-343], therefore it was of interest to determine if these effects were also present in NHDFs.  
NHDFs were treated with the compounds (apart from NAM) for 24 hours, before 40uM tbh7ox 
containing media was added to the cells for 1 hour.  For NAM a 12-hour pre-treatment was used 
given this was the point of maximal NAD+ enhancement previously recorded (Figure 3.4.1), with 
tbh7ox then added for 1-hour as for the other compounds. Following this incubation, the media 
were replaced with fresh media once again containing the compounds used for the pre-treatment 
but without tbh7ox, with viability then assessed using a 4-hour incubation in 0.02% alamar blue 
solution 20 hours post tbh7ox exposure. 
A significant reduction in tbh7ox induced cytotoxicity across a range of concentrations was only 
observed for ALA and quercetin, with NAM, apigenin and RSV unable to offer any protection against 
the oxidative stress (Figure 3.8.1). The efficacy of quercetin was particularly impressive, with 45uM 
quercetin increasing the raw viability (minus the blank) by 81% compared to the 0.2% DMSO (DMSO 
concentration used for all NHDFs) control when pre-treated with 40uM tbh7ox (p<0.001). The 
smallest increase in viability recorded for quercetin and tbh7ox treated cells compared to the tbh7ox 
control was 46% (p<0.01), which was at 9uM quercetin, the lowest concentration used.  
ALA was also capable of protection against the tbh7ox insult, with concentrations of 20uM and 50uM 
increasing viability by 79% (p<0.01) and 76% (p<0.01) compared to the tbh7ox treated control 
respectively. Surprisingly, the higher doses of 67uM, 200uM and 400uM improved viability post 
tbh7ox treatment, but failed to achieve statistical significance. The viability in the non-tbh7ox 
treated NHDFs at these higher concentrations did show a small decline (9% decrease 200uM, 12% 
decrease 400uM, non-significant) however, suggesting there may be some toxic effects of ALA in 
NHDFs at these higher doses. Nonlinear regression analysis to calculate EC50 (half maximal effective 
concentration) was performed for the experiments using quercetin and ALA, however complete 
confidence intervals (at 95% confidence level) were undefined, thus EC50 values are unable to be 
accurately calculated from this data. 
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For the NAM treated NHDFs, no significant increase in viability was recorded across a 10-800uM 
concentration range, suggesting solely increasing NAD+ isn’t sufficient to protect against tbh7ox-











Figure 3.8.1 Viability of NHDFs pre-treated with putative NAD+ enhancers following induced oxidative 
stress. 
NHDFs were pre-treated with (A) ALA, (B) apigenin, (C) quercetin and (D) RSV for 24 hours as well as (E) NAM 
for 12 hours at the concentrations indicated (n=6 technical replicates for all conditions). 40uM tbh7ox was 
then added for 1 hour to half the wells (n=3) for all conditions, before the media was replaced with fresh 
media containing the same compounds as prior to the tbh7ox addition. Viability was then assessed 20 hours 
later by incubating the cells for 4 hours in 0.02% alamar blue solution, after which fluorescence was quantified 
using a fluorometer. The fluorescent values were then expressed as a % of the non-tbh7ox treated control as 
shown here. Error bars represent +/-SD. Significance was tested for in both the tbh7ox and non-tbh7ox groups 
by 1-way ANOVA, followed by a Dunnett’s post hoc test. The data shown is the average of 2 separate 




3.9 NTC Protects Against Oxidative Stress in a PARP1 and SIRT1 Independent Manner 
The NTC supplement combination was next tested for any potential antioxidant capacity in NHDFs 
treated with tbh7ox. As done previously, the cells were treated with NTC for 24 hours before a 1-
hour incubation in the presence of 60uM tbh7ox, after which the cells were returned to the normal 
NTC containing media and viability assessed 24 hours later. A higher concentration of tbh7ox was 
used compared to previous experiments due to a noticeable decrease in the cytotoxicity tbh7ox, 
possibly as a consequence of long-term storage. NHDFs were also pre-treated for 12 hours with 
NAM, to compare NTC to an NAD+ precursor only approach.  
NTC was able to completely protect the NHDFs against any tbh7ox induced cytotoxicity, in contrast 
to the NAM treated cells (Figure 3.9.1 A). Surprisingly, the protective effects of NTC showed no 
attenuation when NTC was added along with 5uM rucaparib, suggesting NTC combats oxidative 
stress in a PARP1-independent manner. As would be expected, inhibition of the DNA repair enzyme 
PARP1 using rucaparib does result in sensitisation of the NHDFs to tbh7ox, with tbh7ox 
concentrations of 60uM and 80uM found by multiple comparisons 2-way ANOVA to significantly 
reduce NHDF viability when combined 5uM rucaparib (both p<0.001).  
Pre-treatment with NTC (Figure 3.9.1 B) was able to partially attenuate the sensitisation to tbh7ox 
induced by rucaparib, as evidenced at tbh7ox doses of 100uM and 140uM whereby NHDF viability 
was significantly increased (2-way ANOVA, p<0.001) when NTC was also added to cells treated with 
tbh7ox and rucaparib. This therefore implies that instead of enhancing PARP1 facilitated DNA repair, 
NTC is protecting against tbh7ox in a mechanism dependent on neutralising the damaging ROS 
(reactive oxygen species).  
The CC50 (50% cytotoxic concentration) and CI (confidence intervals) values for curves generated 
using nonlinear regression were: tbh7ox - 90.6, 95% CI (85.0, 96.2); tbh7ox with rucaparib - 73.8, 
95% CI (57.2, 90.4) and tbh7ox with rucaparib and NTC - 144.5, 95% CI (0.0, 356.5). Although pre-
treatment with rucaparib reduced the CC50 following the tbh7ox insult, there was no statistically 
significant difference between the CC50 values as tested by 1-way ANOVA, emphasising that the 
sensitisation to tbh7ox via PARP1 inhibition is only limited to higher tbh7ox concentrations. Likewise, 
the CC50s for NHDFs treated with tbh7ox, rucaparib and NTC showed no significant difference to the 
other conditions, however this comparison was hindered by the large 95% CI (0.0, 356.5).  
Next, a similar approach was used whereby rucaparib was substituted with the small-molecule SIRT1 
inhibitor EX527 [344]. Pre-treatment with 40uM EX527 failed to enhance tbh7ox induced 
cytotoxicity at all tbh7ox concentrations (2-way ANOVA), suggesting SIRT1 plays a minimal role 
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protecting NHDFs against acute oxidative stress (Figure 3.9.2). Nonlinear regression analysis was 
used to plot a curve of tbh7ox concentrations for the different conditions against viability, with the 
CC50 of tbh7ox for treatment of cells with just tbh7ox 72.1 (CI – 68.6 – 75.5) versus a CC50 of 94.8 
(CI – 88.7 – 100.0) for tbh7ox and an NTC pre-treatment (p<0.05, 1-way ANOVA). 
Co-incubating NTC treated NHDFs with EX527 failed to ameliorate the protective effects of NTC 
following tbh7ox exposure, as determined across all tbh7ox concentrations by 2-way ANOVA. 
Furthermore, the CC50 of tbh7ox in EX527 and NTC treated NHDFs was 93.3 (CI – 83.8 – 139.0), 
compared to 94.8 (CI – 88.7 – 100.0) for just the NTC pre-treatment, with no significant difference 
as determined by comparing the CC50s via 1-way ANOVA.  Hence, it appears SIRT1 activity has no 
beneficial role in NTC-mediated protection against tbh7ox.  
The failure of PARP1 or SIRT1 inhibition to abrogate the capacity of NTC to neutralise oxidative stress 
was surprising, hence it was next investigated whether the unknown mechanism responsible was 
dependent on adequate NAD+ availability by using the NAMPT inhibitor FK866 [345]. Initially, to 
characterise FK866’s ability to deplete NAD+ in NHDFs, NAD+ levels were measured following 24, 48 
and 72-hour treatments with 5, 10, 20 or 50nM of FK866 (Figure 3.9.3 A). Notable downregulation 
of NAD+ didn’t occur until the 48-hour timepoint at which 5uM FK866 reduced NAD+ by 48% 
compared to untreated NHDFs, whilst the other concentrations induced an 81-84% depletion. 
Further depletion occurred by the 72-hour timepoint, where the reduction ranged from 91-96% 
NAD+. 2-way ANOVA found a significant difference between the different timepoints (p<0.001) but 
not FK866 concentrations, although there was a significant interaction between timepoint and 



























Figure 3.9.1 NTC protects NHDFs against oxidative stress and PARP1 inhibition.  
(A) NHDFs were treated for 24 hours with 5uM rucaparib (ruc) or DMSO control with/without NTC or 
100uM NAM. The wells indicated were incubated for 1 hour with tbh7ox after which they were returned 
to normal media containing the compounds previously added (n=3 technical replicates for all conditions). 
After 20 hours cell viability was assessed via a 4-hour incubation in 0.02% alamar blue solution. Data is 
expressed for each condition as the percentage viability of untreated NHDFs, shown as the average of 2 
separate biological experiments. (B) NHDFs were treated for 24 hours with 5uM rucaparib or DMSO control 
with/without NTC. Concentrations of 0, 20, 40, 50, 60, 80, 100 and 140uM tbh7ox were then added to the 
wells for 1 hour. The media was then replaced with fresh media with/without 10uM rucaparib/NTC/DMSO. 
After 20 hours the cell viability was assessed using 0.02% alamar blue solution. Statistical significance in 
panel A was tested for by 1-way ANOVA with a Dunnett’s post hoc test. In panel B significance was tested 
for by 2-way ANOVA, with a Dunnett’s post hoc test where the tbh7ox group is designated as the control. 












As discussed already, severe NAD+ depletion will likely have deleterious consequences, hence cell 
viability was also assessed in response to various FK866 concentrations (1, 5, 10, 20, 50, 100 and 
200nM) after 48, 72 and 96-hour treatments using an alamar blue assay (Figure 3.9.3 B). Once again 
2-way ANOVA found a significant difference between the different timepoints (p<0.001), however 
this time there was also a significant difference between the varying FK866 concentrations 
(p<0.001), hence NHDF viability in response to FK866 is both time and concentration dependent. 
None of the FK866 concentrations induced a significant loss of viability 48 hours post-treatment 
despite all doses >10nM reducing NAD+ >80% at this timepoint, therefore the adverse effects of 
NAD+ depletion aren’t immediately translated to decreased cell viability. 
Taken together, the data for the NAD+ and cell viability analysis finds that a 48-hour treatment with 
10nM FK866 causes an 84% decrease in NAD+ without any notable loss in cell viability (98.4% viability 
of the control), hence these were the conditions chosen to pharmacologically induce NAD+ depletion 
for further experiments. 
Figure 3.9.2 NHDF viability following co-treatment with tbh7ox and EX527. 
NHDFs were treated for 48 hours with 40uM EX527 and/or NTC for 24 hours. The cells were then treated with 
concentrations of 0, 20, 40, 50, 60, 80, 100 and 140uM tbh7ox for 1 hour (n=3 technical replicates for all 
conditions). Afterwards fresh media containing EX527 and/or NTC was added, replicating conditions before 
the tbh7ox stimulus. After 20 hours cell viability was assessed via a 4-hour incubation in 0.02% alamar blue 
solution and the subsequent measurement of fluorescence. Data is represented the % viability of the DMSO 
treated control, shown as the average of two separate biological experiments (n=2). Error bars represent +/-







To test the effect of NAD+ depletion on viability in the presence of tbh7ox and whether reduced 
NAD+ reverses the protective effects of NTC against oxidative stress NHDFs were treated for 48 hours 
with/without 10nM FK866 and/or NTC, along with a 1-hour tbh7ox incubation 24 hours before 
viability was assessed. 
Compared to NHDFs treated with just tbh7ox, those which were also incubated with FK866 had 
significantly reduced viability for all tbh7ox concentrations used (multiple comparisons 2-way 
ANOVA, p<0.001 for all concentrations) (Figure 3.9.4).  
Moreover, the protective effects of NTC against tbh7ox were completely lost when it was added to 
NHDFs in combination with FK866, with the viability of cells treated with NTC, FK866 and tbh7ox 
significantly lower than those treated with just tbh7ox for tbh7ox concentrations of 20, 40, 50, 60, 
80 and 100uM (multiple comparisons 2-way ANOVA).  
Nonlinear regression analysis of the viability data was used to generate CC50 values for all conditions 
as follows: tbh7ox CC50 - 65.8, 95% CI (58.1, 80.5); tbh7ox with NTC CC50 - 96.2, 95% CI (80.7, 389.9); 
tbh7ox with FK866 CC50 - 11.53, 95% CI (0.0 – 103.5); tbh7ox with NTC and FK866 CC50 – 0.3, 95% 
CI (0.0 – 183.4). Hence, once again the beneficial effect of treating NHDFs with NTC before and after 
 
Figure 3.9.3 FK866 suppression of NHDF NAD+ levels and viability. 
(A) NHDFs were treated with 5, 10, 20 or 50nM FK866 for the incubation times indicated (n=3 technical replicates) 
and NAD+ levels were measured by an NAD+ cycling assay before being normalised to protein levels via a BCA 
assay. The data is expressed as % NAD+/ug protein of the untreated NHDFs for each timepoint. (B) NHDFs were 
treated with 1, 5, 10, 20, 50, 100 and 200nM FK866 for the incubation times indicated. 4 hours before the end of 
the incubation period the cells were treated with 0.02% alamar blue solution and viability was assessed by 
measuring fluorescence. The viability for each FK866 concentration is expressed as the % viability of the untreated 
control NHDFs for each timepoint. Error bars represent +/-SD. All data points shown are the average from 2 
separate biological experiments (n=2).  
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the tbh7ox incubation is observed, with FK866 nullifying these effects. It should be noted that due 
to the potent reduction of viability induced by FK866 even at the lowest tbh7ox concentration 
(20uM), the CC50 couldn’t be accurately estimated for curves generated for FK866 treated NHDFs. 
Nonetheless, in contrast to rucaparib and EX527, it is apparent FK866 attenuates the protective 




Of the individual compounds tested, apigenin and quercetin were both found to be effective at 
enhancing NHDF NAD+ levels, however this was restricted to 12 hours post-treatment for apigenin 
and 8 hours post-treatment for quercetin, suggesting limited efficacy. This is particularly problematic 
in the context of a therapeutic intervention where a sustained enhancement of NAD+ would be 
desirable. The precursor NAM was also capable of temporarily increasing NAD+, however by 24 hours 
NAD+ had decreased at the NAM higher doses, suggesting there may be a negative feedback 
mechanism at play. The presence of some sort of negative feedback is further supported by failure 
of the larger NAM doses to significantly increase NAD+, with a significant decrease recorded for the 
two highest doses after 24 hours. 
 
Figure 3.9.4 NHDF viability following co-treatment with tbh7ox and FK866. 
(B) NHDFs were treated for 48 hours with 10nM FK866 and/or NTC for 24 hours. The NHDFs were treated for 
1 hour with tbh7ox concentrations of 0, 20, 40, 50, 60, 80, 100 and 140uM (n=3 technical replicates). Viability 
was subsequently assessed 20 hours later by incubating the cells for 4 hours in 0.02% alamar blue solution 
and then measuring fluorescence. Data is presented as the % viability of the DMSO treated control, shown as 
the average of two separate biological experiments (n=2). Error bars represent +/-SD. Statistical significance 
was assessed by 2-way ANOVA followed by a Bonferroni post hoc test. **p<0.01, ***p<0.001. 
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This problem was partially bypassed by using a multi-compound approach, whereby numerous 
enzymes involved in NAD+ homeostasis are targeted with the intention of upregulating NAD+ 
synthesis and recycling pathways, whilst also reducing NAD+ degradation. NTC is a combination of 
compounds fulfilling this criteria, which was able to significantly increase NAD+ in NHDFs 12 hours 
and 24 hours post-treatment. Its effectiveness was however diminished by the 48-hour timepoint, 
suggesting sensitisation to the treatment may also be an issue for the multi-targeted approach. 
Furthermore, although NTC also enhanced NAD+ in Jurkat cells at 12 and 24-hours post-treatment, 
this failed to achieve statistical significance, undermining the efficacy of NTC in this specific cell type. 
This highlights that the success of interventions with the intent of enhancing NAD+ will likely vary 
between different cells and tissues due to the heterogenous nature of NAD+ homeostasis across 
different cell types [346], linked to the cellular metabolic phenotype which itself is dictated by the 
energy demands of the cell. Additionally, some of the enzymes targeted by NTC such as CD38 and 
NAMPT are expressed differently across tissue types [137, 347]. Hence, the concentration of the 
constituents of NTC would need to be optimised for different cell types to achieve maximal 
upregulation of NAD+, an approach which in retrospect should’ve been undertaken within this work 
for the Jurkat cell line. 
It was also interesting to find that oxidative stress induced by tbh7ox depletes NAD+, with this 
depletion partially reversible under conditions of PARP1 inhibition - provided the levels of oxidative 
stress are below a threshold. Indeed, the paradoxical decrease in NAD+ at higher concentrations of 
tbh7ox in the presence of the PARP1 inhibitor rucaparib was a consequence of extensive decrease 
in cell viability determined by trypan blue staining (data not shown), emphasising the double-edge 
sword that accompanies inhibition of PARP1. Hence, although PARP1 inhibition may increase NAD+ 
levels under specific conditions in vitro, this isn’t a feasible approach for this purpose at the 
organismal level due to the deleterious effects of PARP1 inhibition in the presence of high levels of 
DNA damage. The use of rucaparib as a chemotherapeutic for the treatment of BRCA-deficient 
cancers is an obvious exception [348], given the therapeutic value PARP1 inhibition has in this 
context as a treatment for a life-threatening illness. 
It is important to consider however, that the rate limiting enzyme of the pentose phosphate pathway 
within the endoplasmic reticulum H6PD (hexose-6-phosphate dehydrogenase) has been identified 
as a non-specific target of rucaparib [349]. Consequently, PARP1 inhibition using rucaparib may be 
accompanied by metabolic stress within the endoplasmic reticulum via H6PD inhibition, which could 
influence cell viability measurements in a PARP1-independent manner. Consequently, the relevance 
of the effects of rucaparib on intracellular NHDF NAD+ levels and viability with regards to PARP1 
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inhibition should be verified by repeating these experiments with siRNA/shRNA silencing of PARP1 
in place of rucaparib treatment. 
NTC was able to increase the antioxidant capabilities of NHDFs in the presence of tbh7ox, however 
it was surprising to find that this increased antioxidant capacity was independent of PARP1 and SIRT1 
activity. It should be noted however, due to lack of a bona fide SIRT1 activity biomarker and the 
reported inconsistency of commercial SIRT1 activity assays the inhibitory effect of EX527 on SIRT1 
was never independently validated. 
 It had been posited that increasing NAD+ could be a combative strategy against oxidative stress by 
supporting PARP1 mediated DNA damage repair, however treatment with NAM fails to offer any 
protection against tbh7ox cytotoxicity suggesting increasing NAD+ by itself is insufficient for this 
purpose. This outcome, combined with the redundant impact of PARP1 inhibition in NHDFs co-
treated with NTC and tbh7ox implies that NTC is eliciting an antioxidant effect by preventing 
oxidative damage from occurring, rather than enhancing its repair. Thus, useful experiments in the 
future would be to use enzymatic activity or probe-based cell sorting assays that measure markers 
such as protein carbonylation, DNA oxidation and lipid peroxidation to verify whether NTC protects 
against oxidative damage in the presence of tbh7ox. 
Interestingly, co-treatment with the NAMPT inhibitor FK866 showed that the effects of NTC are 
dependent on an adequate NAD+ supply or functional NAMPT, hence an unknown NAD+ requiring 
mechanism must be supporting the antioxidant capacity of NTC. It is possible this effect could be 
mediated via other sirtuins, for example SIRT3 which is localised to mitochondria where it combats 
oxidative damage via upregulation of the ROS scavenger SOD2 [350]. Indeed, SIRT3 has previously 
been shown to be responsible for protection against tbh7ox in cell lines via an SOD2 dependent 
mechanism [351, 352]. Hence, treating NHDFs with NTC, tbh7ox and an inhibitor of SIRT3 such as 
SDX-437 [353] or SIRT3 siRNA would be one possible approach to test this theory. 
With regards to the viability data for cells treated with various tbh7ox concentrations, only having 
replicate experimental data values for all conditions is a notable drawback, increasing the statistical 
uncertainty within the data. Likewise, experiments measuring NHDF NAD+ levels were only 
performed twice, thus it has to be acknowledged that this is a serious weakness within this work 
which gives less weight to these findings. 
Although subsidiary to the main scope of this chapter, the remarkable capacity of quercetin to 
neutralise induced oxidative stress in NHDFs was a notable discovery. ROS are important 
intermediates in various cell signalling pathways, however their aberrant overproduction (often a 
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result of mitochondrial dysfunction) results in oxidative stress, which when chronic may promote 
the pathogenesis of age-related illnesses such as Alzheimer’s disease [354-356], Parkinson’s disease 
[357-359], cardiovascular disease [360-362] and physiological ageing itself [294, 363, 364]. Hence, 
independent of NAD+, quercetin represents an exciting compound which merits further investigation 
as a potential intervention in pathologies associated with increased oxidative stress. As is the case 
for many polyphenols, its therapeutic application has been hindered by low bioavailability, however 
delivery strategies utilising liposome or nanoparticle loaded quercetin have been shown to enhance 
in vivo potency [365-368]. Therefore, to replicate the NAD+ enhancing and antioxidant properties of 



















Chapter 4. Circadian Regulation of NAD+ and Its Interaction with BMAL1 
4.1 Introduction 
Circadian rhythms are diurnal oscillations of biological processes, a product of evolution to allow 
tailoring of physiological functions to the time of day, or more specifically sunlight hours. The most 
obvious example is the fluctuating levels of the sleep promoting hormone melatonin, which is low 
during the day before steadily increasing throughout the evening. A key co-ordinator of circadian 
rhythms throughout the human body is the hypothalamic structure known as the suprachiasmatic 
nucleus (SCN), which processes environmental cues (e.g. sunlight) and releases circulating factors to 
synchronise circadian processes occurring in the periphery. At the intracellular level, a core group of 
enzymes including BMAL1 and CLOCK are particularly key [369]: integrating signalling from the SCN 
and other molecular events to establish circadian rhythmicity of numerous pathways. 
Although the circadian regulation of genes relating to sleep and feeding are well understood, a 
multitude of other enzymes unrelated to these processes are also under circadian control. One such 
enzyme is SIRT1, which evidence suggests is regulated by the ‘master controller of circadian rhythms’ 
BMAL1 as part of a bidirectional relationship [105]. The exact mechanism by which SIRT1 activity is 
regulated by BMAL1 however remains unclear. Direct binding of the BMAL1:CLOCK dimer to the 
SIRT1 promoter has been suggested, however it’s also been shown that BMAL1 regulates NAMPT 
expression [233, 234], thus modulation of NAD+ levels via NAMPT fluctuations represents another 
mechanism by which BMAL1 may control SIRT1 activity. Furthermore, there have been reports that 
the ability of BMAL1 to dimerise with CLOCK is promoted by SIRT1-mediated deacetylation of PER2 
(period circadian protein homolog 2), another key regulatory protein of circadian rhythms [370-372]. 
PER2 interacts with the BMAL1:CLOCK dimer and represses its ability to bind target promoters, 
however the stability of PER2 and its import into the nucleus is impaired by deacetylation via SIRT1 
[105] – laying the foundation for a positive feedback loop between BMAL1 and SIRT1. 
Dysregulation of circadian rhythms, primarily due to insufficient sleep, is widely accepted as being a 
factor promoting ill-health [373, 374]. The disrupted sleeping patterns of nightshift workers provides 
somewhat of a human model to study the importance of circadian rhythms regarding physiological 
health, with a number of chronic diseases found to be over-represented in these workers [375-377]. 
The likelihood to succumb to certain diseases is also related to time of day and thus under circadian 
influence, whilst outcome following surgery also appears time-dependent [378], although other 
human factors may explain the latter. As we enter an era where therapeutic interventions tailored 
to an individual’s genome is on the horizon, it would seem beneficial to also tailor treatments to 
circadian rhythms. For example, if a protective protein against a disease is particularly low at one 
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daily timepoint, this would identify the optimal timepoint for a therapeutic boosting its levels to be 
active.  
An interesting phenomenon relating to circadian biology in humans is the existence of ‘morning’ and 
‘evening’ chronotypes [379], describing those who prefer waking and being active early in the day 
and vice versa. These two chronotypes are genetically defined [380-382] with a subsidiary layer of 
regulation at the environmental level [383, 384], manifesting as two distinct circadian rhythm 
profiles whereby the timing of the daily rise and fall in melatonin differs. Furthermore, a shift 
towards earlier sleeping and waking times is experienced by people as they age such that they 
become more likely to be a ‘morning’ type [217, 385], strongly suggesting that circadian rhythms are 
altered with age and hence may be a component of age-related physiological decline. What causes 
this, is it tissue-specific and whether it is a consequence of molecular aberrations or changes to the 
hypothalamic structure are key questions that need to be addressed in order to better understand 
the relationship between ageing and circadian rhythms. 
The potential importance of BMAL1 in biological ageing is highlighted by the short-lived Bma1-/- mice 
which were found to have an average lifespan of 37 weeks, in contrast to the wild-type and 
heterozygous genotypes which all survived to the end of a 52-week duration study [226]. Moreover, 
in addition to premature mortality the Bmal1-/- mice also exhibit an accelerated appearance of age-
related pathologies including sarcopenia, organ shrinkage and increased ROS production [226]. 
Interestingly, a separate study found that activity of the nutrient sensor mTOR was enhanced in 
Bmal-/- mice and that inhibiting mTOR was able to significantly extend their lifespan [386]. Thus it 
may be that mTOR is under circadian control and impaired BMAL1 signalling elicits a pro-ageing 
effect via increased mTOR activity: a well-characterised mediator of age-related molecular changes 
[387].  
Given circadian rhythms have been tailored to physiological functions, it’s highly likely that they vary 
for different tissues, thus it isn’t clear how prominent diurnal rhythmic oscillations will be in dermal 
fibroblasts, in which circadian rhythms have been sparsely characterised. From an experimental 
perspective, it is also relevant to consider the absence in vitro of the hormonal control exerted by 
the SCN. Hence, it is important to acknowledge that the in vitro work presented within this chapter 
is limited to examining the endogenous system of circadian regulation in dermal and lung fibroblasts, 






The work within this chapter aims to identify whether BMAL1 regulates NAD+ levels in dermal 
fibroblasts and by extension whether NAD+ levels follow a circadian rhythm. An insight into the wider 
effects of elevated/repressed BMAL1 expression on energy metabolism is also explored. 
4.3 Hypothesis 
It is proposed that NAD+ levels are under endogenous circadian control mediated by BMAL1. 
Specifically, enhanced BMAL1 levels are expected to increase NAD+ levels via upregulation of NAMPT 


















4.4 NAD+ levels Follow a Circadian Rhythm in NHDFs 
Initially, to test whether BMAL1 is a regulator of NAD+ in NHDFs, BMAL1 expression was 
downregulated using siRNA (small interfering RNA). A pool of 4 different siRNAs was used, which 
theoretically should increase the chances of efficient knockdown by targeting multiple sites in the 
target mRNA transcript. The previously shown ability of BMAL1 to regulate NAD+ in other cell types 
led to the hypothesis that knockdown of BMAL1 would reduce NAD+ levels due to the role BMAL1 
plays as a transcriptional activator of NAMPT [234]. The siRNA was able to reduce BMAL1 expression 
as shown by the protein levels of BMAL1 72 hours post-transfection (Figure 4.4.1 A), but only 
resulted in a small and non-significant decrease in NAD+ (8.12 ng NAD+/ug protein for scrambled 
siRNA treated vs 6.98 ng NAD+/ug protein for BMAL1 siRNA treated) (Figure 4.4.1 B). The levels of 
NAMPT and SIRT1 in response to the siRNA mediated knockdown of BMAL1 showed little change 
despite the decrease in BMAL1 mRNA, thus the existence of a regulatory role for BMAL1 in NHDF 
NAMPT levels is questionable. 
It has already been established that NAD+ levels exhibit some degree of circadian regulation in blood 
[388], however this has yet to be established in dermal fibroblasts. In vitro cells lack both the 
hormonal input from the SCN and environmental stimuli such as sunlight and temperature. 
Consequently, the circadian rhythm of cultured fibroblasts would be expected to be ‘out of sync’ 
given the absence of these external inputs. In order to synchronise circadian rhythms under in vitro 
conditions cells can be pre-treated with dexamethasone [389], a corticosteroid previously used for 
this purpose in a number of other studies [390-392].  
 
Figure 4.4.1 The effect of BMAL1 siRNA on NAD+ levels and SIRT1, BMAL1 and NAMPT levels in  
NHDFs. 
(A) NHDFs were transfected with 100nM scrambled siRNA or 100nM BMAL1 siRNA and after 72 hours cells 
were harvested and lysed. The proteins indicated were analysed by western blotting, with the blot shown 
representative of 3 individual experiments. (B) NHDFs were once again transfected with 100nM scrambled 
siRNA or 100nM BMAL1 siRNA for 72 hours (n=3 technical replicates). NAD+ levels were then quantified using 
an NAD+ cycling assay and then normalised to total protein via a BCA assay. Data is shown as mean ng NAD+/ug 
protein for two separate biological experiments and error bars represent +/- SD. Significance testing was 
performed using an unpaired Student’s t-test. 
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To test for the presence of an NAD+ circadian rhythm in NHDFs, cells were treated with 100nM 
dexamethasone for 2 hours before the dexamethasone was removed and the cells returned to 
normal culture media. The NHDFs were then harvested and immediately frozen at -80ᵒC every 4 
hours, allowing NAD+ to be subsequently quantified for the entirety of a 24-hour timecourse (the 
standard diurnal period). Prior to the dexamethasone treatment, half the NHDFs were transfected 
with 100nM scrambled siRNA and the other half transfected with 100nM BMAL1 siRNA for 72 hours. 
This was to test if any observed rhythmicity of NAD+ in the scramble treated cells was a genuine 
consequence of an endogenous circadian rhythm, given this would inevitably be perturbed by 
BMAL1 repression in the BMAL1 siRNA treated cells.  
The scrambled siRNA treated NHDFs exhibit variable NAD+ levels over the 24-hour timecourse, with 
the levels gradually increasing up until 12 hours post dexamethasone incubation before plateauing 
(Figure 4.4.2). Contrastingly, this early increase is absent in the BMAL1 siRNA treated NHDFs which 
remain relatively consistent throughout with no obvious rhythmic pattern. Given the significant 
difference in the 24-hour NAD+ profile for the scrambled and BMAL1 siRNA treated NHDFs (2-way 
ANOVA, p<0.001), this suggests that the NAD+ pattern observed for the scrambled treated cells is 
indeed dependent upon BMAL1 regulation, rather than a consequence of another mechanism 
induced by the dexamethasone pre-treatment. This data therefore provides evidence for the 
existence of endogenous circadian regulation of NAD+ in NHDFs. 
 It should be noted however that despite finding an overall significant difference between the 
scrambled and BMAL1 siRNA treatments, there wasn’t a significant difference at any of the individual 
timepoints. Furthermore, 2-way ANOVA also revealed a significant difference in NAD+ levels 
between the individual timepoints (p<0.05), highlighting NAD+ levels in NHDFs are time-dependent 




4.5 NAD+ Circadian Rhythmicity is Absent in Bmal1KO MLFs 
An important consideration when using siRNA to examine the effects of knockdown of BMAL1 on 
NAD+ levels is the only partial reduction of gene expression that can be achieved using siRNA, 
particularly in difficult to transfect cells like NHDFs. On the other hand, it’s also necessary to consider 
the unlikelihood that BMAL1 expression would ever be completely lost under in vivo conditions, 
hence it can be argued that it provides a more realistic model than the complete ablation of BMAL1 
gene function. Nonetheless, the effects of complete loss of BMAL1 expression on NAD+ levels was a 
pertinent question that remained to be answered. 
To investigate this, NAD+ levels were compared in primary MLFs (mouse lung fibroblasts) derived 
from Bmal1-/- (Bmal1KO) and WT littermate MLFs. Given the small decrease in NHDF NAD+ following 
BMAL1 siRNA treatment it was very surprising to find that the Bmal1KO MLFs had significantly higher 
NAD+ levels compared to the WT MLFs (WT 0.67 ng NAD+/ug protein vs Bmal1KO 1.06 ng NAD+/ug 
protein, p<0.002) (Figure 4.5.1 A). Of course, this could reflect differences in the mouse and human 
genome which may alter regulation of NAD+ metabolism. Additionally, as already alluded to, gene 
knockout doesn’t resemble the less severe perturbations that may occur to gene expression due to 
processes such as physiological ageing. Hence, the loss of BMAL1 may also be impacting other 
pathways which alter NAD+ irrespective of the BMAL1-NAMPT-NAD+ axis. 
 
Figure 4.4.2 NAD+ levels in circadian synchronised NHDFs treated with BMAL1 siRNA. 
NHDFs were transfected with 100nM scrambled siRNA or 100nM BMAL1 siRNA (n=3 technical replicates) and 
after 72 hours the cells were then incubated for 2 hours in media containing 100nM dexamethasone to induce 
synchronisation of circadian rhythms. The cells were returned to regular media and then harvested and frozen 
at -80ᵒC every 4 hours over a 24-hour timecourse. NAD+ levels were subsequently quantified by an NAD+ 
cycling assay and then normalised to total protein via a BCA assay. Significance was tested for by multiple 
comparisons 2-way ANOVA. Data is shown as mean ng NAD+/ug protein of 2 separate biological experiments 
(n=2) and error bars represent +/- SD. 
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However, the regulation BMAL1 elicits is much more relevant under conditions of circadian 
rhythmicity to better replicate the situation occurring in vivo. Hence, the Bmal1KO and WT MLFs 
were synchronised using the standard 2-hour 100nM dexamethasone pre-treatment and NAD+ was 
subsequently measured at 4-hour intervals over a 24-hour period, as done previously (Figure 4.5.1 
B). NAD+ levels in the WT cells somewhat resembled a typical circadian pattern, starting at a nadir 
before gradually rising, although they were yet to show a downward trend towards the end of the 
timecourse as would be typical of a circadian oscillation. On the other hand, the Bmal1KO MLFs 
showed no discernible pattern, with the NAD+ levels remaining relatively stable for the duration of 
the timecourse. This therefore does suggest that BMAL1 plays a role in regulating NAD+ levels in vitro 
– albeit one which is dependent on the establishment of an underlying circadian rhythm.  
It should be noted that 2-way ANOVA found no significant difference between the WT and Bmal1KO 
NAD+ levels over the timecourse, however there was a significant interaction between genotype and 
timepoint, reflecting the static nature of WT NAD+ versus the ascending values for the Bmal1KO 
fibroblasts. 
 
4.6 miR-155 Represses BMAL1 Expression and Circadian Rhythmicity in MDFs 
Additionally, the effects of increased BMAL1 on NAD+ titres and rhythmicity was also of interest. To 
investigate the consequence of BMAL1 overexpression, a BMAL1 overexpressing NHDF cell line was 
generated by inserting an extra copy of the BMAL1 gene into NHDFs using a lentiviral vector. 
 
Figure 4.5.1 NAD+ Levels in Bmal1KO and WT MLFs.  
NAD+ levels were measured in (A) unsynchronised WT and Bmal1KO MLFs (n=2 biological replicates for each 
genotype) and (B) WT and Bmal1KO MLFs (n=2 biological replicates for each genotype) synchronised with 
100nM dexamethasone. After removal of the dexamethasone, cells were harvested every 4 hours over a 24-
hour timecourse (n=3 technical repeats for each condition). NAD+ was measured for both A and B via an NAD+ 
cycling assay before being normalised to total protein after performing a BCA assay. Data is shown as mean 
ng NAD+/ug protein and error bars represent +/-SD. Significance was tested for (A) using an unpaired Student’s 
t-test and (B) by 2-way ANOVA. **p<0.01.  
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However, due to delays experienced generating the cell line, other options were explored, one being 
modulation of BMAL1 expression via miRNAs.  
Using TargetScan, a database which identifies putative gene targets of known miRNAs [393, 394], 
miRNAs predicted to bind Bmal1 mRNA were identified. miR-155 was one such example, which in 
mice is predicted to bind at position 235-241 of the Bmal1 transcript 3' UTR. By using primary mouse 
dermal fibroblasts (MDFs) from mice lacking the miR-155 gene (miR-155KO) and WT littermates, it 
was first sought to determine whether loss of miR-155 did indeed increase BMAL1 levels by removing 
its repressive effect. Western blotting using lysates from the WT and miR-155KO cells showed that 
under basal conditions (without any synchronisation of circadian rhythms) BMAL1 protein levels 
were strongly enhanced in the miR-155KO cells (Figure 4.1 A).   
Next, the efficacy of an miR-155 mimic (synthetically generated miR-155 oligonucleotide) at 
inhibiting Bmal1 gene expression in the WT MDFs was investigated. The optimal treatment 
conditions for miR-155 mimic mediated attenuation of Bmal1 transcription was found to be 48 hours 
post transfection at a concentration of 50nM, resulting in a 41% decrease in Bmal1 mRNA levels 
compared to MDFs transfected with 50nM of a negative control miRNA mimic. By comparison, in 
MDFs treated with Bmal1 or scrambled siRNA, the Bmal1 siRNA was able to reduce Bmal1 gene 
expression by 59%. Thus, this substantiated the prediction made by TargetScan that miR-155 is a 
post-transcriptional repressor of Bmal1 in mouse cells. 
The effect of the miR-155KO genotype on Bmal1 gene expression under conditions of circadian 
rhythmicity was subsequently probed by performing qPCR for cells pre-treated with 100nM 
dexamethasone as done for previous experiments (Figure 4.6.1 B). Additionally, prior to the 
dexamethasone treatment WT and miR-155KO cells were treated with 50nM of the miR-155 mimic 
or 50nM negative control miRNA mimic for 48 hours.  
Bmal1 mRNA levels exhibited a different circadian profile for the miR-155KO and WT MDFs treated 
with the negative control miRNA whereby the Bmal1 mRNA was higher in the miR-155KO cells for 5 
out of the 7 timepoints, with an average increase of 1.7-fold (SD - 2.8-fold).  
Convincing evidence for the inhibitory effect of miR-155 on Bmal1 was observed in the miR-155 
mimic treated cells, where Bmal1 mRNA levels were strongly downregulated in both the WT and 
miR-155KO cells (Figure 4.1 A and C). 6 out of 7 of the timepoints for the miR-155 mimic treated WT 
cells had reduced Bmal1 mRNA levels compared to the negative miRNA treated WT cells, which was 
on average 2.9-fold lower (SD - 2.3-fold). The mimic treated miR-155KO cells on average had a 3.7-
fold reduction in Bmal1 expression (SD - 1.1-fold) compared to the negative control miRNA treated 
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miR-155KO cells, with all 7 timepoints showing reduced Bmal1 mRNA levels. Hence, the miR-155 






Figure 4.6.1 Bmal1 expression over a 24-hour timecourse in miR-155 mimic and negative control miRNA 
treated MDFs.  
(A) Sirt1, Bmal1 and α-tubulin protein levels in WT and miR-155KO MDFs were measured by western blotting. 
The blot shown is presentative of 3 independent experiments. (B-D) WT and miR-155KO MDFs (n=4 biological 
replicates for both genotypes) were incubated with 50nM negative control miRNA or 50nM miR-155 mimic 
for 48 hours. Circadian rhythms were then synchronised by a 2-hour incubation in 100nM dexamethasone. 
After removing the dexamethasone from the media, cells were harvested at 4-hour intervals over a 24-hour 
timecourse and Bmal1 mRNA and 18S rRNA expression was then measured by qPCR, with expression of Bmal1 
relative to 18S calculated using the 2–∆∆Ct method with the negative miRNA control treated WT 0-hour 
timepoint (B and C) and the negative miRNA control treated miR-155KO cells 0-hour timepoint (D) used as the 
control averages respectively. (A) Bmal1 expression in miR-155 mimic treated WT MDFs is shown relative to 
the expression of the negative control miRNA treated MDFs at each timepoint. (C) Bmal1 expression in 
negative control miRNA treated miR-155KO MDFs is shown relative to the expression of the negative control 
miRNA treated MDFs at each timepoint. (D) Bmal1 expression in miR-155 mimic treated miR-155ko MDFs is 
shown relative to the expression of the negative control miRNA treated miR-155KO MDFs at each timepoint. 




It’s ability to negatively regulate Bmal1 introduces the possibility that miR-155 may function as a 
circadian regulator, hence it was next investigated whether the expression of MIR155 itself follows 
a circadian rhythm and whether Bmal1 regulates it as part of a negative feedback loop. To do this, 
WT MDFs were treated with scrambled siRNA or Bmal1 siRNA for 48 hours, after which the cells 
were synchronised using 100nM dexamethasone as done for previous experiments. There wasn’t a 
noticeable oscillatory pattern to the miR-155 levels with or without the Bmal1 siRNA, however the 
average expression of miR155 over the timecourse was less for the siRNA treated cells (1.5-fold 












4.7 miR-155 Regulates NAD+ Circadian Rhythmicity 
Given the established role of BMAL1 in regulating cellular NAD+ levels and the repressive control 
miR-155 exerts on Bmal1 expression, it was postulated that the enhanced BMAL1 levels in miR-
155KO cells under basal conditions would result in higher levels of NAD+. Additionally, over a 24-
hour timecourse it was hypothesised that the NAD+ fluctuations in the miR-155KO cells would mirror 
their pattern of Bmal1 expression, whereby there is a delay in the rise and fall of the NAD+ levels 
compared to the WT cells.  
 
Figure 4.6.2 miR-155 expression over a 24-hour timecourse in Bmal1 siRNA treated MDFs.  
MDFs were pre-treated with 75nm scrambled siRNA or 75nm Bmal1 siRNA for 48 hours before beginning the 
timecourse (n=4 biological replicates for all conditions). Circadian rhythm was then synchronised by a 2-hour 
incubation in 100nM dexamethasone. After removing the dexamethasone from the media, cells were then 
harvested at 4-hour intervals over a 24-hour timecourse. miR-155 and miR-191 gene expression was then 
measured by qPCR, with expression of miR-155 relative to miR-191 calculated using the 2–∆∆Ct method with 
the 0-hour timepoint for the scrambled RNA treated MDFs used as the control average. The miR-155 levels 
in the Bmal1 siRNA treated NHDFs was then expressed as fold-change relative to the miR-155 levels in the 
scrambled siRNA treated MDFs at each timepoint. Data points represent the mean fold change (n=4 biological 





Under basal conditions lacking any synchronisation of circadian rhythms, the miR-155KO cells 
showed significantly lower NAD+ levels compared to the WT cells as determined by multiple 
comparisons 2-way ANOVA for all conditions (scrambled siRNA p<0.001, miR-155 mimic p<0.001, 
Bmal1 siRNA p<0.05) (Figure 4.7.1), surprising given their characteristic high BMAL1 levels. The 72-
hour pre-treatment with either the miR-155 mimic or Bmal1 siRNA failed to significantly change the 
basal NAD+ titres in both the WT and miR-155KO groups however, as tested by 1-way ANOVA.  
The effect of Bmal1 siRNA on NAD+ levels in NHDFs was found to be dependent on circadian 
synchronisation to induce any noticeable effect, hence it stood to reason that a similar situation may 
exist in MDFs. To test this, WT and miR-155KO MDFs were transfected with the miR-155 mimic, 
Bmal1 siRNA or scrambled siRNA for 72 hours. Immediately prior to the timecourse all cells then 
underwent a 2-hour incubation in 100nM dexamethasone to synchronise circadian rhythms. 
The 24-hour NAD+ profiles for the scrambled siRNA treated WT and miR-155KO cells failed to show 
any resemblance to the 24-hour oscillation of Bmal1 mRNA as had been hypothesised (Figure 4.7.2 
A). Instead, the miR-155KO NAD+ remained relatively stable aside from a sharp peak at the 4-hour 
timepoint where NAD+ levels rose from 0.58 ng NAD+/ug protein (0 hours) to 4.8 ng NAD+/ug protein 
(4 hours) and then back to 0.95 ng NAD+/ug protein (8 hours). In contrast, the WT NAD+ levels 
exhibited a slight and steady increase over the timecourse, with 1.07 ng NAD+/ug protein measured 
for the 0 hr timepoint and 2.13 ng NAD+/ug protein for the 24-hour timepoint. 
 
Figure 4.7.1 NAD+ levels in miR-155 mimic, Bmal1 siRNA and scrambled siRNA treated WT and miR-155KO 
MDFs.  
WT and miR-155KO MDFs were transfected with 50nM miR-155 mimic, 75nM Bmal1 siRNA or 75nM 
scrambled siRNA and cells were harvested 72 hours later (n=4 biological replicates for all conditions). NAD+ 
levels were then measured by an NAD+ cycling assay before being normalised to total protein quantified by a 
BCA assay. Data is shown as mean ng NAD+/ug protein of two separate biological experiments (n=2) and error 
bars represent +/- SD. Significance differences were tested for in the WT and miR-155KO groups separately 
by 1-way ANOVA and a Dunnet’s post hoc test, whereby the scrambled treated WT or miR-155KO cells were 




Surprisingly, the miR-155 mimic enhanced the 4-hour peak (scrambled - 4.8 ng NAD+/ug protein vs 
mimic – 8.8 ng NAD+/ug protein), an unexpected finding given the presence of the miR-155 mimic 
would be expected to reverse the effects of miR-155 knockout rather than exacerbate them. 
Furthermore, treatment with Bmal1 siRNA reduced the peak (miR-155KO - 4.8 ng NAD+/ug protein 
vs miR-155KO + siRNA – 1.28 ng NAD+/ug protein), hence it appears its presence is a consequence 
of altered Bmal1 expression. 
It is acknowledged that the use of scrambled siRNA as a negative control for cells treated with the 
miR-155 mimic is against common practice, however given both scrambled siRNA and negative 
control miRNA are 20–25 nucleotides long duplex RNA sequences processed by the RISC:Dicer 
complex, a different relevant biological outcome of using these interchangeably is extremely 
unlikely. 
4.8 miR-155KO MDFs Display a Different Metabolic Phenotype to WT MDFs 
A notable feature of the miR-155KO MDFs compared to the WT MDFs is a vastly enhanced 
proliferation rate, highlighted by the higher optical density change in the media of the miR-155KO 
 Figure 4.7.2 Circadian pattern of NAD+ in miR-155 mimic, Bmal1 siRNA and scrambled siRNA treated WT and 
miR-155KO MDFs. 
 WT and miR-155KO MDFs were transfected with a 50nM miR-155 mimic, 75nM Bmal1 siRNA or 75nM 
scrambled siRNA for 72 hours (n=4 biological replicates for all conditions). The circadian rhythm in all cells was 
then synchronised by a 2-hour incubation in 100nM dexamethasone and the cells were harvested every 4 
hours over a 24-hour timecourse. For each timepoint NAD+ levels were measured by an NAD+ cycling assay 
before being normalised to total protein quantified by a BCA assay. NAD+ levels are presented as the mean ng 
NAD+/ug protein for 2 separate biological experiments (n=2) for (A) scrambled siRNA treated WT and miR-
155KO MDFs, (B) scramble RNA, Bmal1 siRNA and miR-155 mimic treated WT MDFs and (C) scrambled siRNA, 
Bmal1 siRNA and miR-155 mimic treated miR-155KO MDFs. Error bars represent +/- SD. 
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cells when treated with XTT and PMS (phenazine methosulphate) for 24, 48 and 72 hours (Figure 
4.8.1). In a reaction facilitated by an electron donor like PMS, the XTT undergoes reduction to 
formazan in the presence of cellular reductants such as NADH, resulting in a colour and optical 
density change due to the accumulation of formazan in the media. Hence, the increased optical 
density in the media of miR-155KO cells is a consequence of a net increase in metabolic activity - 
corresponding to increased proliferation and cell number. 
Given the very different proliferation phenotypes of the miR-155KO and WT cells it was deemed of 
interest to investigate the potential metabolic changes induced by knockout of miR-155. 
Furthermore, it was posited that an altered metabolic profile may explain why despite enhanced 
Bmal1 expression the miR-155KO cells have significantly reduced NAD+ levels compared to the WT 
cells.  
Initially, mitochondrial function was probed by performing a ‘Seahorse XF cell mitochondrial stress 
assay’, which allows the oxygen consumption rate (OCR, pmol O2/min) as a readout of mitochondrial 
respiration to be measured following the sequential addition of various mitochondrial 
inhibitors/uncouplers. The basal respiration was first measured, prior to the addition of the ATP 
synthase inhibitor oligomycin, followed by the mitochondrial membrane potential uncoupler FCCP 
(carbonyl cyanide-p-trifluoromethoxyphenylhydrazone) and then finally the ETC (electron transport 
chain) inhibitors antimycin A/rotenone. FCCP is an ionophore which facilitates the movement of H+ 
ions across the inner mitochondrial membrane, thus disintegrating the proton gradient which usually 
exists across the membrane and drives ATP synthesis. The loss of the proton gradient forces the ETC 
to function at maximum capacity to try and restore the gradient, thus allowing maximal respiration 
to be quantified i.e. the full capacity of the mitochondria when working flat out. The difference in 
the OCR for the basal respiration and the maximal respiration then allows the spare capacity to be 
deduced – i.e. how much capability the mitochondria have left in reserve when not forced to work 
maximally. Following these measurements the total protein in each assay well is quantified such that 
the values are then expressed as OCR/ug protein. 
There was no significant difference in the basal respiration for WT and miR-155KO cells (WT 11.83 
OCR/ug protein vs miR-155KO 12.27 OCR/ug protein) (Figure 4.8.2 A).  The maximal respiration and 
spare capacity was significantly higher in the miR-155KO cells however, indicating they have a higher 
mitochondrial capacity – i.e. healthier and thus better functioning mitochondria or a greater 
mitochondrial density.  
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It’s important to note that due to the disparity in proliferation rates between the miR-155KO and 
WT cells the passage number of the cells used for these mitochondrial stress assays varied, with an 
average passage number of 15 for the miR-155KO MDFs and 12 for the WT MDFs. To assess the 
effect of increased passage number on mitochondrial function, the mitochondrial stress assays were 
repeated for miR-155KO MDFs with an average passage number of 26 and WTs with an average of 
19 (Figure 4.8.2 B). In contrast to the measurements taken at lower passage numbers, the basal 
respiration was significantly higher in the miR-155KOs (WT 8.07 OCR/ug protein vs miR-155KO 14.67 
OCR/ug protein). Maximal respiration was once again significantly increased in the miR-155KO 
compared to WT cells, however it was 111% higher at high passage compared to 46% higher at low 
passage (average passage number of 15 for miR-155KO, 12 for WT). The spare capacity advantage 
of the miR-155KOs was also enhanced at the higher passages where it was 150% greater than the 
WT, compared to 107% at low passage.  
This suggests that the miR-155KO cells are intrinsically protected against replication induced 
senescence or impaired cellular function. This was very surprising given miR-155 has been widely 
described as having pro-tumourigenic effects [395-397], thus it was unexpected to discover that its 
loss induced a replicative phenotype more typical of cancer cells. There have been other studies 
which have identified lowered miR-155 levels as an important feature in mouse and in vitro models 
of malignant melanoma however [398, 399], consistent with these findings. Interestingly, these 
metabolic features and enhanced proliferation rate, were absent in miR-155KO MLFs derived from 
 
Figure 4.8.1 Proliferation rate of miR-155KO and WT MDFs. 
The proliferation rate of miR-155KO and WT MDFs for 24, 48 and 72-hours post-seeding was measured using 
an XTT assay (n=4 biological replicates for all conditions). After seeding down, the cells were treated with 
300ug/ml XTT and 20ug/ml PMS, with absorbance then measured at an optical density of 490nM after 24, 
48 and 72-hour incubations. Data is shown as the absorbance at 490nm, error bars represent +/-SD. The data 
is representative of 3 separate biological experiments. 
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the same animals (data not shown). Hence, it’s important to note that the effects of absent miR-155 
signalling on in vitro cultures appears to be highly dependent on the tissue cells are derived from. 
A 72-hour pre-treatment with 50nM miR-155 mimic or 75nM Bmal1 siRNA was once again used to 
see if the different mitochondrial phenotype of the miR-155KO cells relative to the WTs could be 
attenuated by either of these treatments, however no significant differences were observed (Figure 
4.8.3 B and D). Similarly, WT MDFs also treated with the miR-155 mimic and Bmal1 siRNA showed 
no significant changes to the parameters of mitochondrial function (Figure 4.8.3 A and C). Hence, 
transient increases in miR-155 or reduced Bmal1 expression are unable to alter mitochondrial 
function, implying that the different mitochondrial phenotype of miR-155KO is an inherent feature 
which may have been acquired due to epigenetic or some other changes that are no longer 
attenuable.  
As already mentioned, the interplay between OXPHOS and glycolysis is the dominant regulator of 
cellular NAD+ levels, hence the glycolytic function of the WT and miR-155KO cells was next measured 
to test the hypothesis that enhanced glycolysis accounts for the reduced NAD+ titres in miR-155KO 
compared to WT MDFs. To probe this, a ‘Seahorse XF glycolysis stress test’ was performed whereby 
the ECAR (extracellular acidification rate, mpH/min) is measured before and after the sequential 
additions of glucose, oligomycin and 2-DG (2-deoxyglucose) to the cells undergoing the assay. The 
initial stimulus of glucose activates glycolysis allowing measurement of basal levels, after which 
OXPHOS is inhibited by the addition of the ATP synthase inhibitor oligomycin. Inhibiting OXPHOS 
forces the cells to only use glycolysis for ATP production, thus the ECAR under these conditions 
provides a readout for maximal glycolysis. By subtracting the basal glycolysis values from the 
maximal glycolysis values also allows the glycolytic capacity to be determined from these 
measurements. Finally, adding 2-DG to the media blocks the first catalytic step in glycolysis, giving a 
value for non-glycolytic ECAR. Similar to the mitochondrial stress assay, total protein is quantified 
following the assay such that the data is presented as ECAR/ug protein. 
All 3 parameters were higher in the miR-155KO cells, however the only significant difference was for 
the basal levels of glycolysis (WT 4.88 ECAR/ug protein vs miR-155KO 6.4 ECAR/ug protein, p<0.05) 
(Figure 4.8.4). The increased basal glycolysis combined with the enhanced maximal respiration 
previously measured suggests that the loss of miR-155 induces a shift toward glycolytic function, 












Figure 4.8.2 Mitochondrial function in low and high passage WT and miR-155KO MDFs. 
 Oxygen consumption rates (OCR, pmol O2/min) as a readout for mitochondrial function were measured for miR-
155KO and WT MDFs (n=3 biological replicates) at low (A) and high (B) passage following the sequential additions 
of oligomycin, FCCP and rotenone/antimycin A using the Seahorse XFp Analyser. Total protein for each assay 
plate well was then quantified by a BCA assay, allowing OCR to be normalised to protein levels. The data is shown 
as mean OCR/ug protein +/- SD. Significant differences between WT and miR-155KO for each parameter was 









Figure 4.8.3 Mitochondrial function in WT and miR-155KO MDFs transfected with a miR-155 mimic or Bmal1 
siRNA.  
(A) WT and (B) miR-155KO MDFs were transfected with 50nM miR-155 mimic or 50nM negative control miRNA 
for 72 hours. Additionally, (C) WT and (D) miR-155KO MDFs were treated for 72 hours with 75nM Bmal1 siRNA 
or 75nM scrambled siRNA (n=3 biological replicates for all conditions). Oxygen consumption rates (OCR, pmol 
O2/min) to quantify mitochondrial activity were then measured following the sequential additions of oligomycin, 
FCCP and rotenone/antimycin A using the Seahorse XFp Analyser. Total protein for each assay plate well was then 
quantified by a BCA assay, allowing OCR to be normalised to protein levels. The data is shown as mean OCR/ug 
protein +/- SD. Significant differences between the miR-155 mimic vs negative control miRNA and Bmal1 siRNA 
vs scrambled siRNA for each parameter was tested for using an unpaired Student’s t-test. Data is representative 






4.9 miR-155KO MDFs Exhibit Enhanced Protection Against Oxidative Stress  
To further characterise the phenotype of the miR-155KO MDFs, their viability in response to the 
oxidative stress inducer tbh7ox (tert-butyl hydroperoxide) was assessed. Tbh7ox functions similar to 
the classical oxidative stress inducer H2O2, inducing oxidative stress due to the high oxidising 
potential of the peroxide group whilst also having a higher stability than H2O2 – hence it’s choice as 
the oxidative insult within this work. 
Viability for miR-155KO and WT cells was expressed as % viability of the non tbh7ox treated cells, 
with viability measured by the fluorescence emitted in assay plate wells following a 4-hour 
incubation in 0.02% alamar blue media. 22 hours prior to the incubation in alamar blue, the treated 
cells were exposed for 2 hours to varying concentrations of tbh7ox (20 – 100uM). 
The lowest dose (20uM tbh7ox) caused a 56% decrease in viability to the WTs, with no loss of viability 
for the miR-155KOs (Figure 4.9.1 B). Up until the 100uM tbh7ox dose the miR-155KO cells 
consistently displayed enhanced viability (tested for by 2-way ANOVA), with the CC50 of tbh7ox 40.0, 
95% CI (31.9 – 50.3) for the miR-155KOs and 17.3, 95% CI (0.29, 1138) for the WT MDFs - suggesting 
the miR-155KOs possess a more potent antioxidant capacity. A possible explanation is their elevated 
levels of SIRT1 (Figure 4.9.1 A) which is a known activator of antioxidant pathways [176, 400, 401].   
 
Figure 4.8.4 Glycolytic parameters of miR-155KO and WT MDFs. 
 Extracellular acidification rates (ECAR, mpH/min) were measured as a readout for glycolytic function in miR-
155KO and WT MDFs (n=3 biological replicates for both genotypes) following the sequential additions of 
glucose, oligomycin and 2-DG using the Seahorse XFp Analyser. Total protein for each assay plate well was then 
quantified by a BCA assay, allowing ECAR to be normalised to protein levels. The data is shown as mean ECAR/ug 
protein, error bars represent +/- SD. Significant differences between WT and miR-155KOs for each parameter 
was tested for using an unpaired Student’s t-test. *p<0.05, **p<0.01. The data shown is representative of two 




miR-155 regulation of SIRT1 levels have yet to demonstrated elsewhere in the literature, however 
its ability to upregulate the pro-inflammatory Wnt/β-catenin pathway is well established [402-404]. 
Hence, protein expression of β-catenin was also measured by western blotting to determine if miR-
155 ablation had the expected outcome of reduced β-catenin levels (Figure 4.9.1 A). The clear 
downregulation of β-catenin observed in the miR-155KO MDFs confirms that the Wnt/β-catenin 
pathway is less active under basal conditions in the absence of miR-155. Consequently, in addition 
to protecting against oxidative stress, it is likely miR-155 knockout in MDFs mediates anti-
inflammatory effects via suppression of Wnt/β-catenin signalling. 
4.10 Bmal1KO MLFs Exhibit Enhanced Proliferation but a Lowered Resistance to Oxidative Stress 
Given the protection offered by the loss of miR-155 in the enhanced Bmal1 expressing MDFs against 
oxidative stress, the effect of the loss of Bmal1 on cell viability in response to tbh7ox was next 
investigated using the Bmal1KO MLFs. An XTT assay was first performed to compare the proliferation 
rates of Bmal1KO and WT MLFs over a 72-hour period under normal growth conditions, with the 
surprising finding that the proliferation rate was higher in the Bmal1KOs. 
To assess the effect of Bmal1 knockout on the intracellular antioxidant capacity, the KO and WTs 
were treated with varying doses of the oxidative stress inducer tbh7ox and viability was assessed 
using alamar blue as done previously. 20uM and 40uM doses induced a 9% and 53% decrease in WT 
viability, whilst the same doses induced a 21% and 71% decrease for the Bmal1KOs, whereby this 
 
Figure 4.9.1 Antioxidant and anti-inflammatory features of miR-155KO MDFs.  
(A) Sirt1, β-catenin and α-tubulin protein levels were measured in WT and miR-155KO MDFs (n=3 mice samples 
were derived from) by western blotting, with α-tubulin expression used as a loading control. The blot shown 
here is representative of 3 individual experiments. (B) WT and miR-155KO MDFs (n=4 mice samples were 
derived from for both genotypes) were treated with doses of 20, 40, 60, 80 or 100uM tbh7ox for 2 hours, before 
being returned to normal media lacking tbh7ox. 24 hours later viability was assessed following a 4-hour 
incubation of all assay plate wells in 0.02% alamar blue. The relative fluorescence (RFU) of all tbh7ox treated 
wells was expressed as a % of the RFU for the untreated WT or miR-155KO wells. The data in the graph is shown 
as mean % viability of the untreated control for 2 separate biological experiments, where error bars represent 
+/- SD.  
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difference in viability was found to be statistically different for both doses via 2-way ANOVA (p<0.05 
for 20uM and p<0.001 for 40uM). Furthermore, the CC50 of tbh7ox was 40.7, 95% CI (38.9, 42.4) for 
the Bmal1KO MDFs and 34.6, 95% CI (23.2, 37.9) for the WTs. Hence, complete loss of Bmal1 has the 
opposite effect of miR-155 knockout with regards to protection against oxidative stress – suggesting 









Although circadian rhythms are a well-established biological mechanism thought to be conserved 
across many multicellular organisms, it is unclear the extent to which cellular processes are under 
their control and how it varies between cell and tissue types. BMAL1 is regarded as a ‘master 
regulator’ of circadian rhythms as well as a transcriptional activator of NAMPT expression, hence it 
was sought to determine whether NAD+ levels exhibit any circadian rhythmicity and if so, whether 
alteration of BMAL1 levels could modulate NAD+. 
NHDFs, MDFs and MLFs all exhibit what appears to be circadian rhythmicity of their NAD+ levels, 
showing the same general trend of levels starting low and gradually rising over the duration of a 24-
hour timecourse. Of course, it is necessary to acknowledge the limitation of measuring mammalian 
circadian rhythms using an in vitro model: not only do these lack the hormonal input that occurs via 
the SCN in vivo, but they require circadian rhythm to be artificially induced. For this purpose, the 
 
Figure 4.10.1 Proliferation and oxidative stress resistance in WT and Bmal1KO MLFs. 
(A) Proliferation was assessed for 24, 48 and 72 hours post seeding by adding 300ug/ml XTT and 20ug/ml PMS 
to WT and Bmal1KO MLFs (n=2 biological replicates for all conditions) for the incubation times indicated. The 
optical density at a wavelength of 490nm was measured, indicating the extent of proliferation that occurred 
during the incubation period. (B) Cell viability in response to a 2-hour incubation with 20, 40, 60, 80 and 100uM 
concentrations of tbh7ox was quantified (n=2 biological replicates for all conditions). 20 hours after the 
oxidative insult, the cells were treated with 0.02% alamar blue for 4 hours and the relative fluorescence units 
(RFU) was then measured as a readout of cell viability. RFU values for each assay well were then expressed as 
a % of the untreated control. Data is shown as mean optical density or % viability +/- SD. The data is the average 
of the means from two separate biological experiments. 
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common approach of a short incubation in dexamethasone was used, however as a corticosteroid it 
is likely to have many off target effects which may influence the timecourse data. Furthermore, it is 
important to stress that this is a crude approach and a poor surrogate for the circadian rhythms that 
occur under physiological conditions, however it does establish rhythmic expression of circadian 
genes - it can be used probe whether other processes are under control of the intracellular circadian 
network. 
Nonetheless, the dexamethasone pre-treatment induced an oscillation of Bmal1 mRNA levels in 
MDFs, hence effectively creating a system of circadian rhythmicity even if not reflecting the exact 
nature of the rhythms that occur in vivo. Importantly, the altered NAD+ profile in NHDFs 
synchronised with dexamethasone and treated with BMAL1 siRNA emphasises a prominent role for 
BMAL1 in the regulation of NAD+. Furthermore, the BMAL1 siRNA failed to induce any significant 
change in NHDF NAD+ under non-circadian synchronised conditions, suggesting BMAL1’s regulation 
of NAD+ is part of a complex network requiring the establishment of a circadian rhythm.  
The mechanism by which BMAL1 regulates NAD+ remains unclear however given siRNA induced 
BMAL1 knockdown failed to reduce NAMPT protein levels - in contrast to be what had been 
hypothesised on the basis of previous studies describing BMAL1 mediated transcriptional control of 
NAMPT [234]. It would therefore be of interest to determine if the ability of BMAL1 siRNA to alter 
NAD+ following dexamethasone treatment corresponds to a change in NAMPT levels. When 
comparing Bmal1 mRNA and NAD+ levels over the 24-hour timecourse for the WT and miR-155KO 
MDFs there is no apparent correlation, therefore the circadian regulation of NAD+ is more complex 
than the simplistic prediction that increased BMAL1 upregulates NAMPT which in turn increases 
NAD+ synthesis and vice versa. 
The complex relationship between BMAL1 and NAD+ is further emphasised by the comparison of 
NAD+ in WT and Bmal1KO MLFs, with NAD+ found to be significantly lower in the Bmal1KO under 
non-synchronised conditions. However, the lack of any NAD+ rhythmicity in the Bmal1KO cells in 
contrast to the WTs following dexamethasone treatment suggests BMAL1 is perhaps more 
important for the establishment of rhythmicity, rather than directly increasing or decreasing NAD+ 
levels per se. 
To investigate the effect of Bmal1 overexpression on NAD+ and metabolism, miR-155KO and WT 
MDFs were used due to the upregulation of Bmal1 in the miR-155KO cells, a consequence of their 
lack of miR-155 which functions as an epigenetic repressor of Bmal1. In addition to increased basal 
Bmal1 protein expression, the Bmal1 mRNA is also higher in the miR-155KO MDFs under 
synchronised conditions, which interestingly display a similar pattern to the WTs but with a phase 
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shift to the right. Despite the higher BMAL1 however, under non-synchronised conditions the NAD+ 
is significantly lower in the miR-155KO MDFs - once again reinforcing the notion of the relationship 
between BMAL1 and NAD+ being highly complex. 
An interesting feature of the NAD+ profile in dexamethasone synchronised miR-155KOs was a 
profound and transient peak at the 4-hour timepoint. This was absent in the WT cells, hence it may 
be that miR-155 plays a specific role in supressing NAD+ early in the timecourse.  
Due to the financial cost of running the NAD+ assays, the experiments measuring NAD+ in this chapter 
were only performed twice, going against standard experimental protocol of conducting all 
experiments at least 3 times. Hence, this has to be noted as a serious limitation of the work. Although 
preventing robust conclusions, the data generated is still informative and creates a foundation on 
which further work investigating the relationship between circadian rhythms, miR-155 and NAD+ can 
be built. 
It is also essential to acknowledge that miR-155KO cells in no way represent a bona fide model of 
enhanced BMAL1 levels despite their characteristically high expression. MiR-155 is a notably 
promiscuous miRNA which has the ability to repress many target genes, thus its knockout will affect 
a wide range of pathways. Indeed, in mice TargetScan identifies 3188 possible transcripts to which 
miR-155 could putatively bind (although in reality, it is unlikely to bind the majority). 
Indeed, the multi-functional role of miR-155 is illustrated by the very different proliferative and 
metabolic phenotypes of the miR-155KO cells. The enhanced proliferation and basal levels of 
glycolysis could explain their significantly lower NAD+ levels given a net increase in glycolysis shifts 
the redox balance between NAD+ and NADH towards the reduced form. Additionally, the miR-155KO 
MDFs exhibit increased SIRT1 protein levels, which may also account for reduced NAD+ if SIRT1 
activity is also increased. 
From a non-NAD+ ageing perspective, the effects of miR-155 knockout merit further investigation. 
As well as increased SIRT1, the miR155KO cells showed strengthened resistance against the oxidative 
stress inducer tbh7ox, whilst their mitochondrial function was less affected by increased replication. 
The latter is particularly interesting, suggesting the potential presence of an anti-senescence 
mechanism in the absence of miR-155, however a common drawback of anti-senescent pathways is 
that they can also be pro-tumourigenic. Hence, it would be of use to the biogerontology field to 
further investigate miR-155 and the potential role of other miRNAs in ageing, given their ability to 
exert post-transcriptional control of many genes.  
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It cannot be ruled out that the different metabolic phenotype of the miR-155KO MDFs could be due 
to the immortalisation that mouse cells can spontaneously undergo under normoxic oxygen 
conditions (as opposed to physiological oxygen). The miR-155KO MDFs were noted for their which 
higher replication rate even at lower passages (<10), which combined with the similar phenotype in 
all the MDFs from 4 different animals however does suggest that this is unlikely, however the 
possibility should still be acknowledged. 
To follow up the findings reported within this chapter, it would be of interest to use the miR-155KO 
mouse model for in vivo studies on lifespan, healthspan and response to senescent/other pro-ageing 
stimuli. With regards to BMAL1 and NAD+, the Bmal1KO mice could also be used for further analysis 
to determine if NAD+ titres within different tissues are affected by loss of Bmal1, which could also 
be performed over a 24-hour timecourse. Finally, to better understand the effect of sleep/wake 
cycles on NAD+ levels, this could be assessed in rodent models or possibly in humans by obtaining 
blood samples from shift workers when working different rotas. Although this work establishes a 
tentative link between miR-155, BMAL1 and NAD+, the aforementioned in vivo studies would be 




















Chapter 5. Interventions to Enhance Human PBMC NAD+ Levels In Vivo 
5.1 Introduction 
Given the recent emergence of NAD+ as a potentially key molecule in physiological ageing, there is 
an intense interest in approaches to reverse the decline in NAD+ levels suspected to occur with 
increasing age. A demonstration of this age-related decline was first provided by Massudi et al. [70], 
who found that in pelvic skin samples there was a linear relationship between increasing age and 
declining NAD+ over a 0 – 80 years age range.  
There is also evidence for an age-related NAD+ decline in the liver, with non-pathological liver tissue 
obtained by hepatectomy from patients >65 years old exhibiting NAD+ levels approximately 30% 
lower than that of non-pathological liver tissue from patients <45 years old (2). Furthermore, using 
MRI Zhu et al. found that brain concentrations of NAD+ declined in a linear fashion over a 21 – 68 
year-old age range (3), hence it appears NAD+ is depleted in multiple tissues with increasing age. It 
is important to consider however, that the large variability in the metabolic phenotype of different 
tissues implies it is likely that certain cell types/tissues will be more susceptible to age-related NAD+ 
decline. In particular, tissues with a high demand for ATP via OXPHOS would be more likely to see a 
reduction in the NAD+/NADH ratio with increasing age due to higher rates of mitochondrial turnover 
and accumulation of mitochondrial oxidative damage. Consequently, this would impair electron 
transport chain function and the resulting oxidation of NADH to NAD+. 
Age-related changes in NAD+ have yet to be investigated for PBMCs, however an effective NAD+ 
enhancing intervention would need to work in multiple tissues, therefore PBMCs were chosen as the 
sample type for the work presented herein – primarily due to the ease of collecting these cells from 
human participants. 
At present, the most common approach to increase NAD+ in vivo is by oral ingestion of the NAD+ 
precursor nicotinamide riboside (NR), currently marketed worldwide as a supplement to enhance 
NAD+. A number of studies (Table 5.1.1) have recorded notable success at increasing NAD+ using NR 
[310, 311, 405], with the largest increases reported being 129% following 21 days of NR 
supplementation in a 70-80 year-old male cohort [310] and 217% for a single individual after 7 days 
of consumption [152]. No data has been published investigating whether there is a difference in the 
efficacy of NR or NR containing combinations for different age groups – a feature which would help 
identify whether a ceiling effect exists, whereby such treatments are more effective with increasing 
age due to greater ‘room’ for NAD+ enhancement. 
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It stands to reason that NAD+ enhancement greater than that reported for NR thus far would indeed 
be possible, mainly given NR is an input into just a single arm of the complex network of enzymes 
and cellular processes that regulate intracellular NAD+. A more tailored approach that targets 
inefficient enzymes that utilise NAD+ and increases the re-cycling of NAD+ metabolites back into the 
NAD+ salvage pathway, in addition to providing precursors for NAD+ synthesis has the advantage of 
targeting numerous mechanisms which regulate NAD+ levels. To this end, many of the enzymes 
fulfilling these roles are known targets of various polyphenols (Table 5.1.2), thus opening the 
possibility to modulate them via dietary based interventions. 
To test this theory, supplement cocktails containing multiple compounds targeting key enzymes 
involved in NAD+ metabolism were given to 2 participants as part of a pilot study. The cocktails were 
conceived and developed by an enterprise specialising in network pharmacology, thus were 
designed with the intent to achieve maximal enhancement of NAD+. The participant NAD+ levels 
were specifically measured in PBMCs rather than whole blood due to the particular interest in 
enhancing NAD+ as a means to promote SIRT1/PARP1 activity, which given the nuclear localisation 
of these two enzymes would be irrelevant in erythrocytes (the most abundant cell type in blood) 
which lack nuclei and mitochondria. It is of course necessary to note that the experimental design is 
limited by the use of only 2 participants, however as a pilot study it is still informative given the lack 
of data available regarding the implementation of multi-targeted approach to enhance NAD+ titres 
in vivo. 
5.2 Aims 
The primary aim was to determine whether combinations of different compounds targeting NAD+ 
related pathways were effective at raising NAD+ levels in human PBMCs and how this compares with 
a precursor only approach. 
5.3 Hypothesis 
It was hypothesised that the supplement cocktails would significantly increase participant NAD+ 
levels, with greater increases than those reported for studies using only using precursors such as NR. 
The cocktail versions with more targets in the NAD+ degradation/recycling pathways should exhibit 






   Table 5.1.1 Studies using precursors to enhance human NAD+. 
Study 
Design 










4g NAM (4x 1g 
doses). 
5 months Whole blood Max ↑ NAD+ of 2400% after 6 weeks of 
treatment. Declined to 600% ↑ NAD+ 






100mg NA. 56 days. PBMCs ↑ NAD+ for all weeks measured. Max 
increase on week 8 of almost 5-fold 
(raw values not given). 
4 groups: 25mg 







25mg NA, 50mg 
NA, 100mg NA, 
placebo. 
98 days. PBMCs Significant ↑ NAD+ only for group 
consuming 50mg niacin. Raw values/% 













1st month – 
250mg NA, 2nd 
month – 500mg 
NA, 3rd month – 
750mg NA, 4th 









At 4 months: 610% ↑ NAD+ for patient 
blood samples and a 470% ↑ NAD+ for 
controls. 30% ↑ NAD+ patient muscle 
NAD+, no change for controls. 
At 10 months: 720% ↑ NAD+ for patient 
blood samples and a 130% ↑ NAD+ 




A 52 year-old 
male. 
1000mg NR. 7 days. PBMCs After 1 day 167% ↑ NAD+, after 7 days 
217% ↑ NAD+. 
3 treatment 




adults aged  
60-80 
(n=120). 
1x NRPT – 250mg 
NR + 50mg 
pterostilbene. 2x 
NRPT – 500mg 
NR + 100mg 
pterostilbene. 
60 days (blood 
taken at 
baseline, day 
30 and day 60). 
Whole blood 1x NPRT: 40% ↑ NAD+ at day 30 and day 
60. 
2x NPRT: 90% ↑ NAD+ at day 30 and 
55% ↑ day 60. 
Crossover: NR 






(500mg 2x daily). 
42 days. PBMCs 60% ↑ NAD+ after 6 weeks NR 









1000mg NR.  21 days. Whole blood, 
skeletal 
muscle 
129% ↑ whole blood NAD+ after 21 
days NR compared to placebo. No 
significant change in skeletal muscle 
NAD+. 
4 treatment 
groups:  100mg 
NR, 300mg NR, 
1000mg NR, 







1000mg NR or 
placebo. 
56 days. Whole blood After 14 days: 100mg – 22%, 300mg – 
51%, 1000mg – 142% ↑ NAD+. 
After 56 days: 100mg – 10%, 300mg – 




13 healthy or 
overweight 
adults (n-13). 




No significant change in NAD+. 677% ↑ 
NAAD, 62% ↑ meNAM. 
 
 
Abbreviations: NAM – nicotinamide, NRPT – nicotinamide riboside + pterostilbene, NR – nioctinamide riboside,    





   
Enzyme Mechanism In vivo In vitro Activators Inhibitors 
AMPK  Upregulates 




↑ NAD+ [411] 




Alpha lipoic acid 
[324] 





















↑ NAD+ [425, 
426] 






Coumarin based  
compounds [431] 
NRK 1/2 Phosphorylates NR 
to produce NMN 
within salvage 
pathway 








NMNAT Converts NMN to 
NAD+ 
↑ NAD+  [181] ↑ NAD+ 
[435],[436] 
Resveratrol [434] Gallotanin [437] 
6-MPRT [438] 
NNMT Methylates NAM, 
removing it from 
salvage pathway 
↓ NAD+ [406, 
439]  
- - BSNF-000088  [440] 
CD38 Hydrolyses 
ADPR/cADPR via an 
NAD+ dependent 
reaction 
↓ NAD+ [141, 
418, 441-443] 
↓ NAD+  [444, 
445] 
- Apigenin [156] 










*Ingredients used in NCD cocktails are highlighted in bold. 
Table 5.1.2 Key enzymes in NAD+ synthesis and degradation pathways. 
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5.4 Enhancement of Human PBMC NAD+ Using NR  
A recent study brought into question the bioavailability of NR by showing that in mice, orally 
delivered NR that was isotopically labelled was almost entirely converted to NAM (nicotinamide) 
[447], an issue overcome if instead delivered intravenously. The conversion of NR to NAM may not 
be an issue if this NAM itself is subsequently converted to NAD+, which is likely given the many 
studies showing the ability of oral NR to enhance blood NAD+ [152, 311, 407]. Nonetheless, it was 
sought to verify whether NR was effective at increasing NAD+ titres in a small human cohort (n=5).  
Given a circadian oscillation of NAD+ has already been characterised in liver tissue of mice [448-450] 
and in vitro within this thesis (Chapter 3) and other studies [234], it was deemed essential that 
samples would always be collected at the same timepoint on all study days, hence controlling for 
circadian rhythms. Participants were also told to keep sleep/wake times consistent for the duration 
of the study, once again to control for circadian rhythms which are strongly influenced by sleep 
patterns. Likewise, the potential effect of diet and time of feeding was controlled for by asking 
participants to keep a food diary and replicate this for both study weeks. 3 baseline blood samples 
were taken on 3 different days (days 1, 3 and 5) during the same week and compared to samples 
collected on days 1, 3 and 5 of the following week in which 500mg NR (Niagen) was taken at the 
same time with breakfast every morning for 5 days.  
4 out of the 5 participants showed an increase in NAD+ levels when comparing the treatment week 
average to the baseline week average (Figure 5.4.1 A), although a statistically significant difference 
wasn’t observed for any of them. Looking at the NAD+ titres for the individual treatment days on 
which samples were collected, 3 out of the 5 participants had a >90% increase in NAD+ compared to 
the baseline average on day three, however for female 1 and 2 the NAD+ returned close to baseline 
levels on day 5 (Figure 5.4.1 B). This is the first time NAD+ levels in response to NR ingestion has been 
monitored on multiple days throughout the same week, indicating that its efficacy is highly variable 






5.5 A Multi-Targeted Approach to Enhancing Human NAD+ Titres  
5.5.1 Human PBMC NAD+ Exhibits a Circadian Rhythm 
To test the hypothesis that a more sophisticated multi-targeted approach would yield improved 
enhancement of NAD+ levels in vivo compared to NR, the efficacy of the supplement cocktails 
NCD201.1, NCD201.2, NCC202, NCD203 and NCD205 at enhancing NAD+ was assessed. All these 
cocktails contain multiple compounds with different targets within the NAD+ network. Given the 
existence of a circadian rhythm of NAD+ and also the possibility that there may be an upper limit to 
physiologically achievable NAD+ levels, whether the cocktails were more efficient at timepoints 
where NAD+ hits a daily nadir was of particular interest. Furthermore, the need for increased NAD+ 
would be most relevant at daily timepoints where an individual experiences a daily low. Thus, for 
both volunteers recruited for the pilot study (52 year-old male and 37-year old female) NAD+ was 
measured over the same 12-hour time period (8am – 8pm) to try and identify any individual peaks 
and troughs and to determine if their NAD+ levels followed a discernible diurnal pattern as predicted.  
 
Figure 5.4.1 PBMC NAD+ levels during 5 days of NR supplementation.  
Blood samples were collected at the same timepoint on days 1, 3 and 5 during a week in which the 5 
participants didn’t consume NR. The following week all participants consumed 500mg of NR at the same time 
every morning for 5 days and blood samples were once again collected on days 1, 3 and 5 at the same timepoint 
as for the previous week. PBMCs were isolated following each blood collection and immediately stored at -
150ᵒC. NAD+ levels were measured using an NAD+ cycling assay, before being normalised to protein 
concentration for each sample by performing a BCA assay. (A) The average ng NAD+/ug protein for the baseline 
week (n=3 separate biological samples) and NR treatment week (n=3 separate biological samples) for each 
participant is shown as mean +/- SD. Statistically significant differences between the baseline and treatment 
average for each participant was tested for using a paired Student’s t-test. (B) The baseline average (n=3) and 
NAD+/ug protein for the individual treatment days (n=1) is shown. Error bars represent +/- SD of the two 
technical replicates for each treatment day sample. 
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For the male two noticeable troughs were identified at 10am (day 1 - 0.23ng NAD+/ug protein, day 
2 - 0.20ng NAD+/ug protein) and 2pm (day 1 – 0.43ng NAD+/ug protein, day 2 – 0.14ng NAD+/ug 
protein, day 3 – 0.21ng NAD+/ug protein), with a noticeable peak at 12pm (day - 1.04ng NAD+/ug 
protein, day 2 – 0.97ng NAD+/ug protein). Although the original intention was to obtain a complete 
profile of the NAD+ fluctuations on 3 different days, only the 10am, 2pm and 6pm timepoints were 
collected on the third baseline day due to cannulation issues. Both days on which all samples were 
collected showed similarity however in that NAD+ levels began low, before a sharp rise at 12pm and 
then a sudden drop at 2pm, after which they continued rising throughout the rest of the day. This 
was also somewhat resembled on baseline day 3, with the 2pm NAD+ representing a low point before 
rising to a peak at 6pm.  
Likewise, for the female there was variability across the 3 baseline days but a general trend was 
observed. The 8am levels were also low, however sharply rose at 10am (day 1 – 0.46ng NAD+/ug 
protein, day 2 – 0.31ng NAD+/ug protein, day 3 – 0.64ng NAD+/ug protein) resembling the peak seen 
for the male at 12pm. This was also then followed by a drop in NAD+, however this was less steep 
and more prolonged, lasting until 4pm before rising again.   
The large variability between the different baseline days is emphasised by a 2-way ANOVA analysis, 
whereby there was a significant difference between all the baseline days for the female (p<0.001) 
and baseline days 1 and 2 for the male (p<0.01). This suggests that in addition to varying within the 
same day, PBMC NAD+ levels show very high day to day variability over the course of the same week.  
It’s important to note that consistent blood drawing and processing is imperative when measuring 
NAD+ given its labile nature and the likelihood that RBCs (due to their lack of nuclei/mitochondria 
and thus unique NAD+ metabolism) possess a very different NAD+ profile to PBMCs - hence their 
contamination must be kept to an absolute minimum when isolating the PBMCs from whole blood. 
For this reason, when it came to calculating the average baseline values for each participant the 2pm 
baseline day 2 value for the male participant was disregarded due to high levels of RBC 
contamination (visually noticeable within the PBMC pellet), whilst the entirety of day 2 was excluded 
for the female due to problems with cannula insertion and the resulting concerns over excessive RBC 
contamination within the PBMC fraction due to clotting. Indeed, this is reflected in the results, with 
the male participant’s baseline day 2 2pm value and the majority of baseline day 2 for the female 
appearing considerably lower than for the other days. Therefore in hindsight, the use of a RBC lysis 
buffer may have overcome these issues. Cell sorting is another method that could used separate 
101 
 
different blood cell types, however given the need to isolate PBMCs at cool temperature and as 
quickly as possibly, wouldn’t be appropriate for this work.     
            
            
            
            






Figure 5.5.1.1 PBMC NAD+ levels fluctuate over a 12-hour timecourse.  
The daily fluctuation of NAD+ levels on three separate days is shown for a male and a female participant. Blood 
samples were collected by cannulation at 2-hour intervals between 8am and 8pm (n=1 biological sample for 
each timepoint) and the PBMCs isolated by density centrifugation prior to freezing at -150ᵒC. Upon thawing 
NAD+ levels were measured by performing an NAD+ cycling assay before being normalised to protein levels using 
a BCA assay. NAD+ levels are therefore shown as mean ng NAD+/ug protein. Error bars represent +/- SD of the 




















↑ SIRT1 [324] 
Animal kidney – 
260 [453] 
Animal heart – 
150 [453] 
Improves memory and reduces oxidative damage, but 
decreased lifespan in an Azheimer’s disease mouse model. 
[454] Increases lifespan in C. elegans. [455] 
apigenin ↑ NQO1 [428] 
↓ CD38 [156, 
456] 
Dried parsley – 
4504 gov [457] 
Fresh parsley – 
216 [458] 
Extends lifespan and improves motor function D. 
melanogaster model of Parkinson’s disease. [459] Reduces 
oxidative stress, improves learning and motor function in D-
galactose induced aged mice. [460] 
rutin ↑ NAMPT [423] 
↑ AMPK [413, 
461, 462] 
Buckwheat flower 
tea – 396 [463] 
Extends lifespan in D. melanogaster [464] Reduces age-
related pathology in ageing mouse model. [465] 
resveratrol ↑ NRK1/2 [434] 
↑ SIRT1 [466] 
↑ NMNAT1 [315] 
Fallopia Japonica 
– 2.1 [467] 
Itadori tea – 0.97 
[468] 
Red wine – 0.85 
[468] 
Increased lifespan in Alzheimer’s mouse model. [314] 
Improves cognition in aged and senescence-accelerated 
mice. [313, 469] 
quercetin ↑ CD73 [470] Capers – 234 
[471] 
Lovage  - 170 
[458] 
Dock leaves - 86 
[472] 
Decreases disease pathology and improves cognitive 
function in Alzheimer’s mouse model. [473] Extends 
lifespan in C. elegans. [474] 
EGCG ↓ PARP1 [475] Green Tea (dried 
leaf) - [476] 
Carob flour – 109 
[477] 
Extends lifespan and prevents age related mitochondrial 
decline in C. elegans. [478] Extends lifespan and reduces 
age-related increase in oxidative stress/inflammation in 
rats. [479] 
curcumin ↑ NQO1 [429] 
↑ AMPK [414, 
415] 
Curcuma roots 
(turmeric)  – 8-
125 [480] 
Extends lifespan in mice [481] and reduces age-related 
brain pathology. [482] 
fisetin ↑ SIRT1 [483, 
484] 
Freeze dried 
strawberries – 16 
[485] 
Extends lifespan, reduces age-related pathology in aged 
mice. [486] Improves cognition in rapid ageing mouse 
model. [487] 
luteolin ↑ NAMPT [488] Dried oregano – 
1029 [489] 
Celery seed – 762  
Reduces neuroinflammation and improves learning and 
memory in aged mice. [490, 491] 
Table 5.5.1.2 Dietary compounds targeting NAD+ related enzymes and in vivo anti-ageing evidence. 
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5.5.2 NCD201 Enhances PBMC NAD+ Levels During a 16-day Treatment Phase 
The first supplement cocktail (named NCD201) tested for its efficacy at enhancing NAD+ levels 
contained 1000mg NR, 1125mg quercetin, 450mg resveratrol, 600mg alpha-lipoic acid and 600mg 
apigenin. The 1000mg represents the largest dose of NR used over a prolonged treatment period 
thus far in clinical studies, previously shown to increase NAD+ up to 217% in PBMCs [152]. The 
components additional to NR within this cocktail were selected for their ability to modulate the 
activity or expression of targets involved in NAD+ metabolism (Table 5.5.1.2).  
Both participants began the consumption of NCD201 3 days after the completion of their baseline 
measurements, consuming it at the same time every morning for 16 consecutive days (no placebo 
or blinding in place). During this time, blood samples were collected for PBMC isolation every 2 or 3 
days at the 2pm timepoint for the male and 4pm for the female. The 2pm timepoint was chosen for 
the male participant due to it giving consistent NAD+ levels across the 3 baseline days, thus 
suggesting this low-point is a reliable feature of his NAD+ profile. Furthermore, as it is of particular 
interest to enhance NAD+ during daily nadirs when an enhancement of NAD+ would be most 
necessary, this reinforced the decision that this was the appropriate timepoint to select. Likewise, 
for the female the 4pm timepoint was a consistent point at which NAD+ levels dipped, hence it was 
chosen for her blood draws during the treatment period.  
For the male participant the average increase of NAD+ at the 2pm timepoint during the 16-day 
NCD201 treatment phase was 301% with a maximum increase of 821% (treatment day 11) and a 
minimum increase of 7.9% (treatment day 3) (Figure 5.5.2.1 A). This average of 301% is well above 
the largest previously reported increases for human studies using NR (Table 5.5.1), although this 
data is very preliminary given it is n=1 and cannot undergo statistical analysis. Interestingly, the 
largest increases were on days 11 and 14 before dropping off on day 16, perhaps suggesting there 
was some sensitisation to the cocktail by day 16 - thus raising the question as to what length of time 
the cocktail can maintain enhanced NAD+ without the levels returning to baseline. 
Furthermore, on treatment days 1 and 16 sampling was performed at multiple timepoints for the 
male (Figure 5.5.2.1 B). Samples were successfully obtained for all timepoints on day 16, however 
for treatment day 1 only the 10am, 12pm and 2pm samples were collected due to cannulation issues 
and concerns about the potential damage this would do to the participants’ veins with numerous 
testing days still ahead. Hence, it was decided to obtain the full NAD+ profile on only a single day and 
to save this for the last study visit. For treatment day 1, whilst the 2pm NAD+ measurement was 
significantly higher than the baseline average, there was only a small increase at 10am (19.6%) and 
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12pm (6.5%). Given the participant consumed the cocktail at 8.30 am, this suggests it takes NCD201 
>3.5hrs to be effective on the first day of consumption. 
In addition to the 2pm timepoint, on treatment day 16 there was also notably large increases in 
NAD+ levels when compared to the corresponding baseline average timepoint at 8am (210%), 10am 
(316%) and 4pm (192%). Overall, when compared to the baseline mean the day 16 NAD+ levels were 
on average 122% higher and indeed elevated at every timepoint, with a maximum increase of 316% 
(10am) and a minimum of 33% (8pm). Therefore, even after 16 days of daily consumption the 
cocktail still maintains its ability to enhance NAD+, although the absence of data for all the timepoints 
on the previous treatment days means it’s unknown whether, as for 2pm, the enhancement at these 
timepoints is also on a downward trend.  
Due to the constraints of the female participant having only one viable vein to use over the course 
of the study, a full day of NAD+ measurements from 8am to 8pm whilst on the treatment wasn’t 
attempted. However for the 4pm blood draws, a similar trend to that of the male participant was 
observed with the largest increases occurring on treatment days 10 (217% increase) and 11 (174% 
increase) before slightly tailing off on day 16 (150% increase) (Figure 5.5.2.1 C). It is interesting to 
note that in contrast to the male, NAD+ was still substantially higher than the baseline on day 16. 
The average increase across the treatment period for the female 147%, with a maximum of 258% 
and minimum of 79%, thus NCD201 induced a lower increase in NAD+ for the female although the 
increases recorded were much more consistent across the treatment days, as evidenced by the 
lower SD (305% for the male vs 48% for the female). 
For the male participant, two further measurements of PBMC NAD+ levels were made at 5 days 
(washout 1) and 9 days (washout 2) following completion of the treatment phase (Figure 5.5.2.1 D). 
This was done to check whether NAD+ levels returned to the baseline values following a short period 
of supplement abstinence. Surprisingly, the 2pm NAD+ levels on washout days 1 and 2 were higher 
than the baseline average (increases of 79% and 54% respectively). It is not clear whether this 
increase is due to long-lasting effects of the cocktail or possibly an unrelated physiological change 
within the participant.  
On both these washout days, in addition to the 2pm timepoint blood was also collected at 2-hour 
intervals from 8am to 8pm so that the 12-hour profile could be compared to that of the baseline 
days. Aside from 2pm, the only other timepoint at which the washout and baseline averages were 
notably different was 8am, with washout 1 182% higher than the baseline average and washout 2 
127% higher. The reason for the prominent change at this particular timepoint isn’t obvious, 
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however given it’s the earliest point measured it may be much more susceptible to the effects of 
sleep quality, which is known to influence circadian rhythms.   
Including all the daily timepoints NAD+ was measured at, on average NAD+ levels on washout day 1 
were 54% higher than the baseline average, whilst on baseline day 2 the average was only 16% 
higher.  
When comparing the day 16 profile to the profiles taken on the two washout days (5 days and 9 days 
later), the day 16 NAD+ is on average 64% greater, with statistically significantly higher levels at 
12pm, 4pm and 6pm. As already discussed, it may be some lasting effects of the cocktail or an 
unrelated physiological change which accounts for the higher washout NAD+ compared to the 




Figure 5.5.2.1 NAD+ titres in the PBMCs of two volunteers after 16 days consumption of NCD201.1.  
(A) The average NAD+ levels measured at 2pm during the pre-treatment baseline week (n=3 biological samples) 
is compared to the NAD+ levels at 2pm (n=1 biological sample for each treatment day) on the days indicated 
during a 16-day treatment period of NCD201 consumption for the male participant. Values are expressed as 
% ng NAD+/ug protein of the baseline 2pm average for the 2 technical replicates. (B) The average NAD+ levels 
measured at 4pm during the pre-treatment baseline week (n=3) is compared to the NAD+ levels at 4pm on the 
days indicated (n=1) during a 16-day treatment period of NCD201 consumption for the female participant. 
Values are expressed as % ng NAD+/ug protein of the baseline 4pm average for the 2 technical replicates. (C) 
The NAD+ levels at the timepoints indicated are shown for the male participant on the pre-treatment baseline 
days (n=3) and on days 1 and 16 of the treatment period (n=1). Values are shown as ng NAD+/ug protein of 2 
technical replicates. (D) The NAD+ levels at the timepoints indicated are shown for the male participant on the 
3 pre-treatment baseline days and on washout days 1 and 2 (n=1), which were 5 and 9 days after the treatment 
phase ended. Values for the timepoints are shown as ng NAD+/ug protein. Error bars represent +/- SD of the 
two technical replicates for each treatment day sample. 
106 
 
5.5.3 NCD201.2 Enhances NAD+ But to a Lesser Extent Than NCD201 
On the Monday of the week following the washout measurements (12 days after finishing the 
NCD201 treatment period), the male participant began an 8-day treatment phase of NCD201.2 - a 
cocktail containing the same ingredients as NCD201.1 but from different manufacturers and at 
different quantities. For this treatment phase blood samples were taken at both the 2pm and 4pm 
timepoints, testing the hypothesis that any changes induced by the cocktail would be greater at the 
timepoint associated with the daily nadir (2pm) compared to a timepoint in which the NAD+ 
appeared to be rising (4pm). Although 4pm wasn’t the point of peak NAD+ during the baseline 
measurements, it was chosen due to the combination of it being a timepoint of rising NAD+ and the 
consistent values across the different baseline and washout days. Because the washout week 
preceded this treatment, the NAD+ averages for the timepoints on the two washout days were taken 
as the new baseline. 
Given the expectation that the effects of the cocktail would be more pronounced at the nadir 
timepoint, it was surprising to find that 4pm showed a significant increase in NAD+ levels on more 
days during the treatment phase (days 3, 6, 7 and 8) compared to 2pm (days 3 and 8) (Figure 5.5.3.1 
A). The average increase across the treatment phase was however greater at 2pm (79% vs 55%), as 
was the maximum increase recorded (2pm day 8 - 176% vs 4pm day 7 - 108%).  
It is therefore possible that the cocktail may simply be having a similar additive effect at all 
timepoints rather than preferentially enhancing at the timepoints associated with a daily low in NAD+ 
levels. Alternatively, the length of time it takes the compounds to be metabolised and subsequently 
interact with their targets may make the cocktail more effective at later daily timepoints. It is also 
important to note that during the washout phase the 2pm NAD+ levels were no longer a nadir, which 
provides another explanation for these results. 
By comparison, the first 8 days for the NCD201.1 treatment caused an average NAD+ increase of 
137% for the 2pm timepoint (Figure 5.5.3.1 B), with the only day it was significantly increased being 
treatment day 1 (264%, p<0.01). Hence the average increase was lower for NCD201.2 (79%), 
although the lack of treatment days beyond day 8 prevents a more robust comparison between the 







5.5.4 Removal of Precursor in the NCD202.1 and NCD202.2 Cocktails Reduces NAD+ Enhancing 
Efficacy 
NCD202.1 was the next cocktail to be tested, which differed from the NCD201 iterations in that it 
lacked the precursor (1000mg nicotinamide riboside) and also had the addition of an NNMT 
inhibitor. NNMT methylates NAM, which signals for it to be excreted from the cell and eventually 
metabolised by the liver. Theoretically, if NNMT is inhibited this will increase cellular NAM, which if 
combined with a NAMPT activator (e.g. resveratrol or quercetin) will allow the increased levels of 
NAM to be converted into NAD+ by providing more substrate for NAMPT. Hence, by removing the 
precursor, it was hypothesised that this cocktail would enhance NAD+ levels simply by modulating 
targets in the NAD+ salvage pathway without the need for precursor, although likely to a lesser extent 
than NCD201. Different forms of NAD+ precursors are found in foods typically consumed as part of a 
daily diet, thus it was anticipated that there would still be an adequate input for the de novo NAD+ 
synthesis pathway to work in tandem with the NAD+ salvage pathway. 
The protocol for supplement consumption and blood collection was kept consistent with the 
NCD201 treatment phase. However, due to issues regarding participant availability, this cocktail was 
only tested for the male participant. After day 5 of consuming NCD202.1 the participant took a 2-
day break from consumption, before replacing NCD202.1 with NCC202.2 which was consumed for a 
Figure 5.5.3.1 NCD201.2 increases PBMC NAD+ levels. 
Blood samples were collected and the PBMCs isolated at 2pm and 4pm (n=1 biological sample each 
treatment day, n=2 biological samples baseline) on the days indicated during an 8-day period consuming the 
supplement cocktail NCD201.2 for the male participant. NAD+ levels were measured using an NAD+ cycling 
assay and normalised to protein concentration quantified by a BCA assay. The NAD+ levels were then 
expressed as a percentage of the baseline average (n=2), which was measured at 2pm and 4pm on two 
different days during the week prior to the initiation of treatment consumption. Data is shown as % NAD+ of 
the baseline. Error bars represent +/- SD of the two technical replicates for each treatment day sample and 




further 5 days. The only variation between NCD202.1 and NCD202.2 was the use of a different NNMT 
inhibitor. 
Over the 5-day treatment period NCD202.1 was much less effective than NCD201.1 and NCD201.2, 
inducing an average NAD+ increase of 64%, with a maximum increase of 140% (day 4) and an 12% 
decrease as the minimum (day 5).  
For the 5-day NCD202.2 treatment phase the average increase in NAD+ was reduced to 32%, with a 
maximum increase of 80% (day 5) and a minimum on day 1 that was 7% less than the baseline 
average. Importantly, both NCD202 versions highlight the negative impact of precursor removal and 
suggest that to achieve maximal enhancements in human NAD+, targeting the key regulators in NAD+ 
metabolism needs to be combined with precursor supplementation.  
 
 
5.5.5 NCD203: Substituting NR with NAM Maintains Cocktail Efficacy 
The next cocktail to be tested was NCD203: which had the same formula as NCD201.2 but with the 
addition of the NNMT inhibitor included for NCD202.1 whilst also using a different precursor (500mg 
NAM instead of 1000mg NR). NR was replaced with NAM on the rationale that supplementation with 
Figure 5.5.4.1 PBMC NAD+ levels following consumption of NCD202.1 and NCD202.2. 
PBMC NAD+ levels are shown for blood samples taken at 2pm during a pre-treatment baseline week (n=3 
baseline days), 1-week consuming NCD202.1 (n=1 biological sample for each treatment day) and also at 2pm 
for the following week consuming NCD202.2 (n=1 biological sample for each treatment day) in a male 
subject. NAD+ levels were measured for the isolated PBMCs using an NAD+ cycling assay and normalised to 
protein concentration quantified by a BCA assay. The NAD+ levels were then expressed as % ng NAD+/ug 
protein of the baseline average. Error bars represent +/- SD of the two technical replicates for each treatment 




NAM yielded the largest recorded human NAD+ enhancement [150], in addition to the recent 
evidence that NR is metabolised to NAM following oral ingestion [447]. Furthermore, due to the 
intention of the supplier to eventually make the cocktail available commercially, NCD203 was 
designed to satisfy various manufacturing and regulatory restraints. As a result, some of the same 
compounds previously used in NCD201 were now in the form of a herbal extract, for example 
apigenin was included as parsley leaf extract rather than pure apigenin.  
NCD203 was only tested in the female participant and was consumed following the same protocol 
as for previous versions. Blood samples were once again collected at the 4pm timepoint, this time 
on days 1, 2, 4, 8, 10 and 14 over a 14-day treatment phase. On average, the NAD+ levels were 76% 
higher than compared to the baseline, with a maximum increase of 134% on day 10 and a minimum 
of 53% on day 4 (Figure 5.5.6.1 A).  
The occurrence of enhanced NAD+ elevation during the second week of consumption reflects what 
was also seen in the previous versions of the cocktails, suggesting consumption on consecutive days 
begins to have a cumulative effect during the second week of consumption. This may be due to the 
key components or their metabolites persisting longer than 24 hours in the body and hence building 
up over time, as has previously been documented for apigenin in rats [492].   
Despite the enhancement of NAD+ that occurs in response to NCD203 consumption, when compared 
vs NCD201.1 it is notably less effective: with an average increase of 76% vs 147%, maximum increase 
of 134% vs 276% and minimum increase of 53% vs 79%.  
Consequently, this also infers that using herbal extracts as a source for the NAD+ targeting 
compounds may be a less effective approach than using the extracted/synthesised compounds 
themselves. Even in lieu of these findings, using the extracts introduces the problem of accurately 
predicting the dosage, given different extract harvests will vary in their polyphenol concentration 
etc. Moreover, there may be additional compounds in the extracts interacting with the NAD+ related 
pathways which may also explain the reduced efficacy at increasing NAD+. Of course, one could argue 
that the additional compounds and nutrients contained within the extracts may offer wider health 
benefits given the health promoting effects of parsley leaf and green tea extract are well-
documented, however from a solely NAD+ enhancing perspective the ambiguity with regards to the 
dosage isn’t ideal.   
5.5.6 NCD205 Failed to Effectively Enhance NAD+ in a Female Participant 
The final cocktail (NCD205) tested was a further modification of NCD203 in which some ingredients 
from the previous versions were excluded so that the supplement could be administered in capsule 
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format rather than as a mix of powders. Each daily dosage contained: 500mg nicotinamide, 660mg 
green tea leaf extract, 632mg parsley leaf powder, 600mg rutin extract, 600mg black pepper fruit 
extract, 10mg zinc and 20mg vitamin C. Within this version, the green tea leaf extract provided the 
EGCG and the parsley leaf powder the apigenin, whilst black pepper extract was included to improve 
absorption of the compounds within the GI tract. 
 The protocol for consumption was slightly altered such that half the daily dose (3x capsules) was to 
be consumed with breakfast and the other half consumed with lunch. This was to ease potential 
issues regarding indigestion and heartburn with the cocktail now in capsule format. Baseline blood 
samples were taken at 2pm on two different days during the week prior to supplement consumption. 
During the 11-day treatment phase, samples were collected on days 1, 3, 5, 8 and 11 however a 
technical error meant the day 8 results needed to be excluded from the final analysis. 
Over the treatment period the average change in NAD+ recorded was a 0.3% increase, with a 
maximum increase of 20% (day 1) and the lowest recorded value a decrease of 40% (day 11) (Figure 




Figure 5.5.6.1 NAD+ titres in a female participant in response to the NCD203 and NCD205 supplement 
cocktails. 
PBMC NAD+ levels are shown as a % of the untreated baseline average (n=3 biological samples) for blood 
samples taken at 4pm on the treatment days indicated for a female volunteer consuming NCD203 and NCD205 
for 11 and 5 days respectively (n=1 biological sample for all treatment days). The untreated baseline blood 
samples were taken on 3 different days the week prior to beginning supplement consumption. NAD+ levels were 
measured for the isolated PBMCs using an NAD+ cycling assay and normalised to total protein quantified by a 
BCA assay. The NAD+ levels were then expressed as a percentage of the baseline average, with error bars 
representing +/- SD of the two technical replicates for each treatment day sample and +/- SD of the biological 
replicates for the baseline.   
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5.6 Variability in NAD+ Across Different Baselines – A Notable Caveat  
It should be noted that there were significant variations in the average baseline NAD+ levels 
measured for the female participant during the different baseline weeks. Unexpectedly, the trend 
showed a chronological increase in average baseline NAD+ levels. As already mentioned, NAD+ levels 
would be expected to decrease with age, however over a short timeframe (19 months) no significant 
differences would be expected to occur as a consequence of physiological ageing. The 3.1-fold 
increase in NAD+ levels for the September 2019 baseline compared to the April 2018 baseline 
suggests that basal NAD+ levels can potentially be drastically altered by nutritional, lifestyle or 
environmental factors. Alternatively, this variation may be a reflection of the high variability in 
running the NAD+ assay on different days, perhaps due to the use of different freshly prepared 
standards for each of the baseline dates. Hence, no conclusions can be drawn from this data, 




5.7 Measuring NAD+ in PBMCs, Erythrocytes, Whole Blood and Plasma Samples 
After testing all the versions of the cocktails, plans were put in place to begin a 30-person 
intervention study using a commercially viable cocktail based on the NCD formulations, named 
Time+. Although NAD+ levels in PBMCs was the focus of the work discussed thus far, whole blood is 
                          
Figure 5.6.1 Average NAD+ levels on 3 different baseline weeks for female participant. 
Baseline NAD+ levels were measured on 3 different days during 3 different weeks for the female participant, 
corresponding to the baselines for each of the three compound cocktails consumed. The average ng NAD+/ug 
protein for each baseline week is shown (n=2 August 2018, n=3 September 2018 and 2019), with error bars 
representing +/- SD. Significance was tested for using 1-way repeated measures ANOVA and a Tukey’s post hoc 
test. *p<0.01.  
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the most common sample type used in recent studies investigating potential NAD+ enhancers in 
human studies. Therefore, it was deemed necessary to measure NAD+ in whole blood in addition to 
PBMCs for the purpose of this intervention study.  Hence as preparation for the study, NAD+ was 
measured in PBMCs, erythrocytes, plasma and whole blood to determine the feasibility of measuring 
all 4 and also to understand how NAD+ levels vary across the different blood fractions. 2 blood 
samples were collected at the same time from 3 healthy individuals by venepuncture, with 500ul 
immediately frozen at -150ᵒC before the rest of the blood was separated into the individual fractions 
as done previously by density centrifugation and also stored at -150ᵒC.  
NAD+ levels were measured following the standard NAD+ cycling assay protocol, however 
quantification of protein concentration in the diluted whole blood and red blood cell fractions was 
problematic. Haemoglobin, the main constituent of red blood cells, absorbs strongly at 562nm which 
is the absorbance used for measuring protein concentration as part of the BCA assay. The lower 
sensitivity of measuring protein concentration at an absorbance of 280nm using a nanodrop proved 
an unreliable alternative due to the low protein concentration of the diluted PBMC, whole blood and 
erythrocyte samples used for the NAD+ assay, resulting in very high standard error. Additionally, 
haemoglobin has a very low molar extinction coefficient due to its lack of tryptophan residues, and 
as the major protein present in whole blood and red blood cell samples this affected the absorbance 
at 280nm when less dilute samples were used. Thus, it was realised that NAD+ levels in whole blood 
and erythrocytes should be expressed in units of molarity (uM) or as ng/ml, given normalisation to 
total protein couldn’t be performed accurately. 
Surprisingly, NAD+ was undetectable in all of the plasma samples (<5nM). Consequently, it appears 
that enzymatic cycling assays aren’t sensitive enough to measure plasma NAD+ and therefore this 
would need to be done by the higher sensitivity mass spectrometry-based techniques. The whole 
blood NAD+ measured was consistent across the participants, ranging from 18-26uM, whilst the 









5.8 NAD+ Degradation in Whole Blood and PBMCs Following Venepuncture 
NAD+ is known to be a highly labile molecule which rapidly degrades when stored in solution [493]. 
Thus, given the need to accurately quantify cellular NAD+, the effect of different incubation times on 
NAD+ titres in blood kept on wet ice (0ᵒC) was assessed. Approximately 30ml of blood was drawn 
into 3x 10ml vacutainers from one person and immediately placed on ice. At 5 minutes, 10 minutes, 
20 minutes, 30 minutes, 40 minutes, 50 minutes and 60 minutes post blood draw 0.4ml from one of 
the 10ml tubes was added to two cryovials and immediately frozen at -80ᵒC. The rest of the blood 
was then used to isolate PBMCs at 10 minutes, 40 minutes, 70 minutes and 110 minutes post draw 
(in duplicate). The time it took to complete the PBMC isolation process means that these PBMCs 
were frozen down on average 53 minutes, 87 minutes, 114 minutes and 157 minutes after the blood 
was drawn from the participant.         
 
Figure 5.7.1 NAD+ levels in different blood fractions. 
2 blood samples were collected at the same time from 3 individuals and separated into whole blood, PBMC 
and erythrocyte fractions by density centrifugation (n=2 technical replicates for each participant). NAD+ was 
then quantified using an NAD+ cycling assay. NAD+ levels were then normalised to protein levels via a BCA 
assay and expressed as ng NAD+/ug protein for the PBMCs, whereas they were expressed in units of molarity 
(uM) for whole blood and the erythrocytes. Error bars represent +/- SD. 
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The NAD+ levels were then measured to assess the effect of different incubation times at 0ᵒC (Figure 
5.8.1). For the whole blood, NAD+ levels only declined by 13% between 5 minutes and 60 minutes 
post blood draw, with none of the incubation times during this interval achieving a statistically 
significant difference compared to the 5-minute sample. For PBMCs, there was a 20% decrease in 
NAD+ measured for the cells frozen down 157 minutes post blood draw compared to those frozen 
down after 53 minutes. As for the whole blood, there was no statistically significant differences 
between the different incubation times. Furthermore, for both PBMCs and whole blood there was 
no inverse correlation between time on wet ice and NAD+ levels as one might expect given the labile 
nature of NAD+. The lines of best fit for PBMC and whole blood NAD+ levels against incubation time 




5.9 Ongoing Time+ Intervention Study   
 
5.9 Ongoing Time+ Intervention Study 
Following on from the work presented within this chapter, an intervention study using the Time+ 
cocktail was initiated and at present is still ongoing, with all sample collection completed and analysis 
in progress. The study design is a randomised, double-blinded, placebo-controlled crossover in which 
participants consume Time+ or placebo for 4 weeks, undergo a 4-week washout phase, then for 
another 4 weeks consume the treatment they didn’t consume during the first arm (Figure 5.9.1). 
Study visits were once a week during the two treatment phases (always the same day), with two 
separate visits to measure baseline NAD+ levels also taken the week prior to each treatment arm. To 
control for daily oscillations of NAD+, time of study visit was kept constant for each participant 
Figure 5.8.1 Degradation of NAD+ in PBMCs and whole blood stored on ice.  
(A) 2 blood samples from 1 individual were simultaneously collected by venepuncture and then incubated on 
ice for varying lengths of time (n=2 technical replicates for all timepoints). The time at which the subsequently 
isolated PBMCs were frozen down post isolation and their corresponding NAD+ levels is shown. NAD+ was 
measured by an NAD+ cycling assay and then normalised to protein levels quantified via a BCA assay. (B) Whole 
blood was incubated on ice post-venepuncture for the times indicated and NAD+ levels were measured by an 
NAD+ cycling assay, expressed here as molarity (uM). Data shown is the mean of two blood samples from 1 




throughout. Additionally, participants were also requested to keep their weekly diet and sleep 
patterns as constant as possible and to avoid any drinks or supplements containing niacin, 
nicotinamide or nicotinamide riboside. Consumption of the treatment (placebo or Time+) was every 
day, keeping the time of consumption the same for all study day visits as well as for the day prior to 
each visit.  
For the 28 participants that completed the study, the most commonly reported adverse side-effect 
was indigestion following capsule consumption (n=3), with impaired sleep (n=2) and excessive 
restlessness (n=1) also noted. Beneficial effects included improved sleep quality (n=4) and enhanced 
energy (n=3). Laboratory testing is currently underway to measure NAD+ levels for all the study visits 
so that placebo and Time+ NAD+ levels can be compared for each participant. Markers of NAD+ 
metabolism (Figure 5.9.2) are also being measured by LC-MS (liquid chromatography-mass 































Figure 5.9.1 Time+ intervention study design.  
A randomised, double-blinded, placebo-controlled crossover study testing Time+ for its ability to enhance 









Metabolite Producers Consumers 
NAD+ NMNAT1-3, NADSYN, NQO1, NADH 
dehydrogenase, NADP+ phosphatase. 
NADK, SIRT1-7, PARP1, CD38, CD157, 
tankyrase -1/2, Malate 
dehydrogenase, OGDC, IDH 
NADH SAM hydrolase, Malate 
dehydrogenase, OGDC, IDH 
NADH dehydrogenase, NQO1 
NAM SIRT1-7, PARP1, CD38, CD157, 
tankyrase -1/2, PNP 
NAMPT 
meNAM NMNT Aldehyde oxidase 
NMN NRK, NAMPT NMNAT, CD73 
NR CD73 NRK, PNP 
NADP+ NADK, HMG-CoA Reductase, 
Nocturnin, NQO1 
IDH, GLDH, NADP-ME, G6PDH, NADP+ 
Phosphatase 
NADPH IDH, GLDH, NADP-ME, G6PDH, 
NADP+ Phosphatase, 
NADPH Oxidase, HMG-CoA Reductase, 
Nocturnin, NQO1 
NAAD NMNAT1-3 NADSYN 
NAMN NAPRT, NRK, QPRT NMNAT1-3, 
cADPR/ADPR CD38 - 
NA - NAPRT, glycine N-acyltransferase 
NAR - NRK, QPRT 
2PY Aldehyde oxidase - 
NUA glycine N-acyltransferase - 
Table abbreviations: 
Enzymes:  
IDH - Isocitrate dehydrogenase, GLDH – glutamate dehydrogenase, NADP-ME – NADP malate dehydrogenase, 
G6PDH – glyceraldehyde-6-phosphate dehydrogenase, NADSYN - Glutamine-dependent NAD+ synthetase, NMNT 
– nicotinamide-N-methyltransferase, NMNAT1-3 – nicotinamide adenylyltransferase 1-3, PNP – purine nucleoside 
phosphorylase, NAPRT – nicotinate phosphoribosyltransferase, NAMPT – nicotinamide 
phosphoribosyltransferase,  NRK – nicotinamide riboside kinase, NADK – NAD+ kinase, OGDC - oxoglutarate 
dehydrogenase complex, QPRT - quinolinate phosphoribosyl transferase. 
Metabolites: 
 NUA – nicotinuric acid, NAR – nicotinic acid riboside, 2PY - N-methyl-2-pyridone-5-carboxamide, NA – nicotinic 
acid, cADPR – cyclic adenosine diphosphate ribose, NAMN – nicotinic acid mononucleotide, NAAD – nicotinic acid 
adenine dinucleotide, NADP – nicotinamide adenine dinucleotide phosphate, NAM – nicotinamide, meNAM – 
methylated nicotinamide. 
 




There is a growing interest in identifying effective interventions to enhance human NAD+ levels, 
driven by the widespread belief that declining NAD+ levels contribute to age-related physiological 
decline and increase the risk for age-associated morbidities. Currently, NR supplementation is the 
most commonly endorsed method to increase NAD+, with its efficacy supported by a number of 
clinical studies [310, 311, 405, 407]. Within this chapter it’s shown that NR does enhance PBMC NAD+ 
levels in a small cohort (n=5), however its effectiveness was highly variable day-to-day within the 
same week, something yet to be investigated in other studies. Therefore, it’s likely that a number of 
external factors may influence the efficacy of NR with variables such as sleep, diet, exercise and 
environmental temperature all possible contributors. To this end, it would’ve been much more 
revealing if other NAD+ related metabolites (Table 5.9.2) had also been measured, thus identifying 
whether the variation was due to increased breakdown of NAD+ or less efficient conversion of NR to 
NAD+. The average increase in NAD+ of 52% across the 5 participants was less than has been typically 
observed in previous human studies using NR (Table 5.3.1), however the dose here was 500mg/day 
opposed to the 1000mg/day used in most of the aforementioned studies. 
Indeed, variation across different days was also observed when measuring daily NAD+ fluctuations 
in the male and female participant PBMCs during their baseline weeks. Despite changes in the mean 
NAD+ measured on different baseline days, the profile of NAD+ during the 8am to 8pm timecourse 
was characterised by the presence of peaks and troughs that were generally consistent for both 
participants throughout the week. Importantly, this suggests that NAD+ levels in human PBMCs do 
indeed follow a circadian rhythm, something which has yet to be verified in the literature.  
Interestingly, there is one study which identified a circadian rhythm of NAD+ levels in whole blood 
[388], however the NAD+ displayed a pattern very different to what was shown here for the PBMCs, 
with the whole blood NAD+ steadily decreasing from 8am to 8pm. This difference may be due to the 
very unique NAD+ metabolism in erythrocytes (the most abundant cell type in blood) which lack 
mitochondria and nuclei. Consequently, unlike PBMCs, there is no expression of the circadian rhythm 
controlling genes which would suggest the circadian NAD+ pattern in erythrocytes is regulated by 
hormones or some other external biomolecules. It’s likely however for PBMCs that the circadian 
regulation of NAD+ is regulated by the interaction between both hormones (e.g. melatonin) and the 
expression of endogenous circadian genes such as BMAL1, CLOCK, PER1-2 etc., thus possibly 
explaining the very different diurnal pattern. 
From a therapeutic perspective, understanding the diurnal variation of an individual’s NAD+ levels 
would be useful to help identify the optimal time of day at which to consume NAD+ enhancing 
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supplements. Of course, it is possible that the circadian profile varies between the different blood 
cell types and possibly different tissue types too, hence the regimens may need to be optimised for 
specific physiological needs. Another important point raised by the diurnal variation in NAD+ is the 
need to keep the time of day at which samples are taken consistent for any clinical/intervention 
study. Hitherto, no studies in the literature mention whether time of day for participant study visits 
has been kept constant, however the data presented here suggests this should be an essential 
feature of any study testing NAD+ boosting interventions.  
To explore whether an approach combining NAD+ precursors with compounds targeting NAD+ 
metabolism could yield superior alternatives to NR, various ‘cocktails’ developed for this purpose by 
Nuchido Ltd. were tested. The first cocktail (NCD201) was tested on 2 participants, with NAD+ levels 
measured on multiple days over a 16-day period - another important aspect of this work given all 
previous studies have only measured NAD+ changes on one or two treatment days. Similar to NR, a 
large variation across the NAD+ measurements on the different days was observed, further 
supporting the belief that NAD+ levels are highly susceptible to multiple external factors. This further 
reinforces the need for clinical studies to measure the efficacy of any NAD+ enhancing interventions 
on multiple treatment days and to take robust approaches to limit the influence of environmental 
variables.  
For NCD201, the average increase in NAD+ levels across the 16-day period was 301% for the male 
and 147% for the female, both larger than the reported increases in NAD+ for 2-3 weeks of NR 
consumption [310, 408]. The most striking finding however was the massive increase in NAD+ on 
days 11 (841%) and 14 (640%) for the male. Surprisingly, for the male there was a significant increase 
in NAD+ on day 1 of treatment consumption but out of the 7 treatment days blood was taken the 
only other significant increases recorded were on days 11 and 14. This finding, along with the wide 
range in NAD+ values recorded across the different treatment days (ranging from an 8% increase to 
821% increase) emphasises the variable day to day efficacy of the cocktail.  
The variation in values across the treatment period was much smaller for the female however, 
ranging from an 89% increase to a 217% increase. Despite the lower treatment average compared 
to the male participant, the consistently high elevation of NAD+ yielded a statistically significant 
increase on all testing days for the female. This stark contrast to the large fluctuations in NAD+ across 
the treatment phase for the male highlights the possibility that the effects of the cocktail will vary 
widely between individuals, although this hypothesis would need to be tested within a much larger 
cohort. Likewise, for both participants the NAD+ levels reached a peak on day 11/14 before partially 
tapering off on day 16, hence it’s essential to determine whether this is an authentic trend that 
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continues beyond day 16 – something that is being tested for in the ongoing study. It is possible that 
some unknown feedback mechanisms may be present which sense the increase in NAD+ and 
consequently over time reduce the expression of enzymes in the NAD+ salvage/synthesis pathways, 
thus dampening the effectiveness of the cocktail. However, supplementation with NR has been 
shown to be effective after a 60 day treatment phase in a large human cohort [405], suggesting that 
increased NAD+ levels can be maintained long-term via dietary supplementation. 
Indeed, the increased NAD+ levels compared to the baseline that were measured for the male 5 days 
after finishing the NCD201 treatment regime hints that there may be a residual effect even once 
supplementation is ended. That said, after 9 days post-study completion the average increase in 
NAD+ across all the daily timepoints measured compared to the baseline had dropped to 16%, 
suggesting that by this time the effects of the cocktail on NAD+ levels had worn off. 
To test whether the components of the cocktail specifically targeting the NAD+ salvage pathway were 
indeed having the desired effect, the male participant consumed the cocktails NCD202.1 and 
NCD202.2, both of which had the same recipe as NCD201 but without the nicotinamide riboside 
precursor. Furthermore, NCD202.1 and NCD202.2 both had an NNMT inhibitor added, although the 
specific compound fulfilling this role varied between the two versions. NNMT methylates NAM, 
which signals for it to be excreted from the cell and eventually metabolised by the liver, thus by 
inhibiting NNMT this in theory would allow more NAM (a by-product of many NAD+-dependent 
reactions) to be recycled by shuttling it back into the salvage pathway, subsequently yielding more 
NAD+. 
Over the course of the 5-day treatment periods for NCD202.1 and NCD202.2, on average the NAD+ 
levels increased by 62% and 32% respectively, suggesting that the combination of compounds 
targeting NAD+ degradation/synthesis pathways is effective at increasing NAD+.  The smaller 
enhancement of NAD+ without the precursor was expected, given that the increased NAD+ synthesis 
resulting from enhanced NAMPT activity also depends on precursor availability. Implementing a 
precursor-free approach to boosting NAD+ using NCD202.1/NCD202.2 would therefore be highly 
dependent on the amount of nicotinamide/nicotinic acid/nicotinamide riboside ingested via the 
diet. 
In order to delve deeper into the mechanics of how NAD+-targeting therapeutics modulate NAD+ 
homeostasis a wider look into the NAD+ metabolome should be employed. This would be particularly 
pertinent for interventions such as the NCD cocktails which target multiple steps in NAD+ 
synthesis/degradation pathways, allowing verification of whether the compounds are working 
through their expected mechanisms. For example, if NAMPT activity - a key purported target of the 
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cocktail - is upregulated then this would increase levels of NMN, the product of NAMPT catalysis. 
Similarly, measuring the levels of the substrate of NAMPT, NAM, would also give an indication of 
NAMPT activity. This overcomes the key limitation in measuring protein expression of the 
supplement targets which doesn’t specifically inform of their enzymatic activity. By contrast, a wider 
metabolomics approach would tackle this problem, although some NAD+ related metabolites are the 
product of multiple enzymatic reactions (Table 5.9.2), hence proteomic data could potentially 
corroborate the metabolomics findings by identifying which enzymes are responsible for specific 
metabolite changes. Specifically combining the metabolomics with a targeted proteomics approach 
using LC-MS would also give a much more comprehensive picture of the protein changes induced by 
the cocktail. Given some of the compounds have numerous predicted targets and NAD+ changes can 
affect many pathways, it’s expected the cocktail would induce extensive changes to the proteome.  
Additionally, to better understand the variables that could contribute to changes in blood NAD+ 
regardless of supplementation, determining NAD+ levels within the different PBMC sub-populations 
is of great interest. A number of factors can alter the circulating levels of different lymphocyte 
subtypes (e.g. CD4+ T cells, CD8+ T cells, NK cells etc.) which could have an impact on the NAD+ levels 
measured in PBMC fractions, particularly if certain subtypes are associated with NAD+ levels 
significantly different to the PBMC average. A cell sorting approach could be employed to separate 
out PBMC fractions into their different populations and characterise their respective NAD+ and NAD+-
related metabolite profile. This would also shed light on whether infection and the subsequent 
increase in specific lymphocyte populations would be expected to alter the NAD+ titre within the 
PBMC blood fraction – another important consideration for intervention studies. 
Future work to supplement the findings reported here should also include characterisation of the 
relationship between age and blood NAD+ levels, which is especially relevant given the literature 
regarding this is still fairly thin. Although Massudi et al. found a significant inverse correlation 
between NAD+ levels and age, for such a wide age range the cohort was small (n=49) and the only 
tissue used was skin [70]. One approach to determine if a similar relationship exists in blood/PBMCs 
would be to measure the NAD+ levels for >100 individuals in the 0 - 80 age range. Although this 
should provide greater insight into the relationship between NAD+ levels and age, the optimal 
approach would be to measure the entire NAD+ metabolome in multiple tissues of young and old 
mice, identifying whether mammalian age-related NAD+ decline is systemic and if specific tissues are 
especially susceptible. Moreover, by measuring the entire NAD+ metabolome this could potentially 
identify the mechanisms driving age-related changes in NAD+. 
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The findings within this chapter also emphasise the requirement for a clear consensus on how to 
measure NAD+ levels from blood samples. Within this work all NAD+ measurements were made using 
an enzymatic cycling assay, which reduces the complexity and costs associated with measurements 
made via LC-MS. Most recent studies assessing NAD+ levels have opted for an LC-MS approach 
however, likely due to the higher sensitivity associated with this technique and the ability to measure 
multiple metabolites at once. Additionally, there is also large variation in blood processing methods 
across the literature, with different studies opting for whole blood, plasma or PBMCs. The rationale 
often cited for the use of whole blood is the ability to freeze it soon after collection, removing the 
need for centrifugation steps to separate the plasma and/or PBMCs. This is done on the basis that 
NAD+ is highly labile and hence would be expected to quickly degrade in collected samples – hence 
the desire for minimal sample processing. When kept on ice however, it’s shown here that the whole 
blood NAD+ levels only decline by 12% over the course of an hour without any statistically significant 
changes detected, suggesting NAD+ levels are much more stable in whole blood than previously 
thought. Similarly, increasing the length of time blood samples were incubated on ice for prior to 
PBMC isolation did reduce detectable NAD+ levels, but again there were no significant differences 
between different incubation times across a 110-minute interval.  
It is therefore likely that the assumption that cellular NAD+ levels rapidly decline ex vivo are based 
on the instability of NAD+ outside of the cell. Indeed, blood cells left incubated on ice are still 
completely viable and in a nutrient rich environment, hence NAD+ homeostasis would continue 
within the cell similar to the blood cells circulating within the sample donor, aside from the slowing 
down of reactions and temperature stress induced by the storage on ice. With regards to sample 
processing, it would therefore seem the extra 45-50 minutes it takes to isolate PBMCs from whole 
blood will minimally reduce the NAD+ levels provided samples are kept on ice/at <4ᵒC throughout.  
An important advantage of focusing on PBMCs identified in this work is the difficulty to accurately 
measure total protein concentration in whole blood (intracellular and extracellular). Consequently, 
this means NAD+ levels in whole blood have to be expressed in units of molarity or ng/ml rather than 
ng NAD+/ug protein. By not normalising to total protein levels, this means NAD+ levels measured will 
be susceptible to changes in blood cell number – particularly problematic for a study collecting 
samples on multiple different days. Many illnesses in addition to nutritional and hormonal changes 
can increases or decrease blood cell levels, thus altering the whole blood uM NAD+ by virtue of cell 
number rather than bona fide changes to NAD+ metabolism. 
Plasma NAD+ levels have been successfully measured elsewhere in the literature [494, 495], however 
they were undetectable by the cycling assay (<5nM) within this work. By contrast, Clement et al. 
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[494] reported plasma NAD+ levels in the 1-70nM range whilst another study detected them at <6nM 
concentrations [495], with both studies using an LC-MS approach. The inability to detect NAD+ 
therefore may not entirely be due to the detection limit of the cycling assay but possibly other 
processing variables. Measuring plasma NAD+ is of secondary importance however given the main 
biological role of NAD+ occurs intracellularly. It’s not clear if it serves a specific physiological function 
or where the plasma pool of NAD+ is derived from, but its release from cells following lysis is a 
possible explanation. 
Although measuring plasma NAD+ may be of limited utility, the circulating levels of secreted NAD+ 
breakdown products such as meNAM and 2PY would provide useful information on intracellular 
NAD+ metabolism. Hence, when investigating the NAD+ metabolome a focus on the changes in 
PBMCs and whole blood combined with plasma levels of meNAM and 2PY would appear the best 
approach. 
In conclusion, it appears that a multi-targeted approach using dietary supplements in combination 
with precursors allows a greater enhancement of NAD+ titres than NR. The analysis of NAD+ targeting 
interventions however is complicated by the endogenous diurnal variations in PBMC NAD+ as well 
as apparent day to day variability, important considerations for future NAD+ intervention studies 
moving forward. Further work is required to verify the biological effects elicited by multi-targeting 

















Chapter 6. The Role of NAD+ and SIRT1 in Skin Fibrosis 
6.1 Introduction 
Although enhancing NAD+ would seem desirable in the context of an anti-ageing approach, there are 
other ailments in which it may have a negative effect. This is highlighted by a number of studies 
which have outlined a pro-tumorigenic effect of increasing NAD+ (reviewed in [496, 497]). On one 
hand NAD+ is essential for PARP1 activity and thus fulfils an anti-cancer role by maintaining genomic 
stability via PARP1, however NAD+ is also an essential substrate for glycolysis and hence may 
facilitate the Warburg effect – the process by which cancer cells shift their energy metabolism 
towards glycolysis. Hence, it is possible that interventions that replenish NAD+ in cancer cells simply 
fuel glycolysis, which would subsequently increase NADH levels rather than NAD+. 
It is therefore paramount to consider the possible adverse effects altering NAD+ levels could have in 
diseases, particularly those defined by metabolic changes. One such disease is systemic sclerosis 
(SSc), a rare autoimmune disorder characterised by skin fibrosis (aka scleroderma) and often the 
gradual spread of fibrosis to other organs, eventually resulting in mortality. Although management 
of the symptoms has extended lifespan, patients still suffer from a poor quality of life with a curative 
treatment yet to be discovered. The potential role played by NAD+ within SSc is unclear: both a pro 
and anti-fibrotic effect has been identified for SIRT1 [498-501], whilst another NAD+-dependent 
enzyme, PARP1, has been implicated as anti-fibrotic [502]. 
Hence, it was sought to determine whether NAD+ levels are relevant to the activation or inhibition 
of fibrotic pathways within an in vitro model of skin fibrosis. Similarly, the role of SIRT1 within these 
pathways was also investigated, allowing the contribution of the NAD+/SIRT1 axis in fibrosis to be 
dissected.  
As already mentioned, upregulated glycolysis is a key feature of cancer cells. Although the reason 
for cancer cells undergoing this metabolic re-modelling is controversial, one common theory is that 
glycolysis increases the production of biosynthetic intermediates which can then be used to support 
protein synthesis and cell proliferation. Interestingly, the requirement of enhanced protein synthesis 
and production of the same biosynthetic intermediates is a hallmark of fibrosis – which requires 
these intermediates as building blocks for increased ECM production. Indeed, an altered metabolic 
profile has already been observed in sera from SSc patients [503] and idiopathic pulmonary fibrosis 
(IPF) lung samples [504], hence it was theorised metabolic changes may be a key event in the 
development of skin fibrosis and thus would be detectable in pro-fibrotic dermal fibroblasts. 
Therefore, it was also of importance to identify any changes in the levels of glycolysis and OXPHOS 
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(regulators of the NAD+/NADH redox balance) in pro-fibrotic fibroblasts to fully understand the role 
played by the NAD+ axis within scleroderma. 
TGF-β is a renowned activator of fibrotic genes and has been heavily implicated in the pathogenesis 
of SSc [505], making it a useful tool to model skin fibrosis in vitro. Thus, TGF-β treated NHDFs in 
addition to fibroblasts derived from SSc patient skin lesions were used within this chapter to 
investigate the role of NAD+, SIRT1 and metabolic changes in skin fibrosis.  
6.2 Aims 
Understanding whether changes in NAD+ levels can modulate fibrotic pathways, namely TGF-β 
signalling, was the key aim of this chapter. Additionally, identifying any changes to the activity of 
different energy metabolism pathways in TGF-β induced NHDFs was also of central importance to 
aid the understanding of the potential role played by NAD+ in skin fibrosis. 
6.3 Hypotheses 
It was hypothesised that changes in energy metabolism would be observed in TGF-β induced NHDFs 
and SSc dermal lesion fibroblasts, likely to be an increase in glycolysis as seen in other autoimmune 
diseases. Thus, interventions that enhance NAD+ would attenuate fibrotic markers under such 













6.4 TGF-β Upregulates Aerobic Glycolysis in NHDFs 
To determine whether the pro-fibrotic activator TGF-β induced any metabolic changes in NHDFs, 
glycolysis and OXPHOS was measured using the Seahorse XFp Analyser for NHDFs treated for 48 
hours with or without 10ng/ml TGF-β. By measuring subtle changes to the pH of the media in the 
assay plates the ECAR (extracellular acidification rate) is recorded, which changes in response to the 
protons released during glycolysis. As a result, glycolysis and specific features of glycolytic function 
can be analysed following the sequential addition of various chemicals to the assay plate wells. In 
total, 4 ECAR measurements are made: before glucose is added to the media, after 10mM glucose 
is added, after 1uM oligomycin is added and finally after 50mM 2-DG (2-deoxyglucose) is added. The 
ECAR recorded after adding glucose indicates basal glycolysis, whereas ECAR following oligomycin 
quantifies maximal glycolysis i.e. glycolytic capacity (due to oligomycin preventing any ATP 
production via OXPHOS and thus making the cells glycolysis dependent). The difference between the 
glycolytic capacity and basal glycolysis can then be calculated to deduce the glycolytic reserve. 
In addition to ECAR, the oxygen consumption rate (OCR) is quantified by measuring changes in the 
oxygen concentration within the assay plate media – thus giving a readout of oxygen consumption 
by the mitochondrial electron transport chain (ETC). The consumption of oxygen to yield H2O 
constitutes the final step in the ETC, therefore the OCR reflects the rate of OXPHOS. 
Whilst there was no change in OXPHOS (Figure 6.4.1 B), basal glycolysis (1.26-fold, p<0.05), glycolytic 
capacity (1.34-fold, p<0.05) and glycolytic reserve (1.26-fold, p<0.05) were all significantly increased 
in the TGF-β treated cells (Figure 6.4.1 A). The lack of any change in OXPHOS suggests that the cells 
are still dependent on OXPHOS for ATP production following the induction of fibrosis, however the 
increase in all glycolytic parameters suggests these may be required for additional energy demands 
or possibly other byproducts of glycolysis. 
Although there was upregulation of glycolysis following TGF-β stimulation, given TGF-β is a multi-
functional cytokine it was sought to identify whether enhanced glycolysis was relevant to the pro-
fibrotic phenotype or merely an unrelated downstream target of TGF-β signalling. To do this, NHDFs 
were treated with the prototypical glycolysis inhibitor 2-DG which inhibits the first step in the 
glycolytic chain. Highlighting the importance of glycolysis for the development of fibrosis, 2-DG was 
able to potently downregulate expression of the fibrotic marker collagen I in NHDFs co-treated with 
10mM 2-DG and 10ng/ml TGF-β for 48 hours (Figure 6.4.1 C-D).  
Densitometry analysis of western blots (n=3) for NHDFs treated with TGF-β and 2-DG reinforces the 
importance of glycolytic function for collagen synthesis, whereby the staining density of collagen I 
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relative to α-tubulin for each sample was expressed as a percentage of the untreated NHDF (control) 
average. TGF-β treatment increased collagen staining density by 88% compared to the control, 
whereas TGF-β and 2-DG reduced collagen staining density by 17%, with a statistically significant 
difference between the TGF-β and TGF-β with 2-DG conditions determined by an unpaired Student’s 
t-test (p<0.01) (Figure 6.4.1 E) Treatment with just 2-DG reduced the collagen staining density by 
51% compared to the control, thus 2-DG doesn’t specifically inhibit TGF-β signalling, but rather 
collagen synthesis in general. 
Within a therapeutic context however, complete inhibition of glycolysis would eventually have 
adverse consequences given its vital role in energy metabolism, hence an approach that 
downregulates rather than completely blocks glycolysis would be preferable. This was done using 
the glycolytic flux inhibitor 3PO (3-[3-pyridinyl]-1-[4-pyridinyl]-2-propen-1-one) which inhibits the 
cellular capacity to quickly upregulate glycolysis rather than directly inhibiting glycolysis per se [506]. 
Indeed, treatment with 3PO results in partial reduction of glycolysis without impairing cell viability 
at appropriate doses (Figure 6.4.3 C).  
Importantly, 8uM 3PO was also able to partially attenuate the TGF-β driven increase of collagen I 
levels in NHDFs (Figure 6.4.1 D), the quintessential marker for fibrotic activity. Densitometry analysis 
of the blots found that the addition of 3PO reduced the collagen staining density in TGF-β treated 
NHDFs, however this difference failed to achieve statistical significance (Figure 6.4.1 F). Compared 
Consequently, these results suggest 3PO may represent a feasible alternative to 2-DG as a 











Figure 6.4.1 Glycolysis is an essential component of TGF-β induction of fibrotic proteins in NHDFs. 
The glycolytic parameters of NHDFs treated with or without 10ng/ml TGF-β for 48 hours were quantified on a 
Seahorse XFp Analyser by performing a glycolysis stress test and measuring the ECAR (n=3 all conditions, 4 
separate biological experiments). Afterwards a BCA assay was performed and ECAR values were then normalised 
to protein levels. The data is presented as the % ECAR/ug protein of the untreated NHDFs. (B) Basal OXPHOS 
was also assessed in NHDFs treated for 48 hours with or without 10ng/ml TGF-β by measuring OCR. Once again, 
a BCA assay was performed and OCR values normalised to protein levels. The data is presented as the % OCR/ug 
protein of the untreated NHDFs (n=3 all conditions, 4 separate biological experiments). (C) NHDFs were also 
treated with or without 10ng/ml TGF-β and/or the hexokinase II inhibitor 2-DG (10mM) for 48 hours, after which 
the proteins indicated were measured by western blotting. (D) Likewise, western blotting was used to observe 
specific protein changes in NHDFs treated for 48 hours with or without 10ng/ml TGF-β and the glycolytic flux 
inhibitor 3PO (8uM) or 0.02% DMSO. The blots in panels C and D are representative of 3 separate biological 
experiments. (E-F) Densitometry analysis was then performed on the blots in panels C and D (n=3) and the 
collagen I levels relative to α-tubulin expressed as a percentage of the untreated control.  Statistical analysis 
was performed using 1-way ANOVA followed by a Dunnett’s post hoc test whereby the TGF-β group was used 
as the control. A Student’s t-test was used to test for significance in panel B and for each glycolytic parameter 
in panel A. Error bars represent +/-SD. Statistical significance between the treated and untreated NHDFs was 







The final step in glycolysis yields two molecules of pyruvate which then undergo one of two fates: 
fermentation into lactate (anaerobic glycolysis) or oxidative decarboxylation to produce acetyl CoA 
(aerobic glycolysis). The excessive production of lactate is synonymous with cancer cells [507], hence 
it was next investigated whether TGF-β induced glycolysis is predominantly anaerobic as in cancer 
or if it is occurring aerobically. 
Given TGF-β increased glycolysis but had no impact on OXPHOS this would suggest that the glycolysis 
was occurring anaerobically, however the lactate levels secreted into the media by 10ng/ml TGF-β 
treated NHDFs failed to show any significant difference compared to untreated NHDFs over a 96-
hour timecourse (Figure 6.4.2). One potential explanation is that whilst glycolysis is upregulated by 
TGF-β, the enhancement isn’t as profound as seen in cancer, hence the failure to detect a significant 
increase in lactate secretion.  Alternatively, it’s possible that the pyruvate yielded in the final step of 
glycolysis is shuttled back into the TCA cycle however the cycle terminates early, hence the absence 








Figure 6.4.2 Lactate levels following TGF-β stimulation.  
NHDFs were serum starved overnight and then treated with or without 10ng/ml TGF-β for 24, 48, 72 or 96 
hours. The media was then removed at each of these timepoints and the lactate concentration (mM) within 
the media measured using an enzymatic assay kit (Sciencecell, Carlsbad, USA). Data is shown as the mean 
lactate concentration of two separate biological experiments, error bars represent +/-SD. Significance was 










6.5 Blocking NAMPT Prevents the Fibrotic Phenotype  
Given the conversion of NAD+ to NADH is a key step in glycolysis, NAD+ is a limiting factor for 
glycolytic activity. As would be expected following increased glycolysis without any change in 
OXPHOS, NAD+ levels in NHDFs are depleted following TGF-β stimulation (3.2-fold, p<0.01, Figure 
6.5.1 A). Because of this dependency on NAD+ availability, diminishing the cellular NAD+ reserve by 
inhibiting NAMPT (the rate limiting enzyme in NAD+ production via the NAD+ salvage pathway) with 
the inhibitor FK866 causes a significant decrease in glycolysis (3.7-fold, p<0.01), glycolytic capacity 
(2.74-fold, p<0.001) and glycolytic reserve (455-fold, p<0.0001) (Figure 6.5.1 B). FK866 was added at 
a concentration of 10nM for 48 hours, conditions that were previously determined to deplete NAD+ 
5-fold without any loss of viability (Chapter 3, Figure 3.9.3). Additionally, FK866 also reduced collagen 
Figure 6.4.3 NHDF Viability in response to varying concentrations of 2-DG, G968 and 3PO.  
NHDF viability assays were performed for the compounds indicated after 24, 48 and 72-hour incubations. At 
the end of the incubation period the culture media was replaced with media containing 0.02% alamar blue 
and the fluorescence for each well was measured 4 hours later using a fluorometric plate reader. 
Concentrations of (A) 0, 1, 2, 5, 10, 20 and 50mM were used for 2-DG, (B) 0, 1, 2, 5, 10, 25 and 50uM for G968 
and (C) 0, 1, 2, 4, 8, 16, 25 and 50uM for 3PO. Viability is expressed as the % fluorescence of the untreated 
control for each timepoint, displayed here as the mean of two separate biological experiments, where error 
bars represent +/- SD. (D) The CC50 values (bold) and corresponding 95% CIs generated from the data in A-C 
is shown for each compound. Nonlinear regression analysis using a least squares fitting method within 





I production in TGF-β treated NHDFs as shown by western blotting and densitometry analysis (Figure 
6.5.1 C-D). Consequently, this implies that available NAD+ is a requirement for TGF-β induced 








Figure 6.5.1 NAD+ levels are key for glycolysis and fibrotic protein levels in TGF-β treated NHDFs. 
(A) NAD+ levels were measured using an NAD+ cycling assay for NHDFs treated with or without 10ng/ml TGF-
β for 48 hours (n=1 all conditions, 3 separate biological experiments). NAD+ values was then normalised to 
protein levels following a BCA assay. Statistical significance was tested for using an unpaired Student’s t-test. 
(B) The glycolytic parameters of NHDFs treated with or without 10ng/ml TGF-β and 10nM FK866 or 0.05% 
DMSO were measured on a Seahorse XFp Analyser by performing a glycolysis stress test (n=2 separate 
biological experiments). Statistical analysis was performed using 1-way ANOVA and significant differences 
between the treatments for each glycolytic parameter tested for using a Bonferroni post hoc test. (C) Protein 
levels of collagen I (Col I) and α-tubulin were measured by western blotting for NHDFs treated with or without 
10ng/ml TGF-β and 10nM FK866 or 0.05% DMSO. The blot shown is representative of 3 separate biological 
experiments. (D) Densitometry analysis was then performed on the blots (n=3) and the collagen I levels relative 
to α-tubulin is expressed as a percentage of the untreated control. Statistical analysis was performed using 1-
way ANOVA followed by a Dunnet’s post hoc test whereby the TGF group was used as the control. Error bars 





6.6 Resveratrol Reduces TGF-β Upregulation of Collagen I 
Given the accumulating evidence that SIRT1 may fulfil an anti-fibrotic role, NHDFs were treated with 
the prototypical SIRT1 activator resveratrol (RSV) to determine whether this could reverse TGF-β 
driven effects. Co-incubating 10ng/ml TGF-β treated NHDFs with 100uM RSV for 48 hours potently 
reversed the TGF-β induced increases in collagen I and α-SMA (Figure 6.6.1 B-C). Having already 
identified TGF-β driven upregulation of glycolysis, it was next investigated whether RSV could 
reverse this aspect of TGF-β signalling. Unlike for the fibrotic markers, 48 hours of 100uM RSV 
treatment was unable to induce any significant change to the glycolytic parameters (Figure 6.6.1 A), 







Figure 6.6.1 RSV reverses TGF-β upregulation of fibrotic markers but not glycolytic parameters. 
NHDFs were treated for 48 hours with 10ng/ml TGF-β, 100uM RSV, 10ng/ml TGF-β and 100uM RSV or 0.1% 
DMSO (n=1 all conditions, 3 separate biological experiments). (A) Glycolytic parameters were assessed by 
performing a glycolysis stress test on the Seahorse XFp Analyser during which ECAR was measured. 
Afterwards, protein levels were measured by a BCA assay to allow normalisation of ECAR to protein. The 
data is shown as mean % ECAR/ug protein of the DMSO treated NHDF controls. (B) Additionally, the 
expression of the fibrotic markers collagen I (Col I) and α-SMA were measured by western blotting, with the 
loading control α-tubulin also probed to verify equal loading of protein lysates. The blot shown is 
representative of 3 separate biological experiments. (C) Densitometry analysis was then performed on the 
blots (n=3) and the collagen I and α-SMA levels relative to α-tubulin is expressed as a percentage of the 
untreated control.  Error bars represent +/- SD. The statistical analysis for panel A was performed using 1-
way ANOVA for each glycolytic parameter and significant differences between the treatments tested using 
a Bonferroni post hoc test. For panel C statistical significance was tested for using an unpaired Student’s t-




6.7 NTC Suppress TGF-β Induction of Glycolysis but not Fibrotic Markers 
NTC (Nuchido Time+ Cocktail) is a combination of naturally occurring compounds chosen for their 
ability to enhance NAD+ levels by targeting pathways that regulate NAD+ metabolism. The 
compounds were tested individually for any efficacy at reducing TGF-β induced collagen I synthesis 
by western blotting, however none showed any noticeable effect. Although the requirement of NAD+ 
for glycolysis had been shown to be important for TGF-β driven effects, the anti-fibrotic role of SIRT1 
suggests that increasing NAD+ may not necessarily promote fibrosis if it fuels enhanced SIRT1 
activity. Hence, to probe this TGF-β stimulated NHDFs were also co-treated with NTC for 48 hours to 
determine whether increasing NAD+ via NTC inhibits/promotes fibrotic marker levels. 
Surprisingly, NTC potently abrogated TGF-β upregulation of all glycolytic parameters (Figure 6.7.1 
A). Despite this however, NTC was unable to reverse the enhanced levels of fibrotic markers (Figure 
6.7.1 B). Whilst it was previously shown that inhibition of glycolysis prevented TGF-β induction of 
fibrotic markers (Figure 6.4.1 C), it appears that returning it to basal levels fails to have the same 
effect. This suggests that whilst TGF-β driven fibrosis is dependent on a fully functional glycolytic 
pathway, increasing its activity isn’t necessary for the pro-fibrotic phenotype. Additionally, the data 
also suggests that targeting NAD+ levels vis NTC isn’t sufficient to inhibit TGF-β upregulation of 





















Figure 6.7.1 NTC attenuates TGF-β upregulation of glycolysis but not fibrotic marker levels. 
NHDFs were treated for 48 hours with 10ng/ml TGF-β, NTC, 10ng/ml TGF-β and NTC or 0.26% DMSO (n=1 all 
conditions, 3 separate biological experiments). After 24 hours the media was replaced with fresh media also 
containing TGF-β, NTC and DMSO as before. (A) Glycolytic parameters were assessed by performing a glycolysis 
stress test on the Seahorse XFp Analyser during which ECAR was measured. Afterwards, protein levels were 
measured by a BCA assay to allow normalisation of ECAR to protein. The data is shown as mean % ECAR/ug 
protein of the DMSO treated NHDF controls. (B) Additionally, the expression of the fibrotic markers collagen I 
(Col I) and α-SMA were measured by western blotting, with the loading control α-tubulin used to verify equal 
loading of protein lysates. The blot shown is representative of 3 separate biological experiments. (C) 
Densitometry analysis was performed on these blots (n=3), whereby collagen I and α-SMA levels relative to α-
tubulin is expressed as a percentage of the untreated control. Error bars represent +/- SD. For panel A statistical 
analysis was performed using 1-way ANOVA for each glycolytic parameter and significant differences between 
the treatments tested using a Bonferroni post hoc test. For panel C 1-way ANOVA was used for collagen I and α-
SMA relative density separately, with a Dunnett’s post hoc test to determine significant differences against the 






6.8 Glutaminolysis Is Essential For TGF-β Induced Fibrosis Independent of mTOR 
Rapamycin, a compound which inhibits mTOR (mechanistic target of rapamycin), downregulates 
protein synthesis and other biosynthetic pathways which has stimulated interest around its potential 
as a novel anti-cancer agent [508-510]. mTOR primarily functions as a nutrient and energy sensor, 
whereby it upregulates cell growth and proliferation under conditions of adequate nutrient and 
energy availability. Hence, if biosynthetic intermediates from glycolysis or the TCA cycle are key for 
fibrosis, inhibition of mTOR should have an anti-fibrotic effect. To test this, NHDFs were stimulated 
with 10ng/ml TGF-β for 48 hours as done in previous experiments, along with the addition of 500nM 
rapamycin. Because rapamycin has been noted for its anti-glycolytic effects in other cell types [511], 
its effect on glycolysis in TGF-β treated NHDFs was first investigated by performing a glycolysis stress 
test. Treatment with rapamycin caused a small reduction in the levels of basal glycolysis, glycolytic 
capacity and glycolytic reserve in the TGF-β treated cells however these differences were statistically 
insignificant (Figure 6.8.1 A). 
Under the same conditions, levels of the fibrotic markers collagen I and α-SMA were probed in TGF-
β and rapamycin treated NHDFs by western blotting (Figure 6.8.1 C and F). The rapamycin failed to 
attenuate TGF-β enhancement of these markers, suggesting inhibition of mTOR fails to suppress 
induction of the pro-fibrotic phenotype in NHDFs.  
To further test the theory that fibrotic cells modified their metabolic pathways to generate 
biosynthetic intermediates for ECM synthesis, the role of glutaminolysis was next investigated. The 
process of glutaminolysis involves two sequential steps whereby glutamine is first converted to 
glutamate, which is then converted to α-ketoglutarate. Subsequently, α-ketoglutarate can then feed 
into the TCA cycle, thus fuelling NADH production. Alternatively, α-ketoglutarate can also act as a 
cofactor for prolyl-4-hydroxylase, facilitating the hydroxylation of proline to yield hydroxyproline – 
the main constituent of collagen (Figure 6.10). Therefore, if an increase in the TCA cycle fuels ECM 
secretion following the upstream enhancement of glycolysis in the presence of TGF-β by yielding α-
ketoglutarate, it is possible that glutaminolysis is also enhanced for the same purpose.  
To determine whether glutamine is a key fuel source for enhanced collagen synthesis in pro-fibrotic 
fibroblasts, glutamine was added at different concentrations ranging from 0-8mM to NHDFs that 
were stimulated with or without 10ng/ml TGF-β. In addition to being serum starved prior to 
incubation with TGF-β, media without glutamine was used for 24 hours before adding the TGF-β and 
the varying concentrations of glutamine. 48 hours after treatment with glutamine and TGF-β the 




Within the TGF-β treated cells there was no pattern of increasing collagen I levels with increasing 
glutamine concentration, (Figure 6.8.1 D and G) however for the NHDFs without TGF-β, collagen I 
production was impaired at the 0 and 1mM glutamine concentrations. Densitometry analysis of the 
blots was performed (Figure 6.8.1 F and G), with 2-way ANOVA finding that altering the glutamine 
concentration wasn’t a significant source of variation in the relative density of collagen or α-SMA 
staining. Furthermore, 1-way ANOVA within both the TGF treated and untreated groups found no 
significant differences in collagen or α-SMA staining density. The 2-way ANOVA did find that TGF-β 
had a significant effect on collagen and α-SMA staining density (collagen p<0.01, α-SMA p<0.001), 
however multiple comparisons found no significant differences between the TGF-β and untreated 
groups for all glutamine concentrations, thus it is likely there was an issue with the TGF-β stock for 
this set of experiments. 
Additionally, on review of the experimental setup, it is possible that the intracellular supply of 
glutamine/glutamate wasn’t adequately depleted during the withdrawal of glutamine and thus 
limited the effect of altering glutamine concentration in the culture media. To address this, an 
inhibitor of glutaminase (which catalyses the first step in glutaminolysis) known as G968 
(glutaminase inhibitor 968) was used. After characterising the relationship between G968 
concentration and NHDF viability (Figure 6.4.3 B), 10uM was selected as an appropriate sub-
cytotoxic dose for G968 and was added to NHDFs alongside 10ng/ml TGF-β for 48 hours before 
collagen I and α-tubulin were measured by western blotting (Figure 6.8.1 B). In contrast to glutamine 
withdrawal from the media, G968 appeared to lower collagen I levels in the TGF-β treated NHDFs, 
suggesting that glutaminolysis could be a key metabolic pathway in the development of a fibrotic 
phenotype in vitro.  
Densitometry analysis of the blots found that TGF-β increased collagen staining density by 47% 
compared to the untreated control, whereas co-treatment with TGF-β and G968 reduced collagen 
staining density 1.5% compared to the untreated control (Figure 6.8.1 E). 1-way ANOVA comparing 
the TGF-β, TGF-β with G968 and G968 only found a statistically significant difference between the 















6.9 Glutaminase But Not Collagen Is Enhanced in SSc Patient Fibroblasts 
Although increased TGF-β signalling is a key driver of pathogenesis in fibrotic lesions of SSc patients, 
cultured fibroblasts derived from lesional tissue exhibit enhanced ECM production even without the 
presence of TGF-β in the culture media [512], suggesting endogenous mechanisms also contribute 
to fibrosis with epigenetic factors thought to be key. Hence, it was investigated whether glycolysis 
and glutaminolysis are altered in dermal fibroblasts derived from SSc patient skin lesions. The SSc 
fibroblasts were obtained from 4 different patients, whilst NHDFs were obtained from 3 age-
matched controls and all experiments were performed with cells at passage ≤6. Due to the limited 
number of wells on a seahorse XFp miniplate, only 6 different samples can be assayed at once, hence 
it was decided to assay two sets of the control fibroblasts against the 4 different SSc fibroblasts. 
Initially, the 3 sets of control fibroblasts were assayed to determine which two should be chosen to 
assay alongside the SSc fibroblasts. Control 1 and 2 were selected given they had the highest and 
lowest ECAR/ug protein values for the glycolytic parameters, with a mean relatively close to the 
mean of control 3 (12% higher).  
There was a high variability in the SSc cohort ECAR/ug protein values, which are expressed as a % of 
the control NHDFs’ mean (Figure 6.9.1 A). For glycolysis, the % ECAR ug protein of the control for the 
SSc fibroblasts was: SSc 1 – 93%, SSc 2 – 80%, SSc 3 – 58% and SSc 4 – 151%. For glycolytic capacity 
the values were: SSc 1 – 93%, SSc 2 – 67%, SSc 3 – 41%, SSc 4 – 116% and for glycolytic reserve: SSc 
1 – 114%, SSc 2 -  138%, SSc 3 – 163%, SSc 4 – 125%. Despite the variable values, there was no 
significant difference between any of the patient fibroblasts and the control mean. 
Figure 6.8.1 Glutaminase activity may contribute to TGF-β driven effects.  
(A) The glycolytic parameters of NHDFs treated for 48 hours with 10ng/ml TGF-β, 500nM rapamycin (Rapa), 
10ng/ml TGF-β and 500nM Rapa or 0.01% DMSO were measured on a Seahorse XFp Analyser by performing a 
glycolysis stress during which ECAR was measured (n=1 for all conditions, three separate biological 
experiments). The ECAR was then normalised to total protein and the ECAR/ug protein was subsequently 
expressed as a % of the untreated control. (B) Collagen I (Col I) and α-tubulin expression was assessed by 
western blotting for NHDFs treated with or without 10ng/ml TGF-β and the glutaminase inhibitor G968 (10uM) 
or 0.2% DMSO for 48 hours. (C) Expression of collagen I, α-SMA and α-tubulin were measured by western 
blotting for NHDFs treated 48 hours with 10ng/ml TGF-β, 500nM rapamycin (Rapa), 10ng/ml TGF-β and 500nM 
Rapa or 0.01% DMSO. (D) NHDFs were treated with or without 10ng/ml TGF-β and various concentrations of 
L-glutamine. Expression of collagen I, α-SMA and α-tubulin was again quantified by western blotting. (E-G) 
Densitometry analysis was performed for the western blots (n=3 separate biological experiments) from the 
experiments in panels B-D, whereby collagen I and α-SMA (F only) levels relative to α-tubulin is expressed as a 
percentage of the untreated control. Error bars represent +/- SD. For panel A the statistical analysis was 
performed using 1-way ANOVA for each glycolytic parameter and significant differences between the 
treatments tested using a Bonferroni post hoc test. For E-G 1-way ANOVA was used to analyse collagen I and 
α-SMA relative density separately, with a Dunnett’s post hoc test to determine significant differences against 
the TGF-β treated group. *p<0.05.    
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To test for differences in the activity of glutaminolysis, levels of the enzyme glutaminase were 
analysed by western blotting performed on protein lysates from the 3 control and 4 patient 
fibroblasts (Figure 6.9.1 C). Glutaminase exists as 2 different isoforms, KGA (kidney-type 
glutaminase) and GAC (glutaminase C), thus produces two separate bands following immunoblotting 
at 65 kDa and 58 kDa respectively. Interestingly, KGA was elevated in all 4 patients compared to 
controls, with the GAC variant also elevated in patients 1 and 4, with this marker the only one 
showing a significant difference between the NHDF and SSc cohort (unpaired Student’s t-test, 
p=0.031) - suggesting upregulated KGA may be a novel characteristic feature of SSc.  
It should be noted that all protein makers measured were elevated (albeit only KGA significantly), 
which was surprising in the instance of SIRT1, which has been found to be antifibrotic in a number 
of studies. It was also surprising to find when comparing the collagen I levels of the controls and 
patients, that only patients 1 and 4 showed a noticeable increase compared to controls 2 and 3, 
hence the signature enhanced collagen production associated with SSc is absent in vitro – possibly 
due to the lack of circulating stimuli such as TGF-β and other in vivo mechanisms. The lack of 
increased collagen I levels does however question whether these SSc patient fibroblasts can be truly 

















Figure 6.9.1 Glycolysis and glutaminase expression in SSc patient derived dermal fibroblasts.  
Glycolytic parameters for NHDFs from healthy controls (n=2) and SSc patients (n=4) were assessed by measuring 
ECAR using a glycolysis stress test and then normalised to protein levels by performing a BCA assay. The 
ECAR/ug protein was then expressed as a % of the healthy control mean, presented here as the average of two 
separate biological experiments. (A) The data for both individual donor samples and (B) the SSc and control 
averages is shown. (C) Expression of glutaminase (KGA/GAC), hexokinase II (Hxk II), collagen I (Col I) and the 
loading control α-tubulin in SSc and the control NHDFs was analysed by western blotting. The blot shown is 
representative of 3 separate biological experiments. (D) Densitometry analysis was performed for these 
western blots (n=3), whereby the levels of all protein markers relative to α-tubulin is expressed as a percentage 
of the NHDF average. The data is shown as the combined average for the healthy controls (n=3) and SSc samples 
(n=4). The panel A statistical analysis was performed using 1-way ANOVA. For panel B significance was tested 
for each of the glycolytic parameters separately using an unpaired Student’s t-test. Similarly, an unpaired 
Student’s t-test was used to compare the relative density of the SSc average to the NHDF average separately 





Metabolic re-programming is a well-established event in the development of tumourgenicity, 
however evidence is starting to accumulate that it is present in numerous other pathologies 
including fibrotic [513-515] and autoimmune diseases [516-518]. 
 Eukaryotic energy metabolism consists of 3 core pathways: glycolysis, the TCA cycle and OXPHOS, 
with all 3 connecting to each other in that order (Figure 1.1.6.1) Glycolysis begins with one molecule 
of glucose which is metabolised to give a net yield of 2 ATP, 4 NADH and 2 pyruvate molecules. The 
pyruvate can then either be reduced to lactate or enter the TCA cycle after being converted to acetyl 
CoA, which will lead to a net gain of 1 ATP, 3 NADH and 1 FADH2 per pyruvate molecule. 
Subsequently, the NADH and FADH2 generated by glycolysis and the TCA cycle can fuel OXPHOS by 
donating their electrons, stimulating further ATP production via complex V. However, various steps 
such as the fermentation of pyruvate or the shuttling of TCA cycle intermediates into other pathways 
means that glycolysis and OXPHOS can become uncoupled – e.g. glycolysis levels can increase, 
accompanied by no change or even a decrease in OXPHOS.  
Here it is shown that the pro-fibrotic stimulus TGF-β increases glycolysis in NHDFs, with no change 
in the levels of OXPHOS. This would suggest that the upregulation of glycolysis is culminating in 
increased lactate production, however the lactate levels in the media of TGF-β treated cells also 
showed no change compared to untreated NHDFs. It is therefore possible that TGF-β is increasing 
glycolysis which in turn increases the input of acetyl CoA into the TCA cycle, which is the point at 
which the uncoupling from OXPHOS occurs.  
Indeed, one of the early intermediates within the TCA cycle is α-ketoglutarate, a precursor for 
hydroxyproline – the subunit required to assemble mature collagen. Given that inhibiting glycolysis 
using 2-DG or 3PO prevented TGF-β driven increases in collagen I, it was posited that the increased 
glycolysis was coupled to increased activity in the TCA cycle, from which α-ketoglutarate was then 
being removed to fuel collagen synthesis. This would stunt the TCA cycle beyond the point α-
ketoglutarate is produced, hence the absence of any notable increase in OXPHOS.  
In addition to the TCA cycle, the other main mechanism for cellular α-ketoglutarate production is 
glutaminolysis, a 2-step pathway in which glutamine is converted to a-ketoglutarate via a glutamate 
intermediate. Hence, if increased α-ketoglutarate is a key requirement for the development of 
fibrosis it was theorised that glutaminolysis may also be contributing to the fibrotic phenotype. 
Levels of glutaminolysis in NHDFs were altered by varying the concentration of glutamine in the 
media, however this had a minimal effect on the levels of fibrotic markers with or without TGF-β in 
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the media. Whether intracellular glutamine was adequately depleted for the changing media 
concentrations of glutamine to have an effect isn’t clear however, hindered by the lack of robust 
methods to accurately measure glutaminolysis. 
Inhibition of glutaminolysis using the glutaminase inhibitor G968 abrogated the increased 
production of collagen I in TGF-β treated NHDFs however, which suggests that glutaminolysis is an 
important pathway for fibrosis. Strikingly, the KGA isoform of glutaminase was ubiquitously elevated 
in fibroblasts obtained from the skin lesions of 4 SSc patients when compared to NHDFs from age-
matched controls. In contrast, the different SSc fibroblasts showed high variation in their basal 
glycolysis, glycolytic capacity and glycolytic reserve suggesting that the involvement of glycolysis may 
be highly variable between different patients and heavily influenced by a number of disease 
independent factors.  
Thus, combining the data from TGF-β induced NHDFs and the SSc fibroblasts depicts a possible 
scenario in SSc whereby circulating TGF-β stimulates increased glycolysis which synergises with 
endogenously enhanced glutaminolysis to ramp up α-ketoglutarate production. Subsequently, this 
increased α-ketoglutarate is used as a precursor for collagen synthesis and hence facilitates 
enhanced ECM secretion – the underlying hallmark of fibrosis. 
Further work is required to test this theory, namely measuring the levels of succinate from TGF-β 
induced NHDFs and the SSc fibroblasts. Succinate is a downstream metabolite of α-ketoglutarate in 
the TCA cycle as well being a byproduct in the chain of reactions leading to collagen synthesis (Figure 
3.11). However, it only exists as an intermediate which is subsequently converted to fumarate in the 
former, hence increased succinate levels along with enhanced glycolysis would be indicative of the 
latter – i.e. α-ketoglutarate being re-directed from the TCA cycle to fuel collagen production.  
Ideally, a comprehensive omics approach would also be used to gain a more nuanced picture of the 
metabolic alterations occurring within skin fibrosis and their relevancy to the disease pathogenesis. 
Characterisation of the levels of the key enzymes involved in the energy pathways mentioned here 
along with those involved in lipid metabolism as well as nucleotide and protein synthesis via LC-MS 
based targeted proteomics would allow a deeper insight into the metabolic differences between SSc 
fibrotic lesion and non-lesion samples. Although LC-MS based proteomics have been performed on 
tissue samples from fibrotic mouse models [519-521], this approach has yet to be extended to SSc 
lesional tissue. 
Furthermore, single cell RNA (scRNA) sequencing within fibrotic lesions could be performed for a 
similar purpose: identifying if there are differences in the expression of metabolic genes in normal 
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and fibrotic fibroblasts within lesional tissue. Indeed, laser microdissection has previously been used 
to select pro-fibrotic myofibroblasts in IPF fibrotic lung samples for a similar purpose [522].  
Finally, the functional effects of modifying glycolytic and glutaminolytic activity performed within 
this work should be extended to in vivo models of skin fibrosis. There is already a precedence for the 
use of glycolysis and glutaminolysis inhibitors in various mouse models [523-525], hence inhibitors 
like 3PO and G968 could be trialled as therapeutics targeting bleomycin or TGF-β induced skin 
















Figure 6.10.1 Interaction between energy metabolism pathways and collagen synthesis. 
The mechanisms by which cellular energy metabolism pathways can fuel collagen synthesis is shown.  Acetyl-
CoA derived from either glycolysis or FAO is shuttled into the TCA cycle which yields α-ketoglutarate as an 
intermediate, which can also be synthesised from glutamine via glutaminolysis. Under fibrotic conditions, this 
α-ketoglutarate can be used as a co-substrate for hydroxyproline synthesis which is a building block for 
collagen – the main constituent of fibrotic lesions. Hypothetically, the use of inhibitors (G968, 3PO and 2-DG) 
targeting glycolysis and glutaminolysis could obstruct energy metabolism mediated upregulation of collagen 
production. 
Abbreviations: KGA/GAC - kidney type glutaminase/glutaminase C, GDH - glutamate dehydrogenase, P4H - 
prolyl 4-hydroxylase, PDH - pyruvate dehydrogenase, LDH - lactate dehydrogenase, ECM - extracellular matrix, 
FAO - fatty acid oxidation. 
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Chapter 7. Concluding Remarks 
As global life expectancy continues to rise, so does the incidence of highly debilitating age-related 
morbidities such as Alzheimer’s disease, Parkinson’s disease, various cancers and cardiovascular 
disease. This results in a low quality of life for those affected, as well as presenting an expanding 
economic and healthcare burden for society. Hence, this emphasises the pressing need to ensure 
human healthspan is also increased in tandem with lifespan, which has stimulated the quest for anti-
ageing interventions. 
With the goal of contributing towards this quest, the work within this thesis was undertaken with 
the primary intent of better understanding the mechanisms regulating NAD+ levels and the 
subsequent implications altering NAD+ has on aspects of cellular health – particularly in the context 
of pathways involved in ageing. Of particular note was the confirmation that NAD+ levels exhibit 
circadian rhythmicity both in vivo and when pharmacologically induced in vitro – with BMAL1 
functioning as a key mediator. 
This raises important considerations for existing and prospective NAD+ enhancing interventions, 
which would ideally be administered in a manner that targets the daily nadir in NAD+ levels for 
maximal enhancement, given this is when cellular function is most susceptible to the adverse 
consequences of reduced NAD+. Such an approach is hindered however by the likelihood that the 
circadian rhythmicity of NAD+ varies between individuals, hence would require profiling prior to 
beginning an NAD+- targeting regimens. 
Given its apparent regulation by BMAL1, the circadian profile of NAD+ may also be modulated 
upstream of BMAL1 by environmental factors such as sunlight exposure and sleep/wake patterns. 
Hence, future studies characterising the effects of these stimuli on the rhythmicity of NAD+ and 
identifying any correlations may allow the circadian NAD+ profile of an individual to be accurately 
predicted based on their environment and lifestyle traits – thus informing the optimal time to 
implement NAD+ enhancing interventions. 
Additionally, determining whether SIRT1 activity mirrors the circadian fluctuation in NAD+ levels 
would also be a key follow on from the work presented within this thesis, providing clarity on the 
intimacy of the interaction that exists between SIRT1 and NAD+ levels. Similarly, although the NTC in 
vitro and NCD201 in vivo interventions significantly increased NAD+, it wasn’t determined whether 
this translates to an increase in SIRT1 activity as predicted - which is another outstanding issue that 
needs addressed.  
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To this end, it should be noted that the measurement of SIRT1 activity is complicated given it shares 
many of its substrates with other enzymes, hence there is a lack of biomarkers which are exclusive 
for SIRT1. The acetylation status of P53 was initially measured by western blotting for this purpose, 
however it was found to be highly inconsistent in the presence of both the SIRT1 activator resveratrol 
and the inhibitor EX527, thus raising doubts over its validity as a bona fide marker of SIRT1 activity. 
Indeed, this reinforces the need to go beyond molecular analyses and test the functional effects of 
the NCD cocktails using in vivo mammalian models. Recent studies have reported improvements in 
the exercise performance of elderly mice in response to NAD+ precursor supplementation [180, 183], 
hence a deeper insight into the likely ‘real world’ utility of a multi-targeted NAD+ intervention would 
be gained by replicating these studies using the multi-targeted approach. Moreover, this would also 
offer an improved characterisation of the widespread effects of the intervention by allowing analysis 
of the biochemical changes occurring across different tissues. Metabolomic and proteomic analysis 
of the changes induced by the multi-targeted approach would not only confirm whether it was 
working as intended, but could also identify off-target effects: good and bad. 
This is especially pertinent given the polyphenolic compounds used within the multi-targeted 
approach are known to be able to influence numerous different pathways [526-529], depending on 
cell type and environmental factors. This is somewhat emphasised by the surprising discovery that 
the NTC in vitro supplement protected NHDFs against oxidative stress via an NAD+-dependent but 
SIRT1/PARP1-independent mechanism.  
Thus, for all future work involving NTC both in vivo and in vitro, a nicotinamide group (NTC without 
the polyphenols) should be included to determine the impact of the polyphenols, especially given 
nicotinamide itself already has been shown to enhance human NAD+ levels [150] and improve health 
in a number of murine models of age-related disease [161, 166, 332, 343].  
Similarly, a large-scale study directly pitting the multiple widely endorsed NAD+ precursors against 
each other (nicotinamide, NR, NMN, NA) and testing their ability to enhance NAD+ in a human cohort 
would clarify the optimal precursor for the purpose of human blood NAD+ enhancement. Given the 
respective precursors are imported and metabolised by different enzymes, the reality may be that 
‘one precursor doesn’t fit all’ and specific precursors perform better for specific disease conditions 
(dependent on the tissues involved and molecular changes in the affected tissue). Again, large-scale 
studies using multiple precursors could determine if a superior precursor exists for specific diseases. 
In summary, this work contributes to the wider efforts to understand and ultimately modify the 
cellular mechanisms implicated in ageing by identifying the presence of a circadian system regulating 
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NAD+ levels, both in human PBMCs and cultured NHDFs. Furthermore, the combined use of dietary 
supplements targeting multiple facets of NAD+ metabolism represents a novel approach to combat 
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